US20040063753A1 - Pyridinone derivatives for treatment of atherosclerosis - Google Patents
Pyridinone derivatives for treatment of atherosclerosis Download PDFInfo
- Publication number
- US20040063753A1 US20040063753A1 US10/399,022 US39902203A US2004063753A1 US 20040063753 A1 US20040063753 A1 US 20040063753A1 US 39902203 A US39902203 A US 39902203A US 2004063753 A1 US2004063753 A1 US 2004063753A1
- Authority
- US
- United States
- Prior art keywords
- ethyl
- int
- alkyl
- oxo
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 11
- 150000005299 pyridinones Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 132
- 102000004190 Enzymes Human genes 0.000 claims abstract description 21
- 108090000790 Enzymes Proteins 0.000 claims abstract description 21
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 claims description 109
- -1 2-(diethylamino)ethyl Chemical group 0.000 claims description 74
- 125000000217 alkyl group Chemical group 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 125000005605 benzo group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 5
- NNBGCSGCRSCFEA-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[1-(2-methoxyethyl)piperidin-4-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CCOC)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 NNBGCSGCRSCFEA-UHFFFAOYSA-N 0.000 claims description 5
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 4
- 239000005864 Sulphur Chemical group 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical class CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- YZFRZEKBIJYRAY-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]-n-[1-(2-methoxyethyl)piperidin-2-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound COCCN1CCCCC1N(C(=O)CN1C2=NC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 YZFRZEKBIJYRAY-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 156
- 239000000543 intermediate Substances 0.000 description 125
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 89
- 239000000203 mixture Substances 0.000 description 75
- 238000005160 1H NMR spectroscopy Methods 0.000 description 73
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 62
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 57
- 239000007787 solid Substances 0.000 description 57
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 52
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 49
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 39
- 239000002904 solvent Substances 0.000 description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000000377 silicon dioxide Substances 0.000 description 27
- 235000019439 ethyl acetate Nutrition 0.000 description 26
- 229910052786 argon Inorganic materials 0.000 description 24
- 239000002243 precursor Substances 0.000 description 23
- 238000003756 stirring Methods 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 0 [1*]CC1=CC(=O)C([2*])=C([3*])N1CC(=O)N([4*])C[5*][6*] Chemical compound [1*]CC1=CC(=O)C([2*])=C([3*])N1CC(=O)N([4*])C[5*][6*] 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 238000010992 reflux Methods 0.000 description 16
- 229910000104 sodium hydride Inorganic materials 0.000 description 16
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 15
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 15
- 239000012458 free base Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000012312 sodium hydride Substances 0.000 description 15
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 229960000583 acetic acid Drugs 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 239000012267 brine Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 8
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 8
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- OBJKLVFDRLAGJI-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]-n-[1-(2-methoxyethyl)piperidin-4-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CCOC)CCC1N(C(=O)CN1C2=NC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 OBJKLVFDRLAGJI-UHFFFAOYSA-N 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 229940043279 diisopropylamine Drugs 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- FTBSGSZZESQDBM-UHFFFAOYSA-N 1-(bromomethyl)-2,3-difluorobenzene Chemical compound FC1=CC=CC(CBr)=C1F FTBSGSZZESQDBM-UHFFFAOYSA-N 0.000 description 5
- UFNIKBVOGVBBOH-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)O)C=1CCC1=CC=CC(F)=C1F UFNIKBVOGVBBOH-UHFFFAOYSA-N 0.000 description 5
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 5
- 206010048554 Endothelial dysfunction Diseases 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000008694 endothelial dysfunction Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- CQBYREFQWDUSJY-UHFFFAOYSA-N n',n'-diethyl-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]ethane-1,2-diamine Chemical compound C1=CC(CNCCN(CC)CC)=CC=C1C1=CC=C(C(F)(F)F)C=C1 CQBYREFQWDUSJY-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 4
- WQAIPNTUCFSZRZ-UHFFFAOYSA-N 3h-1,3-oxazine-2,6-dione Chemical compound O=C1C=CNC(=O)O1 WQAIPNTUCFSZRZ-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- UTKVAIPDUJGYPV-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CCC1=CC(=O)C2=CC=CC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 UTKVAIPDUJGYPV-UHFFFAOYSA-N 0.000 description 4
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000001665 trituration Methods 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- LZWZQYVPLLPAGX-UHFFFAOYSA-N 1h-pyrido[2,3-d][1,3]oxazine-2,4-dione Chemical compound C1=CC=C2C(=O)OC(=O)NC2=N1 LZWZQYVPLLPAGX-UHFFFAOYSA-N 0.000 description 3
- QHTTXSWWWSYDRY-UHFFFAOYSA-N 1h-thieno[3,2-d][1,3]oxazine-2,4-dione Chemical compound O=C1OC(=O)NC2=C1SC=C2 QHTTXSWWWSYDRY-UHFFFAOYSA-N 0.000 description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- BJUPKHQCMFTUEL-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-1,5,6,7-tetrahydrocyclopenta[b]pyridin-4-one Chemical compound FC1=CC=CC(CSC=2NC=3CCCC=3C(=O)C=2)=C1F BJUPKHQCMFTUEL-UHFFFAOYSA-N 0.000 description 3
- QKELQCLJNLJWRI-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxo-1,8-naphthyridin-1-yl]-n-(1-methylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(C)CCC1N(C(=O)CN1C2=NC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 QKELQCLJNLJWRI-UHFFFAOYSA-N 0.000 description 3
- WDKBNDFCVFQUPR-UHFFFAOYSA-N 2-[4-oxo-2-[2-(2,3,4-trifluorophenyl)ethyl]quinolin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)O)C=1CCC1=CC=C(F)C(F)=C1F WDKBNDFCVFQUPR-UHFFFAOYSA-N 0.000 description 3
- LKHFUPSFAKDEPY-UHFFFAOYSA-N 2-[5-[(2,3-difluorophenyl)methylsulfanyl]-7-oxothieno[3,2-b]pyridin-4-yl]acetic acid Chemical compound C=1C(=O)C=2SC=CC=2N(CC(=O)O)C=1SCC1=CC=CC(F)=C1F LKHFUPSFAKDEPY-UHFFFAOYSA-N 0.000 description 3
- HIMSXOOFWOOYFK-UHFFFAOYSA-N 4-[4-(trifluoromethyl)phenyl]benzaldehyde Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=C(C=O)C=C1 HIMSXOOFWOOYFK-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 3
- OCJCEKLSMQNLRL-UHFFFAOYSA-N 5-ethyl-3h-1,3-oxazine-2,6-dione Chemical compound CCC1=CNC(=O)OC1=O OCJCEKLSMQNLRL-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- PYUKPZBUJCFYRQ-UHFFFAOYSA-N [4-(4-chlorophenyl)phenyl]methanamine Chemical compound C1=CC(CN)=CC=C1C1=CC=C(Cl)C=C1 PYUKPZBUJCFYRQ-UHFFFAOYSA-N 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- NVXPMWXWZQUCBD-UHFFFAOYSA-N ethyl 2-(2,4-dioxothieno[3,2-d][1,3]oxazin-1-yl)acetate Chemical compound O=C1OC(=O)N(CC(=O)OCC)C2=C1SC=C2 NVXPMWXWZQUCBD-UHFFFAOYSA-N 0.000 description 3
- HUPHMTPSOCOXKD-UHFFFAOYSA-N ethyl 2-[2-[2-(2,3-difluorophenyl)ethyl]-5-ethyl-4-oxopyridin-1-yl]acetate Chemical compound CCOC(=O)CN1C=C(CC)C(=O)C=C1CCC1=CC=CC(F)=C1F HUPHMTPSOCOXKD-UHFFFAOYSA-N 0.000 description 3
- QYAMSLDHLOMPIY-UHFFFAOYSA-N ethyl 2-[5-[(2,3-difluorophenyl)methylsulfanyl]-7-oxothieno[3,2-b]pyridin-4-yl]acetate Chemical compound C=1C(=O)C=2SC=CC=2N(CC(=O)OCC)C=1SCC1=CC=CC(F)=C1F QYAMSLDHLOMPIY-UHFFFAOYSA-N 0.000 description 3
- JRFCBWYDPKDNPU-UHFFFAOYSA-N ethyl 2-[5-[2-(2,3-difluorophenyl)ethyl]-2-methyl-7-oxo-[1,3]thiazolo[4,5-b]pyridin-4-yl]acetate Chemical compound C=1C(=O)C=2SC(C)=NC=2N(CC(=O)OCC)C=1CCC1=CC=CC(F)=C1F JRFCBWYDPKDNPU-UHFFFAOYSA-N 0.000 description 3
- JLPOLYYUUDJRFD-UHFFFAOYSA-N ethyl 2-[6-[2-(2,3-difluorophenyl)ethyl]-2,3-dimethyl-4-oxopyridin-1-yl]acetate Chemical compound CCOC(=O)CN1C(C)=C(C)C(=O)C=C1CCC1=CC=CC(F)=C1F JLPOLYYUUDJRFD-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- CTLPWLLSKXUTKC-UHFFFAOYSA-N n-[[4-(4-chlorophenyl)phenyl]methyl]-2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-(1-methylpiperidin-4-yl)acetamide Chemical compound C1CN(C)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1 CTLPWLLSKXUTKC-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- OVYDGOGMPFJFTL-UHFFFAOYSA-N (2,3-difluorophenyl)methanethiol Chemical compound FC1=CC=CC(CS)=C1F OVYDGOGMPFJFTL-UHFFFAOYSA-N 0.000 description 2
- RKTRHMNWVZRZJQ-UHFFFAOYSA-N (4-fluorophenyl)methanethiol Chemical compound FC1=CC=C(CS)C=C1 RKTRHMNWVZRZJQ-UHFFFAOYSA-N 0.000 description 2
- HTTHQEKWDRWWGF-UHFFFAOYSA-N 1-(1-ethylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]methanamine Chemical compound C1CN(CC)CCC1CNCC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 HTTHQEKWDRWWGF-UHFFFAOYSA-N 0.000 description 2
- BSNJNLUZUMIYOX-UHFFFAOYSA-N 1-(1-ethylpyrrolidin-2-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]methanamine Chemical compound CCN1CCCC1CNCC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 BSNJNLUZUMIYOX-UHFFFAOYSA-N 0.000 description 2
- GRAPIIDTTQXULL-UHFFFAOYSA-N 1-(2-methoxyethyl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]piperidin-4-amine Chemical compound C1CN(CCOC)CCC1NCC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 GRAPIIDTTQXULL-UHFFFAOYSA-N 0.000 description 2
- AKGILJNFEFWEOO-UHFFFAOYSA-N 1-ethyl-n-[[4-(4-ethylphenyl)phenyl]methyl]piperidin-4-amine Chemical compound C1CN(CC)CCC1NCC1=CC=C(C=2C=CC(CC)=CC=2)C=C1 AKGILJNFEFWEOO-UHFFFAOYSA-N 0.000 description 2
- SYPZAHQBAPOKFN-UHFFFAOYSA-N 1-ethyl-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]piperidin-4-amine Chemical compound C1CN(CC)CCC1NCC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 SYPZAHQBAPOKFN-UHFFFAOYSA-N 0.000 description 2
- ZIGNRGUEEPKOCE-UHFFFAOYSA-N 1-propan-2-yl-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]piperidin-4-amine Chemical compound C1CN(C(C)C)CCC1NCC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 ZIGNRGUEEPKOCE-UHFFFAOYSA-N 0.000 description 2
- YPNJLKYQXUBRHJ-UHFFFAOYSA-N 1h-thieno[2,3-d][1,3]oxazine-2,4-dione Chemical compound O=C1OC(=O)NC2=C1C=CS2 YPNJLKYQXUBRHJ-UHFFFAOYSA-N 0.000 description 2
- IKHIUUFLWGIGMC-UHFFFAOYSA-N 1h-thieno[3,4-d][1,3]oxazine-2,4-dione Chemical compound O=C1OC(=O)NC2=CSC=C21 IKHIUUFLWGIGMC-UHFFFAOYSA-N 0.000 description 2
- JGQRPOZAIBSOHE-UHFFFAOYSA-N 2,4-dichloro-6,7-dihydro-5h-cyclopenta[b]pyridine Chemical compound ClC1=CC(Cl)=C2CCCC2=N1 JGQRPOZAIBSOHE-UHFFFAOYSA-N 0.000 description 2
- QNBJYUUUYZVIJP-UHFFFAOYSA-N 2,4-dichloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC(Cl)=C21 QNBJYUUUYZVIJP-UHFFFAOYSA-N 0.000 description 2
- XEMFEXZVTYGHFB-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-1h-quinolin-4-one Chemical compound FC1=CC=CC(CSC=2NC3=CC=CC=C3C(=O)C=2)=C1F XEMFEXZVTYGHFB-UHFFFAOYSA-N 0.000 description 2
- USXXLTRCGRQHPC-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylsulfanyl]-1,5,6,7-tetrahydrocyclopenta[b]pyridin-4-one Chemical compound C1=CC(F)=CC=C1CSC(N1)=CC(=O)C2=C1CCC2 USXXLTRCGRQHPC-UHFFFAOYSA-N 0.000 description 2
- VMRUJAPJPISAPL-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylsulfanyl]-1h-quinolin-4-one Chemical compound C1=CC(F)=CC=C1CSC1=CC(=O)C2=CC=CC=C2N1 VMRUJAPJPISAPL-UHFFFAOYSA-N 0.000 description 2
- RQCJKGLGZAJCOX-UHFFFAOYSA-N 2-[2-(2,3,4-trifluorophenyl)ethyl]-1h-quinolin-4-one Chemical compound FC1=C(F)C(F)=CC=C1CCC1=CC(=O)C2=CC=CC=C2N1 RQCJKGLGZAJCOX-UHFFFAOYSA-N 0.000 description 2
- FSTALQFPBUQRMP-UHFFFAOYSA-N 2-[2-(2-fluorophenyl)ethyl]-1h-quinolin-4-one Chemical compound FC1=CC=CC=C1CCC1=CC(=O)C2=CC=CC=C2N1 FSTALQFPBUQRMP-UHFFFAOYSA-N 0.000 description 2
- RXLXLKJVPNJIDB-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethyl]-1h-quinolin-4-one Chemical compound ClC1=CC=CC(CCC=2NC3=CC=CC=C3C(=O)C=2)=C1 RXLXLKJVPNJIDB-UHFFFAOYSA-N 0.000 description 2
- OZYZBCZZLUXHTD-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethyl]-1h-quinolin-4-one Chemical compound FC1=CC=CC(CCC=2NC3=CC=CC=C3C(=O)C=2)=C1 OZYZBCZZLUXHTD-UHFFFAOYSA-N 0.000 description 2
- YSYYYEFHIBYDQC-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)ethyl]-1h-quinolin-4-one Chemical compound C1=CC(F)=CC=C1CCC1=CC(=O)C2=CC=CC=C2N1 YSYYYEFHIBYDQC-UHFFFAOYSA-N 0.000 description 2
- VXLPJDOJGIKLAP-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxo-1,8-naphthyridin-1-yl]-n-(1-ethylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C2=NC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 VXLPJDOJGIKLAP-UHFFFAOYSA-N 0.000 description 2
- MDUYMNQOKAAAOD-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxo-1,8-naphthyridin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CN=C2N(CC(=O)O)C=1SCC1=CC=CC(F)=C1F MDUYMNQOKAAAOD-UHFFFAOYSA-N 0.000 description 2
- WDQWQNOQDURTBH-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-(1-ethylpyrrolidin-3-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1N(CC)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 WDQWQNOQDURTBH-UHFFFAOYSA-N 0.000 description 2
- FPCZNMNFWODGOY-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-(1-methylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(C)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 FPCZNMNFWODGOY-UHFFFAOYSA-N 0.000 description 2
- NJEIEWLEJAJAJY-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[[4-(4-ethylphenyl)phenyl]methyl]-n-(1-ethylpiperidin-4-yl)acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(CC)=CC=2)C=C1 NJEIEWLEJAJAJY-UHFFFAOYSA-N 0.000 description 2
- XSXZVWYBJALANE-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-piperidin-4-yl-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound FC1=CC=CC(CSC=2N(C3=CC=CC=C3C(=O)C=2)CC(=O)N(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)C2CCNCC2)=C1F XSXZVWYBJALANE-UHFFFAOYSA-N 0.000 description 2
- ALTNIBBVIBUKQS-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)O)C=1SCC1=CC=CC(F)=C1F ALTNIBBVIBUKQS-UHFFFAOYSA-N 0.000 description 2
- SWIPKGCTUJYOSU-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-7-fluoro-4-oxoquinolin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=C(F)C=C2N(CC(=O)O)C=1SCC1=CC=CC(F)=C1F SWIPKGCTUJYOSU-UHFFFAOYSA-N 0.000 description 2
- VBEUXYBJJZWXCD-UHFFFAOYSA-N 2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)O)C=1SCC1=CC=C(F)C=C1 VBEUXYBJJZWXCD-UHFFFAOYSA-N 0.000 description 2
- NQQQOYARACNVOB-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]-n-(1-methylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(C)CCC1N(C(=O)CN1C2=NC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 NQQQOYARACNVOB-UHFFFAOYSA-N 0.000 description 2
- LDNPOVLETWTBCM-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]-n-piperidin-4-yl-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound FC1=CC=CC(CCC=2N(C3=NC=CC=C3C(=O)C=2)CC(=O)N(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)C2CCNCC2)=C1F LDNPOVLETWTBCM-UHFFFAOYSA-N 0.000 description 2
- PNZRPJUNNFERPQ-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CN=C2N(CC(=O)O)C=1CCC1=CC=CC(F)=C1F PNZRPJUNNFERPQ-UHFFFAOYSA-N 0.000 description 2
- BETUISKNIITDDN-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-(1-ethylpyrrolidin-3-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1N(CC)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 BETUISKNIITDDN-UHFFFAOYSA-N 0.000 description 2
- HARNRRIHMFGUGB-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-(1-propan-2-ylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(C(C)C)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 HARNRRIHMFGUGB-UHFFFAOYSA-N 0.000 description 2
- QDIKJGYQTAFOIK-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-[(1-ethylpiperidin-4-yl)methyl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CC)CCC1CN(C(=O)CN1C2=CC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 QDIKJGYQTAFOIK-UHFFFAOYSA-N 0.000 description 2
- HBSUMCXFBJWFIF-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-[1-(2-hydroxyethyl)piperidin-4-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CCO)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 HBSUMCXFBJWFIF-UHFFFAOYSA-N 0.000 description 2
- VSOURSFOQPSAAQ-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-[[4-(4-ethylphenyl)phenyl]methyl]-n-(1-ethylpiperidin-4-yl)acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(CC)=CC=2)C=C1 VSOURSFOQPSAAQ-UHFFFAOYSA-N 0.000 description 2
- UXGMLAQLMAWDDX-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxothieno[3,4-b]pyridin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CSC=C2N(CC(=O)O)C=1CCC1=CC=CC(F)=C1F UXGMLAQLMAWDDX-UHFFFAOYSA-N 0.000 description 2
- RKIVVEFTTPXNFK-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-5-ethyl-4-oxopyridin-1-yl]acetic acid Chemical compound O=C1C(CC)=CN(CC(O)=O)C(CCC=2C(=C(F)C=CC=2)F)=C1 RKIVVEFTTPXNFK-UHFFFAOYSA-N 0.000 description 2
- ORHDIKKTKZTGSC-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-7-methyl-4-oxo-1,8-naphthyridin-1-yl]-n-(1-ethylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C2=NC(C)=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 ORHDIKKTKZTGSC-UHFFFAOYSA-N 0.000 description 2
- POSHSLQCBNHANF-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-7-methyl-4-oxo-1,8-naphthyridin-1-yl]-n-(1-methylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(C)CCC1N(C(=O)CN1C2=NC(C)=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 POSHSLQCBNHANF-UHFFFAOYSA-N 0.000 description 2
- UQSSAAGJPYLTLH-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-7-methyl-4-oxo-1,8-naphthyridin-1-yl]-n-(1-propan-2-ylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(C(C)C)CCC1N(C(=O)CN1C2=NC(C)=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 UQSSAAGJPYLTLH-UHFFFAOYSA-N 0.000 description 2
- GMSWNVVQPHXBHU-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-7-methyl-4-oxo-1,8-naphthyridin-1-yl]-n-[1-(2-methoxyethyl)piperidin-4-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CCOC)CCC1N(C(=O)CN1C2=NC(C)=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 GMSWNVVQPHXBHU-UHFFFAOYSA-N 0.000 description 2
- ZGIZCRGGOKSYHJ-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-7-methyl-4-oxo-1,8-naphthyridin-1-yl]acetic acid Chemical compound N=1C(C)=CC=C(C(C=2)=O)C=1N(CC(O)=O)C=2CCC1=CC=CC(F)=C1F ZGIZCRGGOKSYHJ-UHFFFAOYSA-N 0.000 description 2
- QTYULAZQJNYFMK-UHFFFAOYSA-N 2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)O)C=1CCC1=CC=C(F)C=C1F QTYULAZQJNYFMK-UHFFFAOYSA-N 0.000 description 2
- DLLWJGGPDVOIDA-UHFFFAOYSA-N 2-[2-[2-(2-fluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)O)C=1CCC1=CC=CC=C1F DLLWJGGPDVOIDA-UHFFFAOYSA-N 0.000 description 2
- ZRNSWJPARHHPEY-UHFFFAOYSA-N 2-[2-[2-(3,4-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)O)C=1CCC1=CC=C(F)C(F)=C1 ZRNSWJPARHHPEY-UHFFFAOYSA-N 0.000 description 2
- VLZMUBBUDPMFHP-UHFFFAOYSA-N 2-[2-[2-(3-chlorophenyl)ethyl]-4-oxoquinolin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)O)C=1CCC1=CC=CC(Cl)=C1 VLZMUBBUDPMFHP-UHFFFAOYSA-N 0.000 description 2
- VCFOBTIZWDFZST-UHFFFAOYSA-N 2-[2-[2-(3-fluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetic acid Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)O)C=1CCC1=CC=CC(F)=C1 VCFOBTIZWDFZST-UHFFFAOYSA-N 0.000 description 2
- APXZDSRMHWMWLZ-UHFFFAOYSA-N 2-[5-[(2,3-difluorophenyl)methylsulfanyl]-7-oxothieno[3,2-b]pyridin-4-yl]-n-(1-ethylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C=2C=CSC=2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 APXZDSRMHWMWLZ-UHFFFAOYSA-N 0.000 description 2
- KNKHNXXLBKESLJ-UHFFFAOYSA-N 2-[5-[2-(2,3-difluorophenyl)ethyl]-1-methyl-7-oxopyrazolo[4,3-b]pyridin-4-yl]-n-(1-ethylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C=2C=NN(C)C=2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 KNKHNXXLBKESLJ-UHFFFAOYSA-N 0.000 description 2
- YHUAXFFRBVHXKZ-UHFFFAOYSA-N 2-[5-[2-(2,3-difluorophenyl)ethyl]-1-methyl-7-oxopyrazolo[4,3-b]pyridin-4-yl]acetic acid Chemical compound C=1C(=O)C=2N(C)N=CC=2N(CC(O)=O)C=1CCC1=CC=CC(F)=C1F YHUAXFFRBVHXKZ-UHFFFAOYSA-N 0.000 description 2
- ALAHVZCPNGKKFJ-UHFFFAOYSA-N 2-[5-[2-(2,3-difluorophenyl)ethyl]-2-methyl-7-oxo-[1,3]thiazolo[4,5-b]pyridin-4-yl]-n-(1-ethylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C=2N=C(C)SC=2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 ALAHVZCPNGKKFJ-UHFFFAOYSA-N 0.000 description 2
- OMCOERLCWCWRAH-UHFFFAOYSA-N 2-[5-[2-(2,3-difluorophenyl)ethyl]-2-methyl-7-oxo-[1,3]thiazolo[4,5-b]pyridin-4-yl]-n-[1-(2-methoxyethyl)piperidin-4-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CCOC)CCC1N(C(=O)CN1C=2N=C(C)SC=2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 OMCOERLCWCWRAH-UHFFFAOYSA-N 0.000 description 2
- YBGPEOJXYRNROE-UHFFFAOYSA-N 2-[5-[2-(2,3-difluorophenyl)ethyl]-2-methyl-7-oxo-[1,3]thiazolo[4,5-b]pyridin-4-yl]acetic acid Chemical compound C=1C(=O)C=2SC(C)=NC=2N(CC(O)=O)C=1CCC1=CC=CC(F)=C1F YBGPEOJXYRNROE-UHFFFAOYSA-N 0.000 description 2
- LBOHRYJMFZPXGS-UHFFFAOYSA-N 2-[5-[2-(2,3-difluorophenyl)ethyl]-2-methyl-7-oxopyrazolo[4,3-b]pyridin-4-yl]-n-(1-ethylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C2=CN(C)N=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 LBOHRYJMFZPXGS-UHFFFAOYSA-N 0.000 description 2
- IZVKXQISTYWZLM-UHFFFAOYSA-N 2-[6-[(2,3-difluorophenyl)methylsulfanyl]-2-methyl-4-oxopyrazolo[3,4-b]pyridin-7-yl]acetic acid Chemical compound N=1N(C)C=C(C(C=2)=O)C=1N(CC(O)=O)C=2SCC1=CC=CC(F)=C1F IZVKXQISTYWZLM-UHFFFAOYSA-N 0.000 description 2
- QCQZWULNIFIWSI-UHFFFAOYSA-N 2-[6-[2-(2,3-difluorophenyl)ethyl]-2,3-dimethyl-4-oxopyridin-1-yl]acetic acid Chemical compound OC(=O)CN1C(C)=C(C)C(=O)C=C1CCC1=CC=CC(F)=C1F QCQZWULNIFIWSI-UHFFFAOYSA-N 0.000 description 2
- RIMISAXPPGWCBA-UHFFFAOYSA-N 2-[6-[2-(2,3-difluorophenyl)ethyl]-2-(2-methoxyethyl)-4-oxopyrazolo[3,4-b]pyridin-7-yl]acetic acid Chemical compound N=1N(CCOC)C=C(C(C=2)=O)C=1N(CC(O)=O)C=2CCC1=CC=CC(F)=C1F RIMISAXPPGWCBA-UHFFFAOYSA-N 0.000 description 2
- XHRKHWGHHMDASW-UHFFFAOYSA-N 2-[6-[2-(2,3-difluorophenyl)ethyl]-2-ethyl-4-oxopyrazolo[3,4-b]pyridin-7-yl]-n-(1-ethylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C2=NN(CC)C=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 XHRKHWGHHMDASW-UHFFFAOYSA-N 0.000 description 2
- MBFVWJJADILGRS-UHFFFAOYSA-N 2-[6-[2-(2,3-difluorophenyl)ethyl]-2-methyl-4-oxopyrazolo[3,4-b]pyridin-7-yl]acetic acid Chemical compound N=1N(C)C=C(C(C=2)=O)C=1N(CC(O)=O)C=2CCC1=CC=CC(F)=C1F MBFVWJJADILGRS-UHFFFAOYSA-N 0.000 description 2
- SWRJJZLJVIJHEV-UHFFFAOYSA-N 2-[6-[2-(2,3-difluorophenyl)ethyl]-4-oxo-2-propan-2-ylpyrazolo[3,4-b]pyridin-7-yl]-n-(1-ethylpiperidin-4-yl)-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C2=NN(C=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)C(C)C)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 SWRJJZLJVIJHEV-UHFFFAOYSA-N 0.000 description 2
- ROZIVQBVHUBNFT-UHFFFAOYSA-N 2-[6-[2-(2,3-difluorophenyl)ethyl]-4-oxo-2-propan-2-ylpyrazolo[3,4-b]pyridin-7-yl]acetic acid Chemical compound N=1N(C(C)C)C=C(C(C=2)=O)C=1N(CC(O)=O)C=2CCC1=CC=CC(F)=C1F ROZIVQBVHUBNFT-UHFFFAOYSA-N 0.000 description 2
- COWSOIAKQKVTPM-UHFFFAOYSA-N 2-methyl-1h-pyrazolo[3,4-d][1,3]oxazine-4,6-dione Chemical compound N1C(=O)OC(=O)C=2C1=NN(C)C=2 COWSOIAKQKVTPM-UHFFFAOYSA-N 0.000 description 2
- RHVPGWVYKJHLRF-UHFFFAOYSA-N 2-piperidin-1-yl-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]ethanamine Chemical compound C1=CC(C(F)(F)F)=CC=C1C(C=C1)=CC=C1CNCCN1CCCCC1 RHVPGWVYKJHLRF-UHFFFAOYSA-N 0.000 description 2
- LMDTWLNPYRNVRP-UHFFFAOYSA-N 2-pyrrolidin-1-yl-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]ethanamine Chemical compound C1=CC(C(F)(F)F)=CC=C1C(C=C1)=CC=C1CNCCN1CCCC1 LMDTWLNPYRNVRP-UHFFFAOYSA-N 0.000 description 2
- WHNQTHDJEZTVHS-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)propanoic acid Chemical compound C1=CC=C2SC(CCC(=O)O)=NC2=C1 WHNQTHDJEZTVHS-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- CTDMVKXECCUFNH-UHFFFAOYSA-N 4,5-dimethyl-3h-1,3-oxazine-2,6-dione Chemical compound CC=1NC(=O)OC(=O)C=1C CTDMVKXECCUFNH-UHFFFAOYSA-N 0.000 description 2
- GUXZLJMGWOGRAH-UHFFFAOYSA-N 4-chloro-2-[2-(2,3-difluorophenyl)ethyl]quinoline Chemical compound FC1=CC=CC(CCC=2N=C3C=CC=CC3=C(Cl)C=2)=C1F GUXZLJMGWOGRAH-UHFFFAOYSA-N 0.000 description 2
- SCDZKHFXHRNLQM-UHFFFAOYSA-N 4-hydroxy-1,5,6,7-tetrahydrocyclopenta[b]pyridin-2-one Chemical compound N1C(O)=CC(=O)C2=C1CCC2 SCDZKHFXHRNLQM-UHFFFAOYSA-N 0.000 description 2
- HDHQZCHIXUUSMK-UHFFFAOYSA-N 4-hydroxy-2-quinolone Chemical compound C1=CC=C2C(O)=CC(=O)NC2=C1 HDHQZCHIXUUSMK-UHFFFAOYSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- VMIWIZKGHLWYBN-UHFFFAOYSA-N 4-pyrrolidin-1-yl-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]butan-1-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1C(C=C1)=CC=C1CNCCCCN1CCCC1 VMIWIZKGHLWYBN-UHFFFAOYSA-N 0.000 description 2
- XBBHKROZUIQCGN-UHFFFAOYSA-N 5-[anilino-[(2,3-difluorophenyl)methylsulfanyl]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound O=C1OC(C)(C)OC(=O)C1=C(SCC=1C(=C(F)C=CC=1)F)NC1=CC=CC=C1 XBBHKROZUIQCGN-UHFFFAOYSA-N 0.000 description 2
- JEVWCMDHSLNNDR-UHFFFAOYSA-N 7-fluoro-1h-3,1-benzoxazine-2,4-dione Chemical compound N1C(=O)OC(=O)C=2C1=CC(F)=CC=2 JEVWCMDHSLNNDR-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 2
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- UHQUGNRSUXWVJH-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(C)C)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(C)C)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 UHQUGNRSUXWVJH-UHFFFAOYSA-N 0.000 description 2
- RYYMVCMPLQTOMX-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1N=C(C)S2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1N=C(C)S2 RYYMVCMPLQTOMX-UHFFFAOYSA-N 0.000 description 2
- KPZGQYXBTABIJS-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 KPZGQYXBTABIJS-UHFFFAOYSA-N 0.000 description 2
- QBQYZJCUCCJYOJ-UHFFFAOYSA-N CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 Chemical compound CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 QBQYZJCUCCJYOJ-UHFFFAOYSA-N 0.000 description 2
- NKZRRNFTCWMICI-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(C)C=C21 Chemical compound CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(C)C=C21 NKZRRNFTCWMICI-UHFFFAOYSA-N 0.000 description 2
- DYGOHQPRYJSRML-UHFFFAOYSA-N CCOC(=O)CNC1=C(C(=O)[CH-][S+](C)(C)=O)C=CC(F)=C1 Chemical compound CCOC(=O)CNC1=C(C(=O)[CH-][S+](C)(C)=O)C=CC(F)=C1 DYGOHQPRYJSRML-UHFFFAOYSA-N 0.000 description 2
- IBXBKIRDMYAKQJ-UHFFFAOYSA-N COCCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 Chemical compound COCCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 IBXBKIRDMYAKQJ-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 2
- HZVVLBKMLATMEP-UHFFFAOYSA-N O=C1C=C(SCC2=C(F)C=C(F)C=C2)NC2=C1C=CC=C2 Chemical compound O=C1C=C(SCC2=C(F)C=C(F)C=C2)NC2=C1C=CC=C2 HZVVLBKMLATMEP-UHFFFAOYSA-N 0.000 description 2
- KOQPVBRMZLHISS-UHFFFAOYSA-N O=C1C=C(SCC2=CC(F)=C(F)C=C2)NC2=C1C=CC=C2 Chemical compound O=C1C=C(SCC2=CC(F)=C(F)C=C2)NC2=C1C=CC=C2 KOQPVBRMZLHISS-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- ALMFIOZYDASRRC-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1 ALMFIOZYDASRRC-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- CQFXNLZDAXORGD-UHFFFAOYSA-M chloro-(triphenyl-$l^{5}-phosphanylidene)rhodium Chemical compound [Rh]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CQFXNLZDAXORGD-UHFFFAOYSA-M 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229960001270 d- tartaric acid Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- PWOQEXMGTQHAOU-UHFFFAOYSA-N ethyl 2-(2,4-dioxopyrido[2,3-d][1,3]oxazin-1-yl)acetate Chemical compound C1=CC=C2C(=O)OC(=O)N(CC(=O)OCC)C2=N1 PWOQEXMGTQHAOU-UHFFFAOYSA-N 0.000 description 2
- ZWBPMXZMMUXFNB-UHFFFAOYSA-N ethyl 2-(2,4-dioxothieno[2,3-d][1,3]oxazin-1-yl)acetate Chemical compound O=C1OC(=O)N(CC(=O)OCC)C2=C1C=CS2 ZWBPMXZMMUXFNB-UHFFFAOYSA-N 0.000 description 2
- WTQKNXYHHCMPBA-UHFFFAOYSA-N ethyl 2-(2,4-dioxothieno[3,4-d][1,3]oxazin-1-yl)acetate Chemical compound O=C1OC(=O)N(CC(=O)OCC)C2=CSC=C21 WTQKNXYHHCMPBA-UHFFFAOYSA-N 0.000 description 2
- KWOKQBGWKRKIBY-UHFFFAOYSA-N ethyl 2-(2-methyl-4,6-dioxopyrazolo[3,4-d][1,3]oxazin-7-yl)acetate Chemical compound O=C1OC(=O)N(CC(=O)OCC)C2=NN(C)C=C21 KWOKQBGWKRKIBY-UHFFFAOYSA-N 0.000 description 2
- BYYSZMSTZNQIRE-UHFFFAOYSA-N ethyl 2-(4,5-dimethyl-2,6-dioxo-1,3-oxazin-3-yl)acetate Chemical compound CCOC(=O)CN1C(C)=C(C)C(=O)OC1=O BYYSZMSTZNQIRE-UHFFFAOYSA-N 0.000 description 2
- AHLFVCHMFGCHTC-UHFFFAOYSA-N ethyl 2-(5-ethyl-2,6-dioxo-1,3-oxazin-3-yl)acetate Chemical compound CCOC(=O)CN1C=C(CC)C(=O)OC1=O AHLFVCHMFGCHTC-UHFFFAOYSA-N 0.000 description 2
- XJINTLSPHGSHHB-UHFFFAOYSA-N ethyl 2-(6-methyl-2,4-dioxothieno[3,2-d][1,3]oxazin-1-yl)acetate Chemical compound O=C1OC(=O)N(CC(=O)OCC)C2=C1SC(C)=C2 XJINTLSPHGSHHB-UHFFFAOYSA-N 0.000 description 2
- JCBRDJREPKBREN-UHFFFAOYSA-N ethyl 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxo-1,8-naphthyridin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CN=C2N(CC(=O)OCC)C=1SCC1=CC=CC(F)=C1F JCBRDJREPKBREN-UHFFFAOYSA-N 0.000 description 2
- VBKAVHIBNSKOAB-UHFFFAOYSA-N ethyl 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-7-fluoro-4-oxoquinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=C(F)C=C2N(CC(=O)OCC)C=1SCC1=CC=CC(F)=C1F VBKAVHIBNSKOAB-UHFFFAOYSA-N 0.000 description 2
- OYEHYXHYYFOAAY-UHFFFAOYSA-N ethyl 2-[2-[(4-methoxyphenyl)methyl]-4,6-dioxopyrazolo[3,4-d][1,3]oxazin-7-yl]acetate Chemical compound C1=C2C(=O)OC(=O)N(CC(=O)OCC)C2=NN1CC1=CC=C(OC)C=C1 OYEHYXHYYFOAAY-UHFFFAOYSA-N 0.000 description 2
- HSJKNZHDTJAEHL-UHFFFAOYSA-N ethyl 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxothieno[3,4-b]pyridin-1-yl]acetate Chemical compound C=1C(=O)C2=CSC=C2N(CC(=O)OCC)C=1CCC1=CC=CC(F)=C1F HSJKNZHDTJAEHL-UHFFFAOYSA-N 0.000 description 2
- KYVYTQVRJNFUJE-UHFFFAOYSA-N ethyl 2-[2-[2-(2,3-difluorophenyl)ethyl]-7-methyl-4-oxo-1,8-naphthyridin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=C(C)N=C2N(CC(=O)OCC)C=1CCC1=CC=CC(F)=C1F KYVYTQVRJNFUJE-UHFFFAOYSA-N 0.000 description 2
- ONRCFNHOIKYYGK-UHFFFAOYSA-N ethyl 2-[4-[[4-[4-(trifluoromethyl)phenyl]phenyl]methylamino]piperidin-1-yl]acetate Chemical compound C1CN(CC(=O)OCC)CCC1NCC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 ONRCFNHOIKYYGK-UHFFFAOYSA-N 0.000 description 2
- RNKUOZOEQFYJKI-UHFFFAOYSA-N ethyl 4-hydroxy-2-oxo-1,5,6,7-tetrahydrocyclopenta[b]pyridine-3-carboxylate Chemical compound CCOC(=O)C1=C(O)N=C2CCCC2=C1O RNKUOZOEQFYJKI-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QHKWCQWRZQFNQM-UHFFFAOYSA-N methyl 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)OC)C=1CCC1=CC=CC(F)=C1F QHKWCQWRZQFNQM-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- GVDKZRPJKZYAIF-UHFFFAOYSA-N n',n'-diethyl-n-[[4-(4-ethylphenyl)phenyl]methyl]ethane-1,2-diamine Chemical compound C1=CC(CNCCN(CC)CC)=CC=C1C1=CC=C(CC)C=C1 GVDKZRPJKZYAIF-UHFFFAOYSA-N 0.000 description 2
- KTELWSKXVCQECI-UHFFFAOYSA-N n',n'-diethyl-n-[[4-(4-methylphenyl)phenyl]methyl]ethane-1,2-diamine Chemical compound C1=CC(CNCCN(CC)CC)=CC=C1C1=CC=C(C)C=C1 KTELWSKXVCQECI-UHFFFAOYSA-N 0.000 description 2
- XOVQTVDGYFNHLM-UHFFFAOYSA-N n',n'-diethyl-n-[[4-(4-propan-2-ylphenyl)phenyl]methyl]ethane-1,2-diamine Chemical compound C1=CC(CNCCN(CC)CC)=CC=C1C1=CC=C(C(C)C)C=C1 XOVQTVDGYFNHLM-UHFFFAOYSA-N 0.000 description 2
- CIUJZOFJRGHVDD-UHFFFAOYSA-N n',n'-diethyl-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]propane-1,3-diamine Chemical compound C1=CC(CNCCCN(CC)CC)=CC=C1C1=CC=C(C(F)(F)F)C=C1 CIUJZOFJRGHVDD-UHFFFAOYSA-N 0.000 description 2
- OMTWYIPCPSYDIZ-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxo-1,8-naphthyridin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CSC1=CC(=O)C2=CC=CN=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 OMTWYIPCPSYDIZ-UHFFFAOYSA-N 0.000 description 2
- GXXDYQKXWMNSJG-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[[4-(3,4-dimethylphenyl)phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CSC1=CC(=O)C2=CC=CC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C)C(C)=C1 GXXDYQKXWMNSJG-UHFFFAOYSA-N 0.000 description 2
- VZHVRPGWKUMEDC-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[[4-(4-ethylphenyl)phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CSC1=CC(=O)C2=CC=CC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(CC)C=C1 VZHVRPGWKUMEDC-UHFFFAOYSA-N 0.000 description 2
- CYHQINLOZZLKQN-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[[4-(4-methylphenyl)phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CSC1=CC(=O)C2=CC=CC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C)C=C1 CYHQINLOZZLKQN-UHFFFAOYSA-N 0.000 description 2
- OIGNLJDPLFMGOR-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CSC1=CC(=O)C2=CC=CC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 OIGNLJDPLFMGOR-UHFFFAOYSA-N 0.000 description 2
- VGFAXSPCRDTLNS-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1CSC1=CC(=O)C2=CC=CC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 VGFAXSPCRDTLNS-UHFFFAOYSA-N 0.000 description 2
- YSZTXCDHGWPGMY-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-[[4-(4-ethylphenyl)phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CCC1=CC(=O)C2=CC=CC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(CC)C=C1 YSZTXCDHGWPGMY-UHFFFAOYSA-N 0.000 description 2
- JGIRTLOOZHFXCO-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-[[4-(4-methylphenyl)phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CCC1=CC(=O)C2=CC=CC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C)C=C1 JGIRTLOOZHFXCO-UHFFFAOYSA-N 0.000 description 2
- SMYFIILNNKNEOV-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-[[4-(4-propan-2-ylphenyl)phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CCC1=CC(=O)C2=CC=CC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(C)C)C=C1 SMYFIILNNKNEOV-UHFFFAOYSA-N 0.000 description 2
- WQIIROSNMNBCAO-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxothieno[3,4-b]pyridin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CCC1=CC(=O)C2=CSC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 WQIIROSNMNBCAO-UHFFFAOYSA-N 0.000 description 2
- NQVVNGLUYUASQR-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-5-ethyl-4-oxopyridin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1=C(CC)C(=O)C=C(CCC=2C(=C(F)C=CC=2)F)N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 NQVVNGLUYUASQR-UHFFFAOYSA-N 0.000 description 2
- AODSSUGFSXJMBT-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-7-methyl-4-oxo-1,8-naphthyridin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CCC1=CC(=O)C2=CC=C(C)N=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 AODSSUGFSXJMBT-UHFFFAOYSA-N 0.000 description 2
- HYQZKZFSLZGAOQ-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[4-oxo-2-[2-(2,3,4-trifluorophenyl)ethyl]quinolin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C(F)=C(F)C=1CCC1=CC(=O)C2=CC=CC=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 HYQZKZFSLZGAOQ-UHFFFAOYSA-N 0.000 description 2
- JRNJHAGMVMQQLC-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[6-[(2,3-difluorophenyl)methylsulfanyl]-2-methyl-4-oxopyrazolo[3,4-b]pyridin-7-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CSC1=CC(=O)C2=CN(C)N=C2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 JRNJHAGMVMQQLC-UHFFFAOYSA-N 0.000 description 2
- TZRWHBLZZRLWLO-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[6-[(2,3-difluorophenyl)methylsulfanyl]-4-oxothieno[2,3-b]pyridin-7-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=C(F)C=1CSC1=CC(=O)C=2C=CSC=2N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 TZRWHBLZZRLWLO-UHFFFAOYSA-N 0.000 description 2
- JQWVMQPMTCHLGX-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[6-[2-(2,3-difluorophenyl)ethyl]-2,3-dimethyl-4-oxopyridin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound CC1=C(C)C(=O)C=C(CCC=2C(=C(F)C=CC=2)F)N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 JQWVMQPMTCHLGX-UHFFFAOYSA-N 0.000 description 2
- DQUCTHMPYGARQV-UHFFFAOYSA-N n-[[4-(3,4-difluorophenyl)phenyl]methyl]-n',n'-diethylethane-1,2-diamine Chemical compound C1=CC(CNCCN(CC)CC)=CC=C1C1=CC=C(F)C(F)=C1 DQUCTHMPYGARQV-UHFFFAOYSA-N 0.000 description 2
- QKYUDNZPKJAYPS-UHFFFAOYSA-N n-[[4-(3,4-dimethylphenyl)phenyl]methyl]-n',n'-diethylethane-1,2-diamine Chemical compound C1=CC(CNCCN(CC)CC)=CC=C1C1=CC=C(C)C(C)=C1 QKYUDNZPKJAYPS-UHFFFAOYSA-N 0.000 description 2
- ZZORXACNBGYHOU-UHFFFAOYSA-N n-[[4-(4-chlorophenyl)phenyl]methyl]-1-(2-methoxyethyl)piperidin-4-amine Chemical compound C1CN(CCOC)CCC1NCC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1 ZZORXACNBGYHOU-UHFFFAOYSA-N 0.000 description 2
- HORLZUPQUPQCAV-UHFFFAOYSA-N n-[[4-(4-chlorophenyl)phenyl]methyl]-1-methylpiperidin-4-amine Chemical compound C1CN(C)CCC1NCC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1 HORLZUPQUPQCAV-UHFFFAOYSA-N 0.000 description 2
- JGESAIKZIJITDA-UHFFFAOYSA-N n-[[4-(4-chlorophenyl)phenyl]methyl]-1-propan-2-ylpiperidin-4-amine Chemical compound C1CN(C(C)C)CCC1NCC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1 JGESAIKZIJITDA-UHFFFAOYSA-N 0.000 description 2
- OVDABCVZSJHSCR-UHFFFAOYSA-N n-[[4-(4-chlorophenyl)phenyl]methyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-(1-ethylpiperidin-4-yl)acetamide Chemical compound C1CN(CC)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1 OVDABCVZSJHSCR-UHFFFAOYSA-N 0.000 description 2
- PJAMXJVRLYFNKT-UHFFFAOYSA-N n-[[4-(4-chlorophenyl)phenyl]methyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-(1-methylpiperidin-4-yl)acetamide Chemical compound C1CN(C)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1 PJAMXJVRLYFNKT-UHFFFAOYSA-N 0.000 description 2
- UIVCBOULXFLNQF-UHFFFAOYSA-N n-[[4-(4-chlorophenyl)phenyl]methyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-(1-propan-2-ylpiperidin-4-yl)acetamide Chemical compound C1CN(C(C)C)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1 UIVCBOULXFLNQF-UHFFFAOYSA-N 0.000 description 2
- SVORDYXGEQNQJN-UHFFFAOYSA-N n-[[4-(4-chlorophenyl)phenyl]methyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]-n-[1-(2-methoxyethyl)piperidin-4-yl]acetamide Chemical compound C1CN(CCOC)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1 SVORDYXGEQNQJN-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229940117953 phenylisothiocyanate Drugs 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- VOXQHFSJPYBZDJ-UHFFFAOYSA-N s-[(2,3-difluorophenyl)methyl] ethanethioate Chemical compound CC(=O)SCC1=CC=CC(F)=C1F VOXQHFSJPYBZDJ-UHFFFAOYSA-N 0.000 description 2
- 231100000489 sensitizer Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- TWLIBVAXRZNBQT-UHFFFAOYSA-N tert-butyl 4-[[2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]acetyl]-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 TWLIBVAXRZNBQT-UHFFFAOYSA-N 0.000 description 2
- YCOYFZBFVJLFIM-UHFFFAOYSA-N tert-butyl 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]acetyl]-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C(=O)CN1C2=NC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 YCOYFZBFVJLFIM-UHFFFAOYSA-N 0.000 description 2
- XTMQTVHPCUEULU-UHFFFAOYSA-N tert-butyl 5-(2,3-difluorophenyl)-3-oxopentanoate Chemical compound CC(C)(C)OC(=O)CC(=O)CCC1=CC=CC(F)=C1F XTMQTVHPCUEULU-UHFFFAOYSA-N 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- KSASJELKLBIMSG-UHFFFAOYSA-N 1,2-difluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1F KSASJELKLBIMSG-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- PQJOSEVTIKYWLH-UHFFFAOYSA-N 1-iodo-4-propan-2-ylbenzene Chemical compound CC(C)C1=CC=C(I)C=C1 PQJOSEVTIKYWLH-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FGFBEHFJSQBISW-UHFFFAOYSA-N 1h-cyclopenta[b]pyridine Chemical compound C1=CNC2=CC=CC2=C1 FGFBEHFJSQBISW-UHFFFAOYSA-N 0.000 description 1
- UNXFCQGFUJLIOR-UHFFFAOYSA-N 1h-pyrido[4,3-d][1,3]oxazine-2,4-dione Chemical compound C1=NC=C2C(=O)OC(=O)NC2=C1 UNXFCQGFUJLIOR-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- YDIYSACLEQVWBZ-UHFFFAOYSA-N 2-[2-(2,4-difluorophenyl)ethyl]-1h-quinolin-4-one Chemical compound FC1=CC(F)=CC=C1CCC1=CC(=O)C2=CC=CC=C2N1 YDIYSACLEQVWBZ-UHFFFAOYSA-N 0.000 description 1
- OFKUXPNWVAXBSD-UHFFFAOYSA-N 2-[2-(3,4-difluorophenyl)ethyl]-1h-quinolin-4-one Chemical compound C1=C(F)C(F)=CC=C1CCC1=CC(=O)C2=CC=CC=C2N1 OFKUXPNWVAXBSD-UHFFFAOYSA-N 0.000 description 1
- FWAXTYXGKZJMCR-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxo-1,8-naphthyridin-1-yl]-n-piperidin-4-yl-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.FC1=CC=CC(CSC=2N(C3=NC=CC=C3C(=O)C=2)CC(=O)N(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)C2CCNCC2)=C1F FWAXTYXGKZJMCR-UHFFFAOYSA-N 0.000 description 1
- GXTVFRBWTQWJBE-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[1-(2-methoxyethyl)piperidin-4-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C1CN(CCOC)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 GXTVFRBWTQWJBE-UHFFFAOYSA-N 0.000 description 1
- DPNQTHASWPPFLT-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[4-(2-methoxyethyl)piperidin-4-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(C=2C=CC(=CC=2)C(F)(F)F)C=CC=1CN(C(=O)CN1C2=CC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)C1(CCOC)CCNCC1 DPNQTHASWPPFLT-UHFFFAOYSA-N 0.000 description 1
- VHOJCRQTWRQXLT-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]-n-[1-(2-methoxyethyl)piperidin-4-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide;hydrochloride Chemical compound Cl.C1CN(CCOC)CCC1N(C(=O)CN1C2=NC=CC=C2C(=O)C=C1CCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 VHOJCRQTWRQXLT-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WTOIOLZTTAONAK-UHFFFAOYSA-N 2-[5-[2-(2,3-difluorophenyl)ethyl]-2-methyl-7-oxopyrazolo[4,3-b]pyridin-4-yl]acetic acid Chemical compound C=1C(=O)C2=NN(C)C=C2N(CC(O)=O)C=1CCC1=CC=CC(F)=C1F WTOIOLZTTAONAK-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- QOGHRLGTXVMRLM-UHFFFAOYSA-N 4-bromo-1,2-dimethylbenzene Chemical group CC1=CC=C(Br)C=C1C QOGHRLGTXVMRLM-UHFFFAOYSA-N 0.000 description 1
- HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 1
- HQAIROMRVBVWSK-UHFFFAOYSA-N 4-chloro-2-methylquinoline Chemical compound C1=CC=CC2=NC(C)=CC(Cl)=C21 HQAIROMRVBVWSK-UHFFFAOYSA-N 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XORHNJQEWQGXCN-UHFFFAOYSA-N 4-nitro-1h-pyrazole Chemical compound [O-][N+](=O)C=1C=NNC=1 XORHNJQEWQGXCN-UHFFFAOYSA-N 0.000 description 1
- GBBPFLCLIBNHQO-UHFFFAOYSA-N 5,6-dihydro-4h-cyclopenta[c]furan-1,3-dione Chemical compound C1CCC2=C1C(=O)OC2=O GBBPFLCLIBNHQO-UHFFFAOYSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical class C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- QUXLCYFNVNNRBE-UHFFFAOYSA-N 6-methylpyridin-2-amine Chemical compound CC1=CC=CC(N)=N1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ZVJIFLRFYOEQMK-UHFFFAOYSA-N C.COCCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 Chemical compound C.COCCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 ZVJIFLRFYOEQMK-UHFFFAOYSA-N 0.000 description 1
- NZXMUHMUQYAQGO-UHFFFAOYSA-N C=CCOC1=C2CCCC2=[N+]([O-])C(Cl)=C1 Chemical compound C=CCOC1=C2CCCC2=[N+]([O-])C(Cl)=C1 NZXMUHMUQYAQGO-UHFFFAOYSA-N 0.000 description 1
- KZYBYEWEMRTWIL-UHFFFAOYSA-N C=CCOC1=C2CCCC2=[N+]([O-])C(SCC2=CC=C(F)C=C2)=C1 Chemical compound C=CCOC1=C2CCCC2=[N+]([O-])C(SCC2=CC=C(F)C=C2)=C1 KZYBYEWEMRTWIL-UHFFFAOYSA-N 0.000 description 1
- IHYAWQQCSITQDF-UHFFFAOYSA-N C=CCOC1=CC(Cl)=NC2=C1C=CC=C2 Chemical compound C=CCOC1=CC(Cl)=NC2=C1C=CC=C2 IHYAWQQCSITQDF-UHFFFAOYSA-N 0.000 description 1
- WVPGTRLYMATPFK-UHFFFAOYSA-N C=CCOC1=CC(Cl)=NC2=C1CCC2 Chemical compound C=CCOC1=CC(Cl)=NC2=C1CCC2 WVPGTRLYMATPFK-UHFFFAOYSA-N 0.000 description 1
- UKJQGGXJBKOQQN-UHFFFAOYSA-N C=CCOC1=CC(SCC2=C(F)C(F)=CC=C2)=NC2=C1C=CC=C2 Chemical compound C=CCOC1=CC(SCC2=C(F)C(F)=CC=C2)=NC2=C1C=CC=C2 UKJQGGXJBKOQQN-UHFFFAOYSA-N 0.000 description 1
- NMVKDBPVCJMHFX-UHFFFAOYSA-N C=CCOC1=CC(SCC2=C(F)C(F)=CC=C2)=[N+]([O-])C2=C1CCC2 Chemical compound C=CCOC1=CC(SCC2=C(F)C(F)=CC=C2)=[N+]([O-])C2=C1CCC2 NMVKDBPVCJMHFX-UHFFFAOYSA-N 0.000 description 1
- RZVALTUYSXWQMQ-UHFFFAOYSA-N C=CCOC1=CC(SCC2=CC=C(F)C=C2)=NC2=C1C=CC=C2 Chemical compound C=CCOC1=CC(SCC2=CC=C(F)C=C2)=NC2=C1C=CC=C2 RZVALTUYSXWQMQ-UHFFFAOYSA-N 0.000 description 1
- KTPXGBNGXUJLSK-UHFFFAOYSA-N CC(=O)N1CCC(NCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)CC1 Chemical compound CC(=O)N1CCC(NCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)CC1 KTPXGBNGXUJLSK-UHFFFAOYSA-N 0.000 description 1
- VZHKRWMHFRDOQL-UHFFFAOYSA-N CC(C)(C)OC(=O)C1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2N=CC=C3)CC1 Chemical compound CC(C)(C)OC(=O)C1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2N=CC=C3)CC1 VZHKRWMHFRDOQL-UHFFFAOYSA-N 0.000 description 1
- AGZLJYNMHUEPDM-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 AGZLJYNMHUEPDM-UHFFFAOYSA-N 0.000 description 1
- XQSGXDJFFHAZES-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 XQSGXDJFFHAZES-UHFFFAOYSA-N 0.000 description 1
- CLNQUVJQSKSRRJ-UHFFFAOYSA-N CC(C)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 Chemical compound CC(C)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 CLNQUVJQSKSRRJ-UHFFFAOYSA-N 0.000 description 1
- IDAJIBIIHVPXSC-UHFFFAOYSA-N CC(C)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2N=CC=C3)CC1 Chemical compound CC(C)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2N=CC=C3)CC1 IDAJIBIIHVPXSC-UHFFFAOYSA-N 0.000 description 1
- HWCUEBFIQFKENW-UHFFFAOYSA-N CC(C)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 Chemical compound CC(C)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 HWCUEBFIQFKENW-UHFFFAOYSA-N 0.000 description 1
- MFKRKHZHTCNJSY-UHFFFAOYSA-N CC(C)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 Chemical compound CC(C)N1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 MFKRKHZHTCNJSY-UHFFFAOYSA-N 0.000 description 1
- WIPUGVSOKUZDBU-UHFFFAOYSA-N CC1=CC2=C(S1)C(=O)C=C(CCC1=C(F)C(F)=CC=C1)N2CC(=O)O Chemical compound CC1=CC2=C(S1)C(=O)C=C(CCC1=C(F)C(F)=CC=C1)N2CC(=O)O WIPUGVSOKUZDBU-UHFFFAOYSA-N 0.000 description 1
- FDGABPBFMZUJGD-UHFFFAOYSA-N CC1=CC2=C(S1)C(=O)OC(=O)N2 Chemical compound CC1=CC2=C(S1)C(=O)OC(=O)N2 FDGABPBFMZUJGD-UHFFFAOYSA-N 0.000 description 1
- HCRYACBXOWPPEH-UHFFFAOYSA-N CC1=CC=CC2=NC(CCC3=C(F)C(F)=CC=C3)=CC(=O)N12 Chemical compound CC1=CC=CC2=NC(CCC3=C(F)C(F)=CC=C3)=CC(=O)N12 HCRYACBXOWPPEH-UHFFFAOYSA-N 0.000 description 1
- NYOKHFHOJGQHSV-UHFFFAOYSA-N CC1=NC2=C(C=C1)C(=O)C=C(CCC1=C(F)C(F)=CC=C1)N2 Chemical compound CC1=NC2=C(C=C1)C(=O)C=C(CCC1=C(F)C(F)=CC=C1)N2 NYOKHFHOJGQHSV-UHFFFAOYSA-N 0.000 description 1
- FVPHZZFYLUPHSC-UHFFFAOYSA-N CC1=NC2=C(S1)C(=O)C=C(CCC1=C(F)C(F)=CC=C1)N2CC(=O)N(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C1CCN(C(C)C)CC1 Chemical compound CC1=NC2=C(S1)C(=O)C=C(CCC1=C(F)C(F)=CC=C1)N2CC(=O)N(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C1CCN(C(C)C)CC1 FVPHZZFYLUPHSC-UHFFFAOYSA-N 0.000 description 1
- FHUGEYMJUPDSFR-UHFFFAOYSA-N CC1=NC2=C(S1)C(=O)OC(=O)N2 Chemical compound CC1=NC2=C(S1)C(=O)OC(=O)N2 FHUGEYMJUPDSFR-UHFFFAOYSA-N 0.000 description 1
- ZWLQUJOKMVNYCA-UHFFFAOYSA-M CCCCCCCCCCOCC(CC(=O)[O-])OC(=O)CCCC(=O)OC1=CC=C([N+](=O)[O-])C=C1 Chemical compound CCCCCCCCCCOCC(CC(=O)[O-])OC(=O)CCCC(=O)OC1=CC=C([N+](=O)[O-])C=C1 ZWLQUJOKMVNYCA-UHFFFAOYSA-M 0.000 description 1
- VIQWKIQTXIZDSU-UHFFFAOYSA-N CCN(CC)CCCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN(CC)CCCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 VIQWKIQTXIZDSU-UHFFFAOYSA-N 0.000 description 1
- VNJYAFTZVQZKHD-UHFFFAOYSA-N CCN(CC)CCCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN(CC)CCCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 VNJYAFTZVQZKHD-UHFFFAOYSA-N 0.000 description 1
- VKVYDJLFDSAHMJ-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC(F)=C(F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC(F)=C(F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 VKVYDJLFDSAHMJ-UHFFFAOYSA-N 0.000 description 1
- JRGZAZUMAARYEB-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=C(C)S2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=C(C)S2 JRGZAZUMAARYEB-UHFFFAOYSA-N 0.000 description 1
- YEMFSGMYVNHQHO-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 YEMFSGMYVNHQHO-UHFFFAOYSA-N 0.000 description 1
- VMKOOCCTXCYNDB-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCCC2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCCC2 VMKOOCCTXCYNDB-UHFFFAOYSA-N 0.000 description 1
- OGJAHFHWHSVANG-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1N=CC=C2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1N=CC=C2 OGJAHFHWHSVANG-UHFFFAOYSA-N 0.000 description 1
- KXPSYGPJKMTLCG-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 KXPSYGPJKMTLCG-UHFFFAOYSA-N 0.000 description 1
- HQSZDOZSTNRLTI-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C=CC=C2)=CC(=O)C2=C1C=CC=C2 HQSZDOZSTNRLTI-UHFFFAOYSA-N 0.000 description 1
- YMFKNUVTDSTAIM-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=CC(Cl)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=CC(Cl)=CC=C2)=CC(=O)C2=C1C=CC=C2 YMFKNUVTDSTAIM-UHFFFAOYSA-N 0.000 description 1
- NMXPQYSZNQDZBG-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=CC(F)=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=CC(F)=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 NMXPQYSZNQDZBG-UHFFFAOYSA-N 0.000 description 1
- OOYZDDHBYNSFCK-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=CC(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=CC(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 OOYZDDHBYNSFCK-UHFFFAOYSA-N 0.000 description 1
- VWOHPGRRVXLDNR-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=CC=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=CC=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 VWOHPGRRVXLDNR-UHFFFAOYSA-N 0.000 description 1
- KZYCWCUSGASIRI-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=CC=CC(F)=C2F)=CC(=O)C2=CN(C)N=C21 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=CC=CC(F)=C2F)=CC(=O)C2=CN(C)N=C21 KZYCWCUSGASIRI-UHFFFAOYSA-N 0.000 description 1
- YCDUPLPBFGQVDF-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=C(F)C=C2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=C(F)C=C2 YCDUPLPBFGQVDF-UHFFFAOYSA-N 0.000 description 1
- CMMRPTRJIXWLBX-UHFFFAOYSA-N CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=CC=C(F)C=C2)=CC(=O)C2=C1CCC2 Chemical compound CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=CC=C(F)C=C2)=CC(=O)C2=C1CCC2 CMMRPTRJIXWLBX-UHFFFAOYSA-N 0.000 description 1
- HSGIPNYEYVAKRK-UHFFFAOYSA-N CCN(CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2)C(C)=O Chemical compound CCN(CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2)C(C)=O HSGIPNYEYVAKRK-UHFFFAOYSA-N 0.000 description 1
- UHSVXNOWXQEVBC-UHFFFAOYSA-N CCN(CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2)C(C)=O Chemical compound CCN(CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2)C(C)=O UHSVXNOWXQEVBC-UHFFFAOYSA-N 0.000 description 1
- NJVOIJNACSWEMK-UHFFFAOYSA-N CCN(CCNCC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(C)=O Chemical compound CCN(CCNCC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(C)=O NJVOIJNACSWEMK-UHFFFAOYSA-N 0.000 description 1
- QZEQOZKGHODJDY-UHFFFAOYSA-N CCN1C(CCC2=C(F)C(F)=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN1C(CCC2=C(F)C(F)=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 QZEQOZKGHODJDY-UHFFFAOYSA-N 0.000 description 1
- HPXSMXCHZVCGHD-UHFFFAOYSA-N CCN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 HPXSMXCHZVCGHD-UHFFFAOYSA-N 0.000 description 1
- KALYDCJVVVTKBD-UHFFFAOYSA-N CCN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=NN2C Chemical compound CCN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=NN2C KALYDCJVVVTKBD-UHFFFAOYSA-N 0.000 description 1
- QHQOBWNKOMAGIJ-UHFFFAOYSA-N CCN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=NN(C)C=C21 Chemical compound CCN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=NN(C)C=C21 QHQOBWNKOMAGIJ-UHFFFAOYSA-N 0.000 description 1
- OANOCPFBKZVGHP-UHFFFAOYSA-N CCN1C(CCC2=C(F)C=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN1C(CCC2=C(F)C=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 OANOCPFBKZVGHP-UHFFFAOYSA-N 0.000 description 1
- ZYQAOKHOBKMTLS-UHFFFAOYSA-N CCN1C(CCC2=C(F)C=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN1C(CCC2=C(F)C=CC=C2)=CC(=O)C2=C1C=CC=C2 ZYQAOKHOBKMTLS-UHFFFAOYSA-N 0.000 description 1
- NZFGONICFFUAAX-UHFFFAOYSA-N CCN1C(CCC2=CC(Cl)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN1C(CCC2=CC(Cl)=CC=C2)=CC(=O)C2=C1C=CC=C2 NZFGONICFFUAAX-UHFFFAOYSA-N 0.000 description 1
- YUHPSADLKYUCAE-UHFFFAOYSA-N CCN1C(CCC2=CC(F)=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN1C(CCC2=CC(F)=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 YUHPSADLKYUCAE-UHFFFAOYSA-N 0.000 description 1
- XGOHYYWSEJRAMR-UHFFFAOYSA-N CCN1C(CCC2=CC(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN1C(CCC2=CC(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 XGOHYYWSEJRAMR-UHFFFAOYSA-N 0.000 description 1
- VHZOZNLZLKZWJM-UHFFFAOYSA-N CCN1C(CCC2=CC=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN1C(CCC2=CC=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 VHZOZNLZLKZWJM-UHFFFAOYSA-N 0.000 description 1
- HURVOUXXXICALX-UHFFFAOYSA-N CCN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 HURVOUXXXICALX-UHFFFAOYSA-N 0.000 description 1
- ZPOUIZNJBJLXKJ-UHFFFAOYSA-N CCN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 Chemical compound CCN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 ZPOUIZNJBJLXKJ-UHFFFAOYSA-N 0.000 description 1
- VBWNPIXPHYLYMC-UHFFFAOYSA-N CCN1C(SCC2=CC=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCN1C(SCC2=CC=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 VBWNPIXPHYLYMC-UHFFFAOYSA-N 0.000 description 1
- RSDTWKONVUXBBB-UHFFFAOYSA-N CCN1C(SCC2=CC=C(F)C=C2)=CC(=O)C2=C1CCC2 Chemical compound CCN1C(SCC2=CC=C(F)C=C2)=CC(=O)C2=C1CCC2 RSDTWKONVUXBBB-UHFFFAOYSA-N 0.000 description 1
- NSESQMNDDIYRDK-UHFFFAOYSA-N CCN1C=C2C(=O)C=C(CCC3=C(F)C(F)=CC=C3)N(CC(=O)O)C2=N1 Chemical compound CCN1C=C2C(=O)C=C(CCC3=C(F)C(F)=CC=C3)N(CC(=O)O)C2=N1 NSESQMNDDIYRDK-UHFFFAOYSA-N 0.000 description 1
- IBRRVQPBUQKOKJ-UHFFFAOYSA-N CCN1CCC(CCN(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=CC=CC(F)=C3F)=CC(=O)C3=CN(CCOC)N=C32)CC1 Chemical compound CCN1CCC(CCN(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=CC=CC(F)=C3F)=CC(=O)C3=CN(CCOC)N=C32)CC1 IBRRVQPBUQKOKJ-UHFFFAOYSA-N 0.000 description 1
- YKRGTEGLOCUKOO-UHFFFAOYSA-N CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=C(F)C=C3)=CC(=O)C3=C2C=CC=C3)CC1 Chemical compound CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=C(F)C=C3)=CC(=O)C3=C2C=CC=C3)CC1 YKRGTEGLOCUKOO-UHFFFAOYSA-N 0.000 description 1
- FWQUBVLQAGQEGZ-UHFFFAOYSA-N CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 Chemical compound CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 FWQUBVLQAGQEGZ-UHFFFAOYSA-N 0.000 description 1
- ZRZNXBNFFZRSOG-UHFFFAOYSA-N CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2N=CC=C3)CC1 Chemical compound CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2N=CC=C3)CC1 ZRZNXBNFFZRSOG-UHFFFAOYSA-N 0.000 description 1
- ISPYBGMNPYDORW-UHFFFAOYSA-N CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=CN(C)N=C32)CC1 Chemical compound CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=CN(C)N=C32)CC1 ISPYBGMNPYDORW-UHFFFAOYSA-N 0.000 description 1
- NBAQRWAJBLBCSL-UHFFFAOYSA-N CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 Chemical compound CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 NBAQRWAJBLBCSL-UHFFFAOYSA-N 0.000 description 1
- ZNJROCWWYVMJNR-UHFFFAOYSA-N CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 Chemical compound CCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 ZNJROCWWYVMJNR-UHFFFAOYSA-N 0.000 description 1
- IDBWSKXXRLKDOQ-UHFFFAOYSA-N CCN1CCC(NCC2=CC=C(C3=CC=C(Cl)C=C3)C=C2)CC1 Chemical compound CCN1CCC(NCC2=CC=C(C3=CC=C(Cl)C=C3)C=C2)CC1 IDBWSKXXRLKDOQ-UHFFFAOYSA-N 0.000 description 1
- SMFTXHSXHSPTKL-UHFFFAOYSA-N CCNCCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCNCCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 SMFTXHSXHSPTKL-UHFFFAOYSA-N 0.000 description 1
- AXDUKXDLJWNZGT-UHFFFAOYSA-N CCNCCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCNCCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 AXDUKXDLJWNZGT-UHFFFAOYSA-N 0.000 description 1
- XBJSBDBQCNUSFZ-XYOKQWHBSA-N CCOC(=O)/C=C(\CCC1=C(F)C(F)=CC=C1)NC1=CNN=C1 Chemical compound CCOC(=O)/C=C(\CCC1=C(F)C(F)=CC=C1)NC1=CNN=C1 XBJSBDBQCNUSFZ-XYOKQWHBSA-N 0.000 description 1
- SPUQDUACWSLYHQ-UHFFFAOYSA-N CCOC(=O)CC(=O)CCC1=CC=CC(F)=C1F Chemical compound CCOC(=O)CC(=O)CCC1=CC=CC(F)=C1F SPUQDUACWSLYHQ-UHFFFAOYSA-N 0.000 description 1
- IPDJRXWFAUWFDH-UHFFFAOYSA-N CCOC(=O)CN(C1=CC=CC=C1)C(SCC1=C(F)C(F)=CC=C1)=C1C(=O)OC(C)(C)OC1=O Chemical compound CCOC(=O)CN(C1=CC=CC=C1)C(SCC1=C(F)C(F)=CC=C1)=C1C(=O)OC(C)(C)OC1=O IPDJRXWFAUWFDH-UHFFFAOYSA-N 0.000 description 1
- OQUFMJAQTUVFGF-UHFFFAOYSA-N CCOC(=O)CN1C(=O)OC(=O)C2=C1C=C(F)C=C2 Chemical compound CCOC(=O)CN1C(=O)OC(=O)C2=C1C=C(F)C=C2 OQUFMJAQTUVFGF-UHFFFAOYSA-N 0.000 description 1
- BJXASEMAFRGURB-UHFFFAOYSA-N CCOC(=O)CN1C(=O)OC(=O)C2=C1CCC2 Chemical compound CCOC(=O)CN1C(=O)OC(=O)C2=C1CCC2 BJXASEMAFRGURB-UHFFFAOYSA-N 0.000 description 1
- KPHKCAXRHLFURU-UHFFFAOYSA-N CCOC(=O)CN1C(=O)OC(=O)C2=C1CCCC2 Chemical compound CCOC(=O)CN1C(=O)OC(=O)C2=C1CCCC2 KPHKCAXRHLFURU-UHFFFAOYSA-N 0.000 description 1
- ZUKGAFNEKLKVIY-UHFFFAOYSA-N CCOC(=O)CN1C(=O)OC(=O)C2=C1N=C(C)S2 Chemical compound CCOC(=O)CN1C(=O)OC(=O)C2=C1N=C(C)S2 ZUKGAFNEKLKVIY-UHFFFAOYSA-N 0.000 description 1
- MJJWNZKUZSOEIM-UHFFFAOYSA-N CCOC(=O)CN1C(C)=C(C)C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 Chemical compound CCOC(=O)CN1C(C)=C(C)C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 MJJWNZKUZSOEIM-UHFFFAOYSA-N 0.000 description 1
- NDILOMGYWSOPRK-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=C(C(C)=O)C(=O)C2=C1N=C(C)S2 Chemical compound CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=C(C(C)=O)C(=O)C2=C1N=C(C)S2 NDILOMGYWSOPRK-UHFFFAOYSA-N 0.000 description 1
- XCUSUIVNLIOYMJ-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=C(C)S2 Chemical compound CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=C(C)S2 XCUSUIVNLIOYMJ-UHFFFAOYSA-N 0.000 description 1
- RPEGNBQGLQNWBF-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 Chemical compound CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 RPEGNBQGLQNWBF-UHFFFAOYSA-N 0.000 description 1
- TVOCYGRPTAHMAO-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCCC2 Chemical compound CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCCC2 TVOCYGRPTAHMAO-UHFFFAOYSA-N 0.000 description 1
- LASSOPHEFBUFRP-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1NN=C2 Chemical compound CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1NN=C2 LASSOPHEFBUFRP-UHFFFAOYSA-N 0.000 description 1
- WPJZGNCEUPFFBO-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(C(C)C)N=C21 Chemical compound CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(C(C)C)N=C21 WPJZGNCEUPFFBO-UHFFFAOYSA-N 0.000 description 1
- GSVZOGGBLNYPNK-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(CC)N=C21 Chemical compound CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(CC)N=C21 GSVZOGGBLNYPNK-UHFFFAOYSA-N 0.000 description 1
- HGEGYXPVWXQIET-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(CC3=CC=C(OC)C=C3)N=C21 Chemical compound CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(CC3=CC=C(OC)C=C3)N=C21 HGEGYXPVWXQIET-UHFFFAOYSA-N 0.000 description 1
- REJLVKGJVUEZCP-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(CCOC)N=C21 Chemical compound CCOC(=O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(CCOC)N=C21 REJLVKGJVUEZCP-UHFFFAOYSA-N 0.000 description 1
- NUPMIEGIMAMNIZ-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=CC=CC(F)=C2F)=C(C(C)=O)C(=O)C2=C1N=CC=C2 Chemical compound CCOC(=O)CN1C(CCC2=CC=CC(F)=C2F)=C(C(C)=O)C(=O)C2=C1N=CC=C2 NUPMIEGIMAMNIZ-UHFFFAOYSA-N 0.000 description 1
- ABBXDJIUYSLRTA-UHFFFAOYSA-N CCOC(=O)CN1C(CCC2=CC=CC(F)=C2F)=CC(=O)C2=C1N=CC=C2 Chemical compound CCOC(=O)CN1C(CCC2=CC=CC(F)=C2F)=CC(=O)C2=C1N=CC=C2 ABBXDJIUYSLRTA-UHFFFAOYSA-N 0.000 description 1
- RXMVKKNFYSCJLE-UHFFFAOYSA-N CCOC(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound CCOC(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2 RXMVKKNFYSCJLE-UHFFFAOYSA-N 0.000 description 1
- CLECWMBYVIGNBR-UHFFFAOYSA-N CCOC(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1SC=C2 Chemical compound CCOC(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1SC=C2 CLECWMBYVIGNBR-UHFFFAOYSA-N 0.000 description 1
- NPESIZSBKCBUPF-UHFFFAOYSA-N CCOC(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(C)C=C21 Chemical compound CCOC(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=CN(C)C=C21 NPESIZSBKCBUPF-UHFFFAOYSA-N 0.000 description 1
- PEMALUTXIQCKDT-UHFFFAOYSA-N CCOC(=O)CN1C2=C(CCCC2)C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 Chemical compound CCOC(=O)CN1C2=C(CCCC2)C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 PEMALUTXIQCKDT-UHFFFAOYSA-N 0.000 description 1
- GNYQBIXGVDWFOU-UHFFFAOYSA-N CCOC(=O)CN1C2=C(SC(C)=C2)C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 Chemical compound CCOC(=O)CN1C2=C(SC(C)=C2)C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 GNYQBIXGVDWFOU-UHFFFAOYSA-N 0.000 description 1
- SMCFBHQNHLAPRN-UHFFFAOYSA-N CCOC(=O)CN1C2=CSC=C2C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 Chemical compound CCOC(=O)CN1C2=CSC=C2C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 SMCFBHQNHLAPRN-UHFFFAOYSA-N 0.000 description 1
- ZFSBIHOSGMBPEA-UHFFFAOYSA-N CCOC(=O)CN1C2=NN(C)C=C2C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 Chemical compound CCOC(=O)CN1C2=NN(C)C=C2C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 ZFSBIHOSGMBPEA-UHFFFAOYSA-N 0.000 description 1
- LZOVRLYUZWHVJZ-UHFFFAOYSA-N CCOC(=O)CN1C=C(CC)C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 Chemical compound CCOC(=O)CN1C=C(CC)C(=O)C(C(C)=O)=C1CCC1=C(F)C(F)=CC=C1 LZOVRLYUZWHVJZ-UHFFFAOYSA-N 0.000 description 1
- JQODGRDGRSYPAO-UHFFFAOYSA-N CCOC(=O)CN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 Chemical compound CCOC(=O)CN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 JQODGRDGRSYPAO-UHFFFAOYSA-N 0.000 description 1
- PALCONIENIHOCD-UHFFFAOYSA-O CCOC(=O)CNC1=C(C(=O)C[S+](C)(C)=O)C=CC=N1 Chemical compound CCOC(=O)CNC1=C(C(=O)C[S+](C)(C)=O)C=CC=N1 PALCONIENIHOCD-UHFFFAOYSA-O 0.000 description 1
- XNRZDIVTSZXRPK-UHFFFAOYSA-O CCOC(=O)CNC1=C(C(=O)C[S+](C)(C)=O)C=CS1 Chemical compound CCOC(=O)CNC1=C(C(=O)C[S+](C)(C)=O)C=CS1 XNRZDIVTSZXRPK-UHFFFAOYSA-O 0.000 description 1
- WCMPZMRPXQPCNC-UHFFFAOYSA-O CCOC(=O)CNC1=C(C(=O)C[S+](C)(C)=O)SC=C1 Chemical compound CCOC(=O)CNC1=C(C(=O)C[S+](C)(C)=O)SC=C1 WCMPZMRPXQPCNC-UHFFFAOYSA-O 0.000 description 1
- LFIUFOMCRROJIB-UHFFFAOYSA-N CCOC(=O)CNC1=C(C(=O)[CH-][S+](C)(C)=O)C=CC=C1 Chemical compound CCOC(=O)CNC1=C(C(=O)[CH-][S+](C)(C)=O)C=CC=C1 LFIUFOMCRROJIB-UHFFFAOYSA-N 0.000 description 1
- ZRIKKGJEWYVFOS-UHFFFAOYSA-N CCOC(=O)CNC1=NN(C)C=C1C(=O)C[S+](C)(C)=O Chemical compound CCOC(=O)CNC1=NN(C)C=C1C(=O)C[S+](C)(C)=O ZRIKKGJEWYVFOS-UHFFFAOYSA-N 0.000 description 1
- TVNXSDYZIWIICU-UHFFFAOYSA-O CCOC(CNc(cc(cc1)F)c1C(C[S+](C)(C)=O)=O)=O Chemical compound CCOC(CNc(cc(cc1)F)c1C(C[S+](C)(C)=O)=O)=O TVNXSDYZIWIICU-UHFFFAOYSA-O 0.000 description 1
- TTZNBYAFGOSGPU-UHFFFAOYSA-N CN1C=C2C(=O)C=C(CCC3=C(F)C(F)=CC=C3)N(CC(=O)O)C2=C1 Chemical compound CN1C=C2C(=O)C=C(CCC3=C(F)C(F)=CC=C3)N(CC(=O)O)C2=C1 TTZNBYAFGOSGPU-UHFFFAOYSA-N 0.000 description 1
- KADDEFSMXCNEPA-UHFFFAOYSA-N CN1C=C2N=C(CCC3=C(F)C(F)=CC=C3)C=C(Cl)C2=N1.CN1N=CC2=C1C(Cl)=CC(CCC1=C(F)C(F)=CC=C1)=N2 Chemical compound CN1C=C2N=C(CCC3=C(F)C(F)=CC=C3)C=C(Cl)C2=N1.CN1N=CC2=C1C(Cl)=CC(CCC1=C(F)C(F)=CC=C1)=N2 KADDEFSMXCNEPA-UHFFFAOYSA-N 0.000 description 1
- UBPCYUIQWHPVSY-UHFFFAOYSA-N CN1C=C2NC(CCC3=C(F)C(F)=CC=C3)=CC(=O)C2=N1 Chemical compound CN1C=C2NC(CCC3=C(F)C(F)=CC=C3)=CC(=O)C2=N1 UBPCYUIQWHPVSY-UHFFFAOYSA-N 0.000 description 1
- OXOUHNMGFNYBLV-UHFFFAOYSA-N CN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 Chemical compound CN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 OXOUHNMGFNYBLV-UHFFFAOYSA-N 0.000 description 1
- TTWLYRMNCQLOMC-UHFFFAOYSA-N CN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 Chemical compound CN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 TTWLYRMNCQLOMC-UHFFFAOYSA-N 0.000 description 1
- NIXOXURBZLAQIP-UHFFFAOYSA-N CN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 Chemical compound CN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 NIXOXURBZLAQIP-UHFFFAOYSA-N 0.000 description 1
- CXCBFQUDYSDSKU-UHFFFAOYSA-N CN1CCC(NCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)CC1 Chemical compound CN1CCC(NCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)CC1 CXCBFQUDYSDSKU-UHFFFAOYSA-N 0.000 description 1
- XWVXEAZXIYMWMD-UHFFFAOYSA-N CN1N=CC2=C1C(=O)C=C(CCC1=C(F)C(F)=CC=C1)N2 Chemical compound CN1N=CC2=C1C(=O)C=C(CCC1=C(F)C(F)=CC=C1)N2 XWVXEAZXIYMWMD-UHFFFAOYSA-N 0.000 description 1
- YAOFEZMAPGMUPX-UHFFFAOYSA-N COC1=CC=C(CN2C=C3C(=O)OC(=O)NC3=N2)C=C1 Chemical compound COC1=CC=C(CN2C=C3C(=O)OC(=O)NC3=N2)C=C1 YAOFEZMAPGMUPX-UHFFFAOYSA-N 0.000 description 1
- JSGIAZIYXBDYLQ-UHFFFAOYSA-N COCCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 Chemical compound COCCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2C=CC=C3)CC1 JSGIAZIYXBDYLQ-UHFFFAOYSA-N 0.000 description 1
- KJZQKZKMRGGYPN-UHFFFAOYSA-N COCCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 Chemical compound COCCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(CCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2CCC3)CC1 KJZQKZKMRGGYPN-UHFFFAOYSA-N 0.000 description 1
- OPUJWWVHUADTIZ-UHFFFAOYSA-N COCCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2N=CC=C3)CC1 Chemical compound COCCN1CCC(N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(=O)CN2C(SCC3=C(F)C(F)=CC=C3)=CC(=O)C3=C2N=CC=C3)CC1 OPUJWWVHUADTIZ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 description 1
- ALHOIDFZNZGPBP-UHFFFAOYSA-N ClC1=CC=CC(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)=C1 Chemical compound ClC1=CC=CC(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)=C1 ALHOIDFZNZGPBP-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CXFYSEHJGXEGGB-UHFFFAOYSA-N FC1=C(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)C=CC=C1 Chemical compound FC1=C(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)C=CC=C1 CXFYSEHJGXEGGB-UHFFFAOYSA-N 0.000 description 1
- UTFMRGMIMNZKEU-UHFFFAOYSA-N FC1=C(F)C(F)=C(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)C=C1 Chemical compound FC1=C(F)C(F)=C(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)C=C1 UTFMRGMIMNZKEU-UHFFFAOYSA-N 0.000 description 1
- BFSHCLXBWWJAHC-UHFFFAOYSA-N FC1=C(F)C=C(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)C=C1 Chemical compound FC1=C(F)C=C(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)C=C1 BFSHCLXBWWJAHC-UHFFFAOYSA-N 0.000 description 1
- RKIDZKZHOOYNNR-UHFFFAOYSA-N FC1=CC(F)=C(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)C=C1 Chemical compound FC1=CC(F)=C(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)C=C1 RKIDZKZHOOYNNR-UHFFFAOYSA-N 0.000 description 1
- WPAFSQYOEQUMRU-UHFFFAOYSA-N FC1=CC=C(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)C=C1 Chemical compound FC1=CC=C(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)C=C1 WPAFSQYOEQUMRU-UHFFFAOYSA-N 0.000 description 1
- QYSFSOFWYPRLJL-UHFFFAOYSA-N FC1=CC=CC(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)=C1 Chemical compound FC1=CC=CC(CCC2=NC3=C(C=CC=C3)C(Cl)=C2)=C1 QYSFSOFWYPRLJL-UHFFFAOYSA-N 0.000 description 1
- RWGYLKKDEWQMPD-UHFFFAOYSA-N FC1=CC=CC(CCC2=NC3=CNN=C3C(Cl)=C2)=C1F Chemical compound FC1=CC=CC(CCC2=NC3=CNN=C3C(Cl)=C2)=C1F RWGYLKKDEWQMPD-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 125000000815 N-oxide group Chemical group 0.000 description 1
- RVNFCJGQVWHMKN-UHFFFAOYSA-N NCC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1 Chemical compound NCC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1 RVNFCJGQVWHMKN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- QELXQKWLGXROAL-UHFFFAOYSA-N O=C(O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 Chemical compound O=C(O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 QELXQKWLGXROAL-UHFFFAOYSA-N 0.000 description 1
- HXBWQCUSARPEJJ-UHFFFAOYSA-N O=C(O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCCC2 Chemical compound O=C(O)CN1C(CCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCCC2 HXBWQCUSARPEJJ-UHFFFAOYSA-N 0.000 description 1
- JQOCWYBQGVCAEQ-UHFFFAOYSA-N O=C(O)CN1C(CCC2=CC=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 Chemical compound O=C(O)CN1C(CCC2=CC=C(F)C=C2)=CC(=O)C2=C1C=CC=C2 JQOCWYBQGVCAEQ-UHFFFAOYSA-N 0.000 description 1
- IYAIKLNBDSPTLG-UHFFFAOYSA-N O=C(O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 Chemical compound O=C(O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1CCC2 IYAIKLNBDSPTLG-UHFFFAOYSA-N 0.000 description 1
- REZFQYAFHPQRQP-UHFFFAOYSA-N O=C(O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1SC=C2 Chemical compound O=C(O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1SC=C2 REZFQYAFHPQRQP-UHFFFAOYSA-N 0.000 description 1
- ZWGFMRMMVPOZTO-UHFFFAOYSA-N O=C(O)CN1C(SCC2=CC=C(F)C=C2)=CC(=O)C2=C1CCC2 Chemical compound O=C(O)CN1C(SCC2=CC=C(F)C=C2)=CC(=O)C2=C1CCC2 ZWGFMRMMVPOZTO-UHFFFAOYSA-N 0.000 description 1
- LIXPNMSMKGGBEJ-UHFFFAOYSA-N O=C1C=C(CCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2CCNCC2)C2=C1C=CC=C2 Chemical compound O=C1C=C(CCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2CCNCC2)C2=C1C=CC=C2 LIXPNMSMKGGBEJ-UHFFFAOYSA-N 0.000 description 1
- LGBZJFZUJSQKQU-UHFFFAOYSA-N O=C1C=C(CCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2CCNCC2)C2=C1CCC2 Chemical compound O=C1C=C(CCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2CCNCC2)C2=C1CCC2 LGBZJFZUJSQKQU-UHFFFAOYSA-N 0.000 description 1
- NZYHDODBOLDSNE-UHFFFAOYSA-N O=C1C=C(CCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CCCCN2CCCC2)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2=C1C=CC=C2 Chemical compound O=C1C=C(CCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CCCCN2CCCC2)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2=C1C=CC=C2 NZYHDODBOLDSNE-UHFFFAOYSA-N 0.000 description 1
- BNDFNXDZQSZTHZ-UHFFFAOYSA-N O=C1C=C(CCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CCN2CCCC2)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2=C1C=CC=C2 Chemical compound O=C1C=C(CCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CCN2CCCC2)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2=C1C=CC=C2 BNDFNXDZQSZTHZ-UHFFFAOYSA-N 0.000 description 1
- WGHANYPPQUCIRO-UHFFFAOYSA-N O=C1C=C(CCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CCN2CCCCC2)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2=C1C=CC=C2 Chemical compound O=C1C=C(CCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CCN2CCCCC2)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2=C1C=CC=C2 WGHANYPPQUCIRO-UHFFFAOYSA-N 0.000 description 1
- BSMZEZHIOXRNHW-UHFFFAOYSA-N O=C1C=C(CCC2=C(F)C(F)=CC=C2)NC2=C1C=CC=C2 Chemical compound O=C1C=C(CCC2=C(F)C(F)=CC=C2)NC2=C1C=CC=C2 BSMZEZHIOXRNHW-UHFFFAOYSA-N 0.000 description 1
- DGBSERBICZHGEV-UHFFFAOYSA-N O=C1C=C(CCC2=C(F)C(F)=CC=C2)NC2=CNN=C12 Chemical compound O=C1C=C(CCC2=C(F)C(F)=CC=C2)NC2=CNN=C12 DGBSERBICZHGEV-UHFFFAOYSA-N 0.000 description 1
- MJLAHIIWFZRDGQ-UHFFFAOYSA-N O=C1C=C(SCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2CCNCC2)C2=C1C=CC=N2 Chemical compound O=C1C=C(SCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2CCNCC2)C2=C1C=CC=N2 MJLAHIIWFZRDGQ-UHFFFAOYSA-N 0.000 description 1
- ROWZKNSZUCTXRD-UHFFFAOYSA-N O=C1C=C(SCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CCCCN2CCCC2)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2=C1C=CC=C2 Chemical compound O=C1C=C(SCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CCCCN2CCCC2)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2=C1C=CC=C2 ROWZKNSZUCTXRD-UHFFFAOYSA-N 0.000 description 1
- PGTMHJOCQIZDIE-UHFFFAOYSA-N O=C1C=C(SCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CCN2CCCC2)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2=C1C=CC=C2 Chemical compound O=C1C=C(SCC2=C(F)C(F)=CC=C2)N(CC(=O)N(CCN2CCCC2)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C2=C1C=CC=C2 PGTMHJOCQIZDIE-UHFFFAOYSA-N 0.000 description 1
- AWPODVWBJCGJFY-UHFFFAOYSA-N O=C1NC2=C(CCC2)C(=O)O1 Chemical compound O=C1NC2=C(CCC2)C(=O)O1 AWPODVWBJCGJFY-UHFFFAOYSA-N 0.000 description 1
- SEMIIYLLPWLNMR-UHFFFAOYSA-N O=C1NC2=C(CCCC2)C(=O)O1 Chemical compound O=C1NC2=C(CCCC2)C(=O)O1 SEMIIYLLPWLNMR-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- VCPGLJMOBJNJLF-UHFFFAOYSA-N [C-]#[N+]C1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1 Chemical compound [C-]#[N+]C1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1 VCPGLJMOBJNJLF-UHFFFAOYSA-N 0.000 description 1
- XYVUXHRPICEVIG-UHFFFAOYSA-N [O-][N+]1=C(SCC2=C(F)C(F)=CC=C2)C=C(O)C2=C1CCC2 Chemical compound [O-][N+]1=C(SCC2=C(F)C(F)=CC=C2)C=C(O)C2=C1CCC2 XYVUXHRPICEVIG-UHFFFAOYSA-N 0.000 description 1
- YHFFWMNAGQSGFX-UHFFFAOYSA-N [O-][N+]1=C2CCCC2=C(O)C=C1SCC1=CC=C(F)C=C1 Chemical compound [O-][N+]1=C2CCCC2=C(O)C=C1SCC1=CC=C(F)C=C1 YHFFWMNAGQSGFX-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N alpha-Butylen-alpha-carbonsaeure Natural products CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229940062310 avandia Drugs 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- DKWOHBPRFZIUQL-UHFFFAOYSA-N dimethyl-methylidene-oxo-$l^{6}-sulfane Chemical compound C[S+](C)([CH2-])=O DKWOHBPRFZIUQL-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- DOUCORPAKHZFHM-UHFFFAOYSA-N ethyl 2-(2,4-dioxo-3,1-benzoxazin-1-yl)acetate Chemical compound C1=CC=C2C(=O)OC(=O)N(CC(=O)OCC)C2=C1 DOUCORPAKHZFHM-UHFFFAOYSA-N 0.000 description 1
- NVVBDCZCKZAOKX-UHFFFAOYSA-N ethyl 2-[6-[(2,3-difluorophenyl)methylsulfanyl]-2-methyl-4-oxopyrazolo[3,4-b]pyridin-7-yl]acetate Chemical compound C=1C(=O)C2=CN(C)N=C2N(CC(=O)OCC)C=1SCC1=CC=CC(F)=C1F NVVBDCZCKZAOKX-UHFFFAOYSA-N 0.000 description 1
- AKFHWIDWJJYHDO-UHFFFAOYSA-N ethyl 2-[6-[2-(2,3-difluorophenyl)ethyl]-2-methyl-4-oxopyrazolo[3,4-b]pyridin-7-yl]acetate Chemical compound C=1C(=O)C2=CN(C)N=C2N(CC(=O)OCC)C=1CCC1=CC=CC(F)=C1F AKFHWIDWJJYHDO-UHFFFAOYSA-N 0.000 description 1
- FMEHILPGLKGSCA-UHFFFAOYSA-N ethyl 2-aminocyclopentene-1-carboxylate Chemical compound CCOC(=O)C1=C(N)CCC1 FMEHILPGLKGSCA-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- MCQOWYALZVKMAR-UHFFFAOYSA-N furo[3,4-b]pyridine-5,7-dione Chemical compound C1=CC=C2C(=O)OC(=O)C2=N1 MCQOWYALZVKMAR-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- FVKMOPIFLCMZMI-UHFFFAOYSA-N methyl 3-amino-5-methylthiophene-2-carboxylate Chemical compound COC(=O)C=1SC(C)=CC=1N FVKMOPIFLCMZMI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- QPPBAMCDNPQHKF-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-n-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-2-methyl-7-oxo-3h-thieno[3,2-b]pyridin-4-yl]-4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound CCN(CC)CCN(C(C)=O)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1N(C=1C2)C=CC(=O)C=1SC2(C)CCC1=CC=CC(F)=C1F QPPBAMCDNPQHKF-UHFFFAOYSA-N 0.000 description 1
- PFSYIUIQFFIRNP-UHFFFAOYSA-N n-[[4-(2-chlorophenyl)phenyl]methyl]-1-ethylpiperidin-4-amine Chemical compound C1CN(CC)CCC1NCC1=CC=C(C=2C(=CC=CC=2)Cl)C=C1 PFSYIUIQFFIRNP-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000012587 nuclear overhauser effect experiment Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- QRAHVUOEWDFCFA-UHFFFAOYSA-N oxazine-4,6-dione Chemical compound O=C1CC(=O)C=NO1 QRAHVUOEWDFCFA-UHFFFAOYSA-N 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical class NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000207 pro-atherogenic effect Effects 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000008318 pyrimidones Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- HBROZNQEVUILML-UHFFFAOYSA-N salicylhydroxamic acid Chemical compound ONC(=O)C1=CC=CC=C1O HBROZNQEVUILML-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- UQJLSMYQBOJUGG-UHFFFAOYSA-N tert-butyl 2,2,2-trifluoroacetate Chemical group CC(C)(C)OC(=O)C(F)(F)F UQJLSMYQBOJUGG-UHFFFAOYSA-N 0.000 description 1
- BRKRUKCBFPJFBN-UHFFFAOYSA-N tert-butyl 2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)OC(C)(C)C)C=1SCC1=CC=C(F)C=C1 BRKRUKCBFPJFBN-UHFFFAOYSA-N 0.000 description 1
- CTDDKIURLBKHMA-UHFFFAOYSA-N tert-butyl 2-[2-[2-(2,3-difluorophenyl)ethyl]-1-(2-ethoxy-2-oxoethyl)-4-oxo-1,8-naphthyridin-3-yl]acetate Chemical compound CC(C)(C)OC(=O)CC=1C(=O)C2=CC=CN=C2N(CC(=O)OCC)C=1CCC1=CC=CC(F)=C1F CTDDKIURLBKHMA-UHFFFAOYSA-N 0.000 description 1
- UZYMYLUCRNBLSQ-UHFFFAOYSA-N tert-butyl 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)OC(C)(C)C)C=1CCC1=CC=CC(F)=C1F UZYMYLUCRNBLSQ-UHFFFAOYSA-N 0.000 description 1
- QNETVFQDBYFFHP-UHFFFAOYSA-N tert-butyl 2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)OC(C)(C)C)C=1CCC1=CC=C(F)C=C1F QNETVFQDBYFFHP-UHFFFAOYSA-N 0.000 description 1
- MIQLWPOAYBHBQE-UHFFFAOYSA-N tert-butyl 2-[2-[2-(2-fluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)OC(C)(C)C)C=1CCC1=CC=CC=C1F MIQLWPOAYBHBQE-UHFFFAOYSA-N 0.000 description 1
- HATFTYFIERIGSH-UHFFFAOYSA-N tert-butyl 2-[2-[2-(3,4-difluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)OC(C)(C)C)C=1CCC1=CC=C(F)C(F)=C1 HATFTYFIERIGSH-UHFFFAOYSA-N 0.000 description 1
- GBZQXKJYYKKHEN-UHFFFAOYSA-N tert-butyl 2-[2-[2-(3-chlorophenyl)ethyl]-4-oxoquinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)OC(C)(C)C)C=1CCC1=CC=CC(Cl)=C1 GBZQXKJYYKKHEN-UHFFFAOYSA-N 0.000 description 1
- CRULPQFRIIODJP-UHFFFAOYSA-N tert-butyl 2-[2-[2-(3-fluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)OC(C)(C)C)C=1CCC1=CC=CC(F)=C1 CRULPQFRIIODJP-UHFFFAOYSA-N 0.000 description 1
- TWMKBLRJGYRKBV-UHFFFAOYSA-N tert-butyl 2-[2-[2-(4-fluorophenyl)ethyl]-4-oxoquinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)OC(C)(C)C)C=1CCC1=CC=C(F)C=C1 TWMKBLRJGYRKBV-UHFFFAOYSA-N 0.000 description 1
- RPLHNZXCJCAYAA-UHFFFAOYSA-N tert-butyl 2-[4-oxo-2-[2-(2,3,4-trifluorophenyl)ethyl]quinolin-1-yl]acetate Chemical compound C=1C(=O)C2=CC=CC=C2N(CC(=O)OC(C)(C)C)C=1CCC1=CC=C(F)C(F)=C1F RPLHNZXCJCAYAA-UHFFFAOYSA-N 0.000 description 1
- FSAOITQLMRJFJA-UHFFFAOYSA-N tert-butyl 2-[5-[2-(2,3-difluorophenyl)ethyl]-1-methyl-7-oxopyrazolo[4,3-b]pyridin-4-yl]acetate Chemical compound C=1C(=O)C=2N(C)N=CC=2N(CC(=O)OC(C)(C)C)C=1CCC1=CC=CC(F)=C1F FSAOITQLMRJFJA-UHFFFAOYSA-N 0.000 description 1
- AECGOZZMNFRXFQ-UHFFFAOYSA-N tert-butyl 2-[5-[2-(2,3-difluorophenyl)ethyl]-2-methyl-7-oxopyrazolo[4,3-b]pyridin-4-yl]acetate Chemical compound C=1C(=O)C2=NN(C)C=C2N(CC(=O)OC(C)(C)C)C=1CCC1=CC=CC(F)=C1F AECGOZZMNFRXFQ-UHFFFAOYSA-N 0.000 description 1
- QYPDJIDQEZDFLS-UHFFFAOYSA-N tert-butyl 2-iodoacetate Chemical compound CC(C)(C)OC(=O)CI QYPDJIDQEZDFLS-UHFFFAOYSA-N 0.000 description 1
- JKUYRAMKJLMYLO-UHFFFAOYSA-N tert-butyl 3-oxobutanoate Chemical compound CC(=O)CC(=O)OC(C)(C)C JKUYRAMKJLMYLO-UHFFFAOYSA-N 0.000 description 1
- DZWRDMVOZLULPB-UHFFFAOYSA-N tert-butyl 4-[[2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxo-1,8-naphthyridin-1-yl]acetyl]-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C(=O)CN1C2=NC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 DZWRDMVOZLULPB-UHFFFAOYSA-N 0.000 description 1
- DTZJLHFFXOILIY-UHFFFAOYSA-N tert-butyl 4-[[4-[4-(trifluoromethyl)phenyl]phenyl]methylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NCC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 DTZJLHFFXOILIY-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to certain novel pyrimidinone compounds, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the treatment of atherosclerosis.
- WO 95/00649 (SmithKline Beecham plc) describes the phospholipase A 2 enzyme Lipoprotein Associated Phospholipase A 2 (Lp-PLA 2 ), the sequence, isolation and purification thereof, isolated nucleic acids encoding the enzyme, and recombinant host cells transformed with DNA encoding the enzyme. Suggested therapeutic uses for inhibitors of the enzyme included atherosclerosis, diabetes, rheumatoid arthritis, stroke, myocardial infarction, reperfusion injury and acute and chronic inflammation.
- Lp-PLA 2 is responsible for the conversion of phosphatidylcholine to lysophosphatidylcholine, during the conversion of low density lipoprotein (LDL) to its oxidised form.
- the enzyme is known to hydrolyse the sn-2 ester of the oxidised phosphatidylcholine to give lysophosphatidylcholine and an oxidatively modified fatty acid.
- Both products of Lp-PLA 2 action are biologically active with lysophosphatidylcholine, in particular having several pro-atherogenic activities ascribed to it including monocyte chemotaxis and induction of endothelial dysfunction, both of which facilitate monocyte-derived macrophage accumulation within the artery wall. Inhibition of the Lp-PLA 2 enzyme would therefore be expected to stop the build up of these macrophage enriched lesions (by inhibition of the formation of lysophosphatidylcholine and oxidised free fatty acids) and so be useful in the treatment of atherosclerosis.
- Lp-PLA 2 The increased lysophosphatidylcholine content of oxidatively modified LDL is also thought to be responsible for the endothelial dysfunction observed in patients with atherosclerosis. Inhibitors of Lp-PLA 2 could therefore prove beneficial in the treatment of this phenomenon. An Lp-PLA 2 inhibitor could also find utility in other disease states that exhibit endothelial dysfunction including diabetes, hypertension, angina pectoris and after ischaemia and reperfusion.
- Lp-PLA 2 inhibitors may also have a general application in any disorder that involves activated monocytes, macrophages or lymphocytes, as all of these cell types express Lp-PLA 2 .
- disorders include psoriasis.
- Lp-PLA 2 inhibitors may also have a general application in any disorder that involves lipid oxidation in conjunction with Lp-PLA 2 activity to produce the two injurious products, lysophosphatidylcholine and oxidatively modified fatty acids.
- Such conditions include the aforementioned conditions atherosclerosis, diabetes, rheumatoid arhritis, stroke, myocardial infarction, ischaemia, reperfusion injury and acute and chronic inflammation.
- Patent applications WO 96/12963, WO 96/13484, WO 96/19451, WO 97/02242, WO 97/217675, WO 97/217676, WO 96/41098, and WO 97/41099 disclose inter alia various series of 4-thionyl/sulfinyl/sulfonyl azetidinone compounds which are inhibitors of the enzyme Lp-PLA 2 . These are irreversible, acylating inhibitors (Tew et al, Biochemistry, 37, 10087, 1998).
- R 1 is an aryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C (1-6) alkyl, C (1-6) alkoxy, C (1-6) alkylthio, hydroxy, halogen, CN, mono to perfluoro-C (1-4) alkyl, mono to perfluoro-C (1-4) alkoxyaryl, and arylC (1-4) alkyl;
- R 2 is halogen, C (1-3) alkyl, C (1-3) alkoxy, hydroxyC (1-3) alkyl, C (1-3) alkylthio, C (1-3) alkylsulphinyl, aminoC (1-3) alkyl, mono- or di-C (1-3) alkylaminoC (1-3) alkyl, C (1-3) alkylcarbonylaminoC (1-3) alkyl, C (1-3) alkoxyC (1-3) alkylcarbonylaminoC (1-3) alkyl, C (1-3) alkylsulphonylaminoC (1-3) alkyl, C (1-3) alkylcarboxy, C (1-3) alkylcarboxyC (1-3) alkyl, and
- R 3 is hydrogen, halogen, C (1-3) alkyl, or hydroxyC (1-3) alkyl; or
- R 2 and R 3 together with the pyridone ring carbon atoms to which they are attached form a fused 5-or 6-membered carbocyclic ring; or
- R 2 and R 3 together with the pyridone ring carbon atoms to which they are attached form a fused benzo or heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from halogen, C (1-4) alkyl, cyano, C (1-3) alkoxyC (1-3) alkyl, C (1-4) alkoxy or C (1-4) alkylthio, or mono to perfluoro-C (1-4) alkyl;
- R 4 is hydrogen, C (1-6) alkyl which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from hydroxy, halogen, OR 7 , COR 7 , carboxy, COOR 7 , CONR 9 R 10 , NR 9 R 10 , NR 7 COR 8 , mono- or di-(hydroxyC (1-6) alkyl)amino and N-hydroxyC (1-6) alkyl-N—C (1-6) alkylamino; or
- R 4 is Het-C (0-4) alkyl in which Het is a 5- to 7-membered heterocyclyl ring comprising N and optionally O or S, and in which N may be substituted by COR 7 , COOR 7 , CONR 9 R 10 , or C (1-6) alkyl optionally substituted by 1, 2 or 3 substituents selected from hydroxy, halogen, OR 7 , COR 7 , carboxy, COOR 7 , CONR 9 R 10 or NR 9 R 10 , for instance, piperidin-4-yl, pyrrolidin-3-yl;
- R 5 is an aryl or a heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C (1-6) alkyl, C (1-6) alkoxy, C (1-6) alkylthio, arylC (1-6) alkoxy, thydroxy, halogen, CN, COR 7 , carboxy, COOR 7 , NR 7 COR 8 , CONR 9 R 10 , SO 2 NR 9 R 10 , NR 7 SO 2 R 8 , NR 9 R 10 , mono to perfluoro-C (1-4) alkyl and mono to perfluoro-C (1-4) alkoxy;
- R 6 is an aryl or a heteroaryl ring which is further optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C (1-6) alkyl, C (1-6) alkoxy, C (1-6) alkylthio, C (1-6) alkylsulfonyl, arylC (1-6) alkoxy, hydroxy, halogen, CN, COR 7 , carboxy, COOR 7 , CONR 9 R 10 , NR 7 COR 8 , SO 2 NR 9 R 10 , NR 7 SO 2 R 8 , NR 9 R 10 , mono to perfluoro-C (1-4) alkyl and mono to perfluoro-C (1-4) alkoxy, or C (5-10) alkyl;
- R 7 and R 8 are independently hydrogen or C (1-12) alkyl, for instance C (1-4) alkyl (e.g. methyl or ethyl);
- R 9 and R 10 which may be the same or different is each selected from hydrogen, or C (1-12) alkyl, or R 9 and R 10 together with the nitrogen to which they are attached form a 5- to 7 membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C (1-4) alkyl, C (1-4) alkylcarboxy, aryl, e.g. phenyl, or aralkyl, e.g benzyl, for instance morpholine or piperazine; and
- X is a C (2-4) alkylene group (optionally substituted by 1, 2 or 3 substituents selected from methyl and ethyl), CH ⁇ CH, (CH 2 ) n S or (CH 2 ) n O where n is 1, 2 or 3.
- R 2 and R 3 together with the pyridone ring carbon atoms to which they are attached form a fused benzo or heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from halogen, C (1-4) alkyl, cyano, C (1-4) alkoxy or C (1-4) alkylthio, or mono to perfluoro-C (1-4) alkyl.
- R 1 when an aryl group include phenyl and naphthyl.
- R 1 is phenyl optionally substituted by halogen, C (1-6) alkyl, trifluoromethyl, C (1-6) alkoxy, preferably, from 1 to 3 fluoro, more preferably, 2,3-difluoro.
- R 2 include methyl, ethyl, and trifluoroethyl when R 3 is hydrogen.
- Representative examples of R 3 include methyl when R 2 is methyl.
- R 2 and R 3 include when R 2 and R 3 together with the pyridone ring carbon atoms to which they are attached form a fused 5-membered carbocyclic (cyclopentenyl) ring, or a fused benzo, pyrido, pyrazolo or thieno ring.
- R 2 and R 3 include when R 2 and R 3 , together with the pyridone ring carbon atoms to which they are attached, form a pyrazolo ring substituted on the N atom by C (1-3) alkyl or methoxyethyl; and when R 2 and R 3 , together with the pyridone ring carbon atoms to which they are attached, form either a thiazolyl, thieno or pyrido ring substituted by methyl.
- R 2 and R 3 together with the pyridone ring carbon atoms to which they are attached form a fused 5-membered carbocyclic (cyclopentenyl) ring or a fused benzo, pyrido, thieno or pyrazolo ring.
- R 2 and R 3 together with the pyridone ring carbon atoms to which they are attached, form a fused thiazolyl ring substituted by methyl.
- R 4 include hydrogen, methyl, 2-(diethylamino)ethyl, 2-(piperidin-1-yl)ethyl, 2-(pyrrolidin-1-yl)ethyl, 3-(morpholin-4-yl)propyl, 1-ethyl-piperidin-4-yl and 1-ethyl-pyrrolidin-2-ylmethyl.
- R 4 is 2-diethylamino)ethyl or 1-ethyl-piperidin-4-yl.
- R 4 include piperidin-4-yl substituted at the 1-position by methyl, isopropyl, 1-(2-methoxyethyl), 1-(2-hydroxyethyl), t-butoxycarbonyl or ethoxycarbonylmethyl; ethyl substituted at the 2-position by aminoethyl; 1-ethylpiperidinylmethyl; piperidin-4-yl; 3-diethylaminopropyl; 4-pyrrolidin-1-ylbutyl and 1-ethylpyrrolidin-3-yl.
- R 4 is 1-(2-methoxyethyl)piperidin-4-yl, 1-methylpiperidin-4-yl or 1-ethylpyrrolidin-3-yl.
- R 5 include phenyl and pyridyl.
- R 5 is phenyl.
- R 6 include phenyl optionally substituted by halogen, or trifluoromethyl, preferably at the 4-position and hexyl.
- R 6 is phenyl substituted by trifluoromethyl at the 4-position.
- R 6 include phenyl substituted by 1 or more C (1-3) alkyl.
- R 6 is phenyl substituted by ethyl in the 4-position.
- R 5 and R 6 together form a 4-(phenyl)phenyl or a 2-(phenyl)pyridinyl substituent in which the remote phenyl ring may be optionally substituted by halogen or trifluoromethyl, preferably at the 4-position.
- X is C (2-4) alkylene, more preferably C (2-3) alkylene, most preferably, (CH 2 ) 2 , or CH 2 S.
- R 1 is phenyl substituted by 2,3-difluoro
- R 2 and R 3 together with the pyridone ring carbon atoms to which they are attached, form a fused 5-membered carbocyclic (cyclopentenyl) ring, or a fused benzo or pyrido ring;
- R 4 is 2-(diethylamino)ethyl, 1-ethyl-piperidin-4-yl, 1-(2-methoxyethyl)piperidin-4-yl, 1-methylpiperidin-4-yl or 1-ethylpyrrolidin-3-yl;
- R 5 is phenyl
- R 6 is phenyl substituted by ethyl or trifluoromethyl in the 4-position.
- X is CH 2 S.
- R 1 is phenyl substituted by 2,3-difluoro
- R 2 and R 3 together with the pyridone ring carbon atoms to which they are attached, form a fused thiazolyl ring substituted by methyl, or a benzo or pyrido ring;
- R 4 is 2-(diethylamino)ethyl, 1-ethyl-piperidin-4-yl, 1-(2-methoxyethyl)piperidin-4-yl, 1-methylpiperidin-4-yl or 1-ethylpyrrolidin-3-yl;
- R 5 is phenyl
- R 6 is phenyl substituted by trifluoromethyl in the 4-position
- X is (CH 2 ) 2 .
- R 1 is phenyl substituted by 2,3-difluoro
- R 2 and R 3 together with the pyridone ring carbon atoms to which they are attached, form a fused benzo or pyrido ring;
- R 4 is 1-(2-methoxyethyl)piperidin-4-yl
- R 5 and R 6 together form a 4-(phenyl)phenyl substituent in which the remote phenyl ring is substituted by trifluoromethyl, preferably at the 4-position;
- X is CH 2 S or (CH 2 ) 2 .
- compounds of the present invention may comprise one or more chiral centres so that stereoisomers may be formed.
- the present invention covers all such stereoisomers, including individual diastereoisomers and enantiomers, and mixtures thereof.
- compounds of the present invention may include a basic function such as an amino group as a substituent.
- Such basic functions may be used to form acid addition salts, in particular pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts include those described by Berge, Bighley, and Monkhouse, J. Pharm. Sci., 1977, 66, 1-19. Such salts may be formed from inorganic and organic acids.
- Representative examples thereof include maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, taurocholic acid, benzenesulfonic, p-toluenesulfonic, hydrochloric, hydrobromic, sulfuric, cyclohexylsulfamic, phosphoric and nitric acids.
- compounds of the present invention may include a carboxy group as a substituent.
- Such carboxy groups may be used to form salts, in particular pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts include those described by Berge, Bighley, and Monkhouse, J. Pharm. Sci., 1977, 66, 1-19.
- Preferred salts include alkali metal salts such as the sodium and potassium salts.
- alkyl and similar terms such as “alkoxy” includes all straight chain and branched isomers. Representative examples thereof include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, t-butyl, n-pentyl and n-hexyl.
- aryl refers to, unless otherwise defined, a mono- or bicyclic aromatic ring system containing up to 10 carbon atoms in the ring system, for instance phenyl or naphthyl.
- heteroaryl refers to a mono- or bicyclic heteroaromatic ring system comprising up to four, preferably 1 or 2, heteroatoms each selected from oxygen, nitrogen and sulphur. Each ring may have from 4 to 7, preferably 5 or 6, ring atoms.
- a bicyclic heteroaromatic ring system may include a carbocyclic ring.
- halogen and “halo” include fluorine, chlorine, bromine and iodine and fluoro, chloro, bromo and iodo, respectively.
- the compounds of the present invention are intended for use in pharmaceutical compositions, it will be understood that they are each provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compounds of formula (I) may be used for preparing the more pure forms used in the pharmaceutical compositions.
- the purity of intermediate compounds of the present invention is less critical, it will be readily understood that the substantially pure form is preferred as for the compounds of formula (I).
- the compounds of the present invention are obtained in crystalline form.
- solvent of crystallisation may be present in the crystalline product.
- This invention includes within its scope such solvates.
- some of the compounds of this invention may be crystallised or re-crystallised from solvents containing water. In such cases water of hydration may be formed.
- This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
- different crystallisation conditions may lead to the formation of different polymorphic forms of crystalline products.
- This invention includes within its scope all polymorphic forms of the compounds of formula (I).
- Compounds of the present invention are inhibitors of the enzyme lipoprotein associated phospholipase A 2 (Lp-PLA 2 ) and as such are expected to be of use in therapy, in particular in the treatment of atherosclerosis.
- the present invention provides a compound of formula (I) for use in therapy.
- the compounds of formula (I) are inhibitors of lysophosphatidylcholine production by Lp-PLA 2 and may therefore also have a general application in any disorder that involves endothelial dysfunction, for example atherosclerosis, diabetes, hypertension, angina pectoris and after ischaemia and reperfusion.
- compounds of formula (I) may have a general application in any disorder that involves lipid oxidation in conjunction with enzyme activity, for example in addition to conditions such as atherosclerosis and diabetes, other conditions such as rheumatoid arthritis, stroke, inflammatory conditions of the brain such as Alzheimer's Disease, myocardial infarction, ischaemia, reperfusion injury, sepsis, and acute and chronic inflammation.
- Further applications include any disorder that involves activated monocytes, macrophages or lymphocytes, as all of these cell types express Lp-PLA 2 .
- disorders include psoriasis.
- the present invention provides for a method of treating a disease state associated with activity of the enzyme Lp-PLA 2 which method involves treating a patient in need thereof with a therapeutically effective amount of an inhibitor of the enzyme.
- the disease state may be associated with the increased involvement of monocytes, macrophages or lymphocytes; with the formation of lysophosphatidylcholine and oxidised free fatty acids; with lipid oxidation in conjunction with Lp-PLA 2 activity; or with endothelial dysfunction.
- Compounds of the present invention may also be of use in treating the above mentioned disease states in combination with an anti-hyperlipidaemic, anti-atherosclerotic, anti-diabetic, anti-anginal, anti-inflammatory, or anti-hypertension agent or an agent for lowering Lp(a).
- examples of the above include cholesterol synthesis inhibitors such as statins, anti-oxidants such as probucol, insulin sensitisers, calcium channel antagonists, and anti-inflammatory drugs such as NSAIDs.
- agents for lowering Lp(a) include the aminophosphonates described in WO 97/02037, WO 98/28310, WO 98/28311 and WO 98/28312 (Symphar SA and SmithKline Beecham).
- a preferred combination therapy will be the use of a compound of the present invention and a statin.
- the statins are a well known class of cholesterol lowering agents and include atorvastatin, simvarstatin, pravastatin, cerivastatin, fluvastatin, lovastatin and rosuvastatin (also referred to as S-4522 or ZD 4522, Astra Zeneca).
- the two agents may be administered at substantially the same time or at different times, according to the discretion of the physician.
- a further preferred combination therapy will be the use of a compound of the present invention and an anti-diabetic agent or an insulin sensitiser, as coronary heart disease is a major cause of death for diabetics.
- preferred compounds for use with a compound of the present invention include the PPARgamma activators, for instance GI262570 (GlaxoSmithlhine) and the glitazone class of compounds such as rosiglitazone (Avandia, GlaxoSmithKline), troglitazone and pioglitazone.
- the compounds of the present invention are usually administered in a standard pharmaceutical composition.
- the present invention therefore provides, in a further aspect, a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
- Suitable pharmaceutical compositions include those which are adapted for oral or parenteral administration or as a suppository.
- Suitable pharmaceutical compositions include those which are adapted for oral or parenteral administration or as a suppository.
- Compounds of formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
- a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
- a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
- a composition in the form of a capsule can be prepared using routine encapsulation procedures.
- pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- Typical parenteral compositions consist of a solution or suspension of the compound of formula (I) in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
- a typical suppository formulation comprises a compound of formula (I) which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
- the composition is in unit dose form such as a tablet or capsule.
- Each dosage unit for oral administration contains preferably from 1 to 500 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I).
- the daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 1000 mg, preferably between 1 mg and 500 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the formula (I), the compound being administered 1 to 4 times per day.
- the compounds will be administered for a period of continuous therapy, for example for a week or more.
- a compound of formula (I) may be prepared by reacting an acid compound of formula (II):
- Suitable amide forming conditions are well known in the art and include treating the acid of formula (II) with the amine of formula (III) in the presence of a coupling agent such as 1-(3-dimethyl-aminopropyl)-3-ethylcarbodiimide (DEC) and 1-hydroxybenzotriazole (HOBt), or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) and di-isopropylethylamine, in an aprotic solvent such as dichloromethane or dimethylfomiamide.
- a coupling agent such as 1-(3-dimethyl-aminopropyl)-3-ethylcarbodiimide (DEC) and 1-hydroxybenzotriazole (HOBt), or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyl
- a compound of formula (II) may be readily prepared from a corresponding ester of formula (IV):
- R 11 is C (1-6) alkyl, for example ethyl or t-butyl
- the ester (IV) is usually prepared by N-1 alkylation of (V) using (VI), in which R 11 is as hereinbefore defined e.g. (VI) is t-butyl bromoacetate or ethyl bromoacetate, in the presence of a bas e.g. BuLi THF or sodium hydride in N-methyl pyrrolicinone (NMP) (step c).
- R 11 is as hereinbefore defined e.g. (VI) is t-butyl bromoacetate or ethyl bromoacetate
- NMP N-methyl pyrrolicinone
- the key intermediate (IV) may be synthesised by reacting (XX) with dimethyloxosulfonium methylide, generated via the treatment of trimethylsulfoxonium iodide with sodium hydride at low temperature, to yield a sulfur ylid (XXII) (step q). Subsequent treatment of (XXII) with carbon disulfide in the presence of diisopropylamine, followed by R 1 CH 2 —L 4 , where L 4 is a leaving group, yields intermediate (IV) (step r).
- the R 1 X substituent may be introduced by displacement of a leaving group L 2 (e.g. Cl) (step e) either on a pyridine (VIII) or pyridine N-oxide (XIV), to give 2-substituted pyridines (VII) and (XV). Transformation of (VII) or (XV) to the 4-pyridone (V) is accomplished by deprotection of the 4-oxygen (e.g. using (Ph 3 P) 3 RhCl when in aq.
- a leaving group L 2 e.g. Cl
- XIV pyridine N-oxide
- Transformation of (VII) or (XV) to the 4-pyridone (V) is accomplished by deprotection of the 4-oxygen (e.g. using (Ph 3 P) 3 RhCl when in aq.
- pyridine (VIII) or pyridine N-oxide (XIV) may be prepared by steps (i), (h), (g), (f), and (j), in which:
- R 1 —CH 2 SH (XIX) is typically prepared from the thioacetate, which is formed from the corresponding alkyl bromide R 1 —CH 2 Br.
- intermediate (IV) may be synthesised from known starting materials by steps (s), (c) and (v) in which:
- Intermediate (XIX) is formed from the 2,6-dioxo-1,3-oxazine (XX) and ester (XXI) by treatment with a base such as NaH in DMF or 1,8-diazabicyclo[5.4.0]undec-7-ene in dichloromethane.
- Synthesis of (XX) from known starting materials may be achieved via steps (w) and (c) or steps (y) and (c) in which:
- A1 N-(3-diethylaminopropyl)-4-(4- trifluoromethylphenyl)benzylamine A25 Int.
- A1 N-(1-ethylpiperidin-4-ylmethyl)-4-(4- trifluoromethylphenyl)benzylamine A26 Int.
- A7 N-(2-diethylaminoethyl)-4-(4-methyl- phenyl)benzylamine A27 Int.
- A8 N-(2-diethylaminoethyl)-4-(4-ethyl- phenyl)benzylamine A28 Int.
- N-(2-diethylaminoethyl)-4-(4- isopropylphenyl)benzylamine A29 Int.
- N-(1-ethylpiperidin-4-yl)-4-(4-ethyl- phenyl)benzylamine A30 Int.
- A10 N-(2-diethylaminoethyl)-4-(3,4- dimethylphenyl)benzylamine
- A11 N-(2-diethylaminoethyl)-4-(3,4- difluorophenyl)benzylamine A32 Int.
- A1 N-(4-(pyrrolidin-1-yl)butyl)-4-(4- trifluoromethylphenyl)benzylamine A33 Int.
- A6 N-(1-ethylpiperidin-4-yl)-4- (chlorophenyl)benzylamine A45 Int.
- A6 N-(1-methylpiperidin-4-yl)-4-(4- chlorophenyl)benzylamine A46 Int.
- Butyllithium (4.76 ml, 2.5M in hexanes, 1 equiv) was added dropwise to a solution of 4-chloroquinaldine (2.4 ml, 1 equiv) in tetrahydrofuran (30 ml) at ⁇ 78° C. and the reaction mixture stirred for 15 min.
- 2,3-Difluorobenzyl bromide (1.82 ml, 1.2 equiv) was added dropwise and stirring was continued for 1 h. After warming to room temperature the solution was diluted with water and ethyl acetate and the organic phase dried and evaporated.
- Tetrarnethylsilylazide (1.28 ml, 1 equiv) was added dropwise to a solution of 1-cyclopentene-1,2-dicarboxylic anhydride (1.33 g, 1 equiv) in dichloromethane (20 ml) and the mixture was warmed to 35° C. After ca. 4 h gas evolution had ceased. Ethanol (1 equiv) was added and stirring continued for 10 min, then the solvent was removed in vacuo and the residue triturated with ether to obtain the title compound (0.74 g).
- B32 ethyl(2,4-dioxo-4H-thieno[2,3-d]- [1,3]oxazin-1-yl)acetate
- B58 Int.
- B34 ethyl(6-methyl-2,4-dioxo-4H- thiazolo[4,5-d][1,3]oxazin-1-yl)acetate
- B59 Int.
- B35 ethyl(2-methyl-4,6-dioxo-2,4-dihydro- pyrazolo[3,4-d][1,3]oxazin-7-yl)acetate
- B60 Int.
- B36 ethyl(2-(4-methoxybenzyl)-4,6-dioxo-2,4- dihydropyrazolo[3,4-d][1,3]oxazin-7-yl)acetate
- B61 Int.
- B45 ethyl(2,4-dioxo-1,5,6,7-tetrahydro- cyclopenta[d][1,3]oxazin-3-yl)acetate
- B62 Int.
- B46 ethyl(2,4-dioxo-5,6,7,8-tetrahydro-1H- benzo[d][1,3]oxazin-3-yl)acetate
- B58 2-[5-(2,3-difluorophenyl)ethyl)-6-tert- butoxycarbonyl-2-methyl-7-oxo-7H- thiazolo[4,5-b]pyridin-4-yl]acetic acid, ethyl ester B77 Int.
- B59 2-[6-(2,3-difluorophenyl)ethyl)-5-tert- butoxycarbonyl-2-methyl-4-oxo-4H- pyrazolo[3,4-b]pyridin-7-yl]acetic acid, ethyl ester B78 Int.
- B61 2-[2-(2,3-difluorophenyl)ethyl)-3-tert- butoxycarbonyl-4-oxo-5,6- trimethylenepyridin-1-yl]acetic acid, ethyl ester B79 Int.
- B62 2-[2-(2,3-difluorophenyl)ethyl)-3-tert- butoxycarbonyl-4-oxo-5,6- tetramethylenepyridin-1-yl]acetic acid, ethyl ester
- NMP N-methylpyrrolidone
- 2,2-Dimethyl-1,3-dioxane-4,6-dione 26.8 g was added portionwise over 20 min keeping the temperature between 5-10° C. Effervescence was noted during the addition.
- the mixture was stirred at room temperature for 1 h and phenylisothiocyanate (25.2 g) added over 15 min.
- the mixture was stirred at room temperature for 2.5 h and cooled to 15° C. in a cold water bath.
- Butyllithium (2.5 M in hexanes, 1.52 ml, 1.05 equiv) was added dropwise to a solution of 2-(2,3-difluorobenzylthio)-1H-quinolin-4-one (Int. C1) (1.1 g, 1 equiv) in tetrahydrofuran (20 ml) at 0° C. under argon. The reaction mixture was stirred for 10 min prior to the addition of t-butyl bromoacetate (1.76 ml), 3 equiv) and stirring continued for 60 h at 45° C.
- Int. C1 2-(2,3-difluorobenzylthio)-1H-quinolin-4-one
- D5 Int. C5 [2-(2-(3,4-Difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester.
- D6 Int. C6 [2-(2-(2,4-Difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester.
- D7 Int. C7 [2-(2-(2-Fluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester.
- B74 Ethyl 5-[2-(2-(2,3- difluorophenyl)ethyl)-2-methyl-7-oxo- 7H-thieno[3,2-b]pyridin-4-yl]acetate D30 Int.
- B75 Ethyl [2-(2-(2,3-difluorophenyl)ethyl)- 4-oxo-4H-thieno[3,4-b]pyridin-1-yl]- acetate D31 Int.
- B76 Ethyl [5-(2-(2,3-difluorophenyl)ethyl)- 2-methyl-7-oxo-7H-thiazolo[4,5-b]- pyridin-4-yl]acetate D32 Int.
- B103 Ethyl [5-(2,3-difluorobenzylthio)-7- oxo-7H-thieno[2,3-b]pyridin-4-yl]- acetate D43 Int.
- B104 Ethyl [6-(2,3-difluorobenzylthio)-2- methyl-4-oxo-2,4-dihydro- pyrazolo[3,4-b]pyridin-7-yl]acetate D44 Int.
- B105 Ethyl [2-(2,3-difluorobenzylthio)-4- oxo-4H-[1,8]naphthyridin-1-yl]acetate
- the free base was prepared from Int. E12 and Int. A2 by the method of Example 1.
- the bitartrate was formed as in example 1.
- the free base was prepared from Int. E1 and Int. A42 by the method of Example 1, except using DMF as solvent in place of dichloromethane. 1.97 g of this material was crystallised from n.butyl acetate (10 ml) to give the title compound (1.35 g).
- the free base was prepared from Int. E1 and Int A29 by the method of Example 1, except using DMF as solvent in place of dichloromethane.
- Example 5 was converted to the bitartrate by the method of example 1.
- Example 5 (1.0 g) was dissolved in isopropanol (10 ml) and 1 M HCl in diethyl ether (4 ml) added. A thick precipitate formed. The mixture was evaporated under reduced pressure and the residue dissolved in isopropanol (10 ml) with heating. On cooling a thick precipitate formed that was filtered and dried. 0.2 g of this material was recrystallised from further isopropanol (10 ml) to give the title compound (0.132 g).
- Example 8 (8 g, 1 equiv) together with L-tartaric acid (1.67 g, 1 equiv) was dissolved in methanol (50 ml) and evaporated to a thick syrup which was triturated with ether to give the bitartrate salt as an off-white solid (9.54 g).
- Example 8 (0.5 g) in methylethylketone (4 ml) was mixed with 4M HCl in dioxane (0.174 ml). After 18 h at 0° C., a small amount of solid was filtered off. The mother liquors were evaporated under reduced pressure and the residue crystallised from acetone (4 ml). The solid so formed was recrystallised from acetone to give the title compound (0.336 g).
- Example 8 (0.321 g) in ethanol (3 ml) was stirred overnight with 4M HCl in dioxan (0.25 ml). The solid was collected by filtration, washed with ethanol and dried to give the title compound (0.31 g).
- Example 2 The following Examples were made by the general method of Example 1, using an appropriate solvent such as dimethylformamide or dichloromethane: Ex. No. Precursors Structure Name 20 Int. E3 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(4- fluorobenzylthio)-4-oxo-4H-quinolin-1- yl]-N-(4′-trifluoromethylbiphenyl-4- ylmethyl)-acetamide bitartrate 21 Int. E4 Int.
- d-Tartaric acid (0.028 g, 0.19mmol) was added to a solution of the free base (0.13 g, 0.19 mmol) in methanol (5 ml) with stirring. The resulting solution was evaporated to yield the salt (0.158 g).
- Example 105 The following examples were prepared by the method of Example 105: Ex. No. Precursors Structure Name 106 Int. F2 N-(piperidin-4-yl)-2-[2-(2-(2,3- difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 107 Int.
- Example 59 A mixture of Example 59 (0.18 g, 1 equiv), lithium borohydride (0.12 ml, 2M in THF, 1 equiv) and dry THF (2 ml) was heated at reflux under argon overnight, then a further 0.06 ml portion of lithium borohydride solution was added and heating continued for 4 h. Evaporation, aqueous workup and chromatography (silica, 0-10% methanol in dichloromethane) gave the title compound (0.06 g).
- the bitartrate was prepared as in example 1.
- Enzyme activity was determined by measuring the rate of turnover of the artificial substrate (A) at 37 C in 50 mM HEPES (N-2-hydroxyethylpiperazine-N′-2-ethanesulphonic acid) buffer containing 150 mM NaCl, pH 7.4.
- HEPES N-2-hydroxyethylpiperazine-N′-2-ethanesulphonic acid
- Recombinant LpPLA2 was purified to homogeneity from baculovirus infected Sf9 cells, using a zinc chelating column, blue sepharose affinity chromatography and an anion exchange column. Following purification and ultrafiltration, the enzyme was stored at 6 mg/ml at 4° C. Assay plates of compound or vehicle plus buffer were set up using automated robotics to a volume of 170 ⁇ l. The reaction was initiated by the addition of 20 ⁇ l of 10 ⁇ substrate (A) to give a final substrate concentration of 20 ⁇ M and 10 ⁇ l of diluted enzyme to a final 0.2 nM LpPLA2.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Materials Engineering (AREA)
- Rheumatology (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis.
Description
- The present invention relates to certain novel pyrimidinone compounds, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the treatment of atherosclerosis.
- WO 95/00649 (SmithKline Beecham plc) describes the phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2), the sequence, isolation and purification thereof, isolated nucleic acids encoding the enzyme, and recombinant host cells transformed with DNA encoding the enzyme. Suggested therapeutic uses for inhibitors of the enzyme included atherosclerosis, diabetes, rheumatoid arthritis, stroke, myocardial infarction, reperfusion injury and acute and chronic inflammation. A subsequent publication from the same group further describes this enzyme (Tew D et al, Arterioscler Thromb Vas Biol 1996:16;591-9) wherein it is referred to as LDL-PLA2. A later patent application (WO 95/09921, Icos Corporation) and a related publication in Nature (Tjoelker et al, vol 374, Apr. 6, 1995, 549) describe the enzyme PAF-AH which has essentially the same sequence as Lp-PLA2 and suggest that it may have potential as a therapeutic protein for regulating pathological inflammatory events.
- It has been shown that Lp-PLA2 is responsible for the conversion of phosphatidylcholine to lysophosphatidylcholine, during the conversion of low density lipoprotein (LDL) to its oxidised form. The enzyme is known to hydrolyse the sn-2 ester of the oxidised phosphatidylcholine to give lysophosphatidylcholine and an oxidatively modified fatty acid. Both products of Lp-PLA2 action are biologically active with lysophosphatidylcholine, in particular having several pro-atherogenic activities ascribed to it including monocyte chemotaxis and induction of endothelial dysfunction, both of which facilitate monocyte-derived macrophage accumulation within the artery wall. Inhibition of the Lp-PLA2 enzyme would therefore be expected to stop the build up of these macrophage enriched lesions (by inhibition of the formation of lysophosphatidylcholine and oxidised free fatty acids) and so be useful in the treatment of atherosclerosis.
- A recently published study (WOSCOPS—Packard et al,N. Engl. J. Med. 343 (2000) 1148-1155) has shown that the level of the enzyme Lp-PLA2 is an independent risk factor in coronary artery disease.
- The increased lysophosphatidylcholine content of oxidatively modified LDL is also thought to be responsible for the endothelial dysfunction observed in patients with atherosclerosis. Inhibitors of Lp-PLA2 could therefore prove beneficial in the treatment of this phenomenon. An Lp-PLA2 inhibitor could also find utility in other disease states that exhibit endothelial dysfunction including diabetes, hypertension, angina pectoris and after ischaemia and reperfusion.
- In addition, Lp-PLA2 inhibitors may also have a general application in any disorder that involves activated monocytes, macrophages or lymphocytes, as all of these cell types express Lp-PLA2. Examples of such disorders include psoriasis.
- Furthermore, Lp-PLA2 inhibitors may also have a general application in any disorder that involves lipid oxidation in conjunction with Lp-PLA2 activity to produce the two injurious products, lysophosphatidylcholine and oxidatively modified fatty acids. Such conditions include the aforementioned conditions atherosclerosis, diabetes, rheumatoid arhritis, stroke, myocardial infarction, ischaemia, reperfusion injury and acute and chronic inflammation.
- Patent applications WO 96/12963, WO 96/13484, WO 96/19451, WO 97/02242, WO 97/217675, WO 97/217676, WO 96/41098, and WO 97/41099 (SmithKline Beecham plc) disclose inter alia various series of 4-thionyl/sulfinyl/sulfonyl azetidinone compounds which are inhibitors of the enzyme Lp-PLA2. These are irreversible, acylating inhibitors (Tew et al, Biochemistry, 37, 10087, 1998).
- A further class of compounds has now been identified which are non-acylating inhibitors of the enzyme Lp-PLA2. Thus, WO 99/24420, WO 00/10980, WO 00/66566, WO 00/66567 and WO 00/68208 (SmithKline Beecham plc) disclose a class of pyrimidone compounds. We have now found that the pyrimidone ring may be replaced by a pyridone ring, to give compounds having good activity as inhibitors of the enzyme Lp-PLA2.
-
- in which:
- R1 is an aryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-6)alkyl, C(1-6)alkoxy, C(1-6)alkylthio, hydroxy, halogen, CN, mono to perfluoro-C(1-4)alkyl, mono to perfluoro-C(1-4)alkoxyaryl, and arylC(1-4)alkyl;
- R2 is halogen, C(1-3)alkyl, C(1-3)alkoxy, hydroxyC(1-3)alkyl, C(1-3)alkylthio, C(1-3)alkylsulphinyl, aminoC(1-3)alkyl, mono- or di-C(1-3)alkylaminoC(1-3)alkyl, C(1-3)alkylcarbonylaminoC(1-3)alkyl, C(1-3)alkoxyC(1-3)alkylcarbonylaminoC(1-3)alkyl, C(1-3)alkylsulphonylaminoC(1-3)alkyl, C(1-3)alkylcarboxy, C(1-3)alkylcarboxyC(1-3)alkyl, and
- R3 is hydrogen, halogen, C(1-3)alkyl, or hydroxyC(1-3)alkyl; or
- R2 and R3 together with the pyridone ring carbon atoms to which they are attached form a fused 5-or 6-membered carbocyclic ring; or
- R2 and R3 together with the pyridone ring carbon atoms to which they are attached form a fused benzo or heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from halogen, C(1-4)alkyl, cyano, C(1-3)alkoxyC(1-3)alkyl, C(1-4)alkoxy or C(1-4)alkylthio, or mono to perfluoro-C(1-4)alkyl;
- R4 is hydrogen, C(1-6)alkyl which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from hydroxy, halogen, OR7, COR7, carboxy, COOR7, CONR9R10, NR9R10, NR7COR8, mono- or di-(hydroxyC(1-6)alkyl)amino and N-hydroxyC(1-6)alkyl-N—C(1-6)alkylamino; or
- R4 is Het-C(0-4)alkyl in which Het is a 5- to 7-membered heterocyclyl ring comprising N and optionally O or S, and in which N may be substituted by COR7, COOR7, CONR9R10, or C(1-6)alkyl optionally substituted by 1, 2 or 3 substituents selected from hydroxy, halogen, OR7, COR7, carboxy, COOR7, CONR9R10 or NR9R10, for instance, piperidin-4-yl, pyrrolidin-3-yl;
- R5 is an aryl or a heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-6)alkyl, C(1-6)alkoxy, C(1-6)alkylthio, arylC(1-6)alkoxy, thydroxy, halogen, CN, COR7, carboxy, COOR7, NR7COR8, CONR9R10, SO2NR9R10, NR7SO2R8, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy;
- R6 is an aryl or a heteroaryl ring which is further optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-6)alkyl, C(1-6)alkoxy, C(1-6)alkylthio, C(1-6)alkylsulfonyl, arylC(1-6)alkoxy, hydroxy, halogen, CN, COR7, carboxy, COOR7, CONR9R10, NR7COR8, SO2NR9R10, NR7SO2R8, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy, or C(5-10)alkyl;
- R7 and R8 are independently hydrogen or C(1-12)alkyl, for instance C(1-4)alkyl (e.g. methyl or ethyl);
- R9 and R10 which may be the same or different is each selected from hydrogen, or C(1-12)alkyl, or R9 and R10 together with the nitrogen to which they are attached form a 5- to 7 membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C(1-4)alkyl, C(1-4)alkylcarboxy, aryl, e.g. phenyl, or aralkyl, e.g benzyl, for instance morpholine or piperazine; and
- X is a C(2-4)alkylene group (optionally substituted by 1, 2 or 3 substituents selected from methyl and ethyl), CH═CH, (CH2)nS or (CH2)nO where n is 1, 2 or 3.
- In a further aspect the present invention provides a compound of formula (I) as defined above in which:
- R2 and R3 together with the pyridone ring carbon atoms to which they are attached form a fused benzo or heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from halogen, C(1-4)alkyl, cyano, C(1-4)alkoxy or C(1-4)alkylthio, or mono to perfluoro-C(1-4)alkyl.
- Representative examples of R1 when an aryl group include phenyl and naphthyl. Preferably, R1 is phenyl optionally substituted by halogen, C(1-6)alkyl, trifluoromethyl, C(1-6)alkoxy, preferably, from 1 to 3 fluoro, more preferably, 2,3-difluoro.
- Representative examples of R2 include methyl, ethyl, and trifluoroethyl when R3 is hydrogen. Representative examples of R3 include methyl when R2 is methyl.
- Further representative examples of R2 and R3 include when R2 and R3 together with the pyridone ring carbon atoms to which they are attached form a fused 5-membered carbocyclic (cyclopentenyl) ring, or a fused benzo, pyrido, pyrazolo or thieno ring.
- Further representative examples of R2 and R3 include when R2 and R3, together with the pyridone ring carbon atoms to which they are attached, form a pyrazolo ring substituted on the N atom by C(1-3)alkyl or methoxyethyl; and when R2 and R3, together with the pyridone ring carbon atoms to which they are attached, form either a thiazolyl, thieno or pyrido ring substituted by methyl.
- Preferably, R2 and R3 together with the pyridone ring carbon atoms to which they are attached form a fused 5-membered carbocyclic (cyclopentenyl) ring or a fused benzo, pyrido, thieno or pyrazolo ring.
- Preferably, R2 and R3, together with the pyridone ring carbon atoms to which they are attached, form a fused thiazolyl ring substituted by methyl.
- Representative examples of R4 include hydrogen, methyl, 2-(diethylamino)ethyl, 2-(piperidin-1-yl)ethyl, 2-(pyrrolidin-1-yl)ethyl, 3-(morpholin-4-yl)propyl, 1-ethyl-piperidin-4-yl and 1-ethyl-pyrrolidin-2-ylmethyl. Preferably R4 is 2-diethylamino)ethyl or 1-ethyl-piperidin-4-yl.
- Further representative examples of R4 include piperidin-4-yl substituted at the 1-position by methyl, isopropyl, 1-(2-methoxyethyl), 1-(2-hydroxyethyl), t-butoxycarbonyl or ethoxycarbonylmethyl; ethyl substituted at the 2-position by aminoethyl; 1-ethylpiperidinylmethyl; piperidin-4-yl; 3-diethylaminopropyl; 4-pyrrolidin-1-ylbutyl and 1-ethylpyrrolidin-3-yl.
- Preferably R4 is 1-(2-methoxyethyl)piperidin-4-yl, 1-methylpiperidin-4-yl or 1-ethylpyrrolidin-3-yl.
- Representative examples of R5 include phenyl and pyridyl. Preferably, R5 is phenyl.
- Representative examples of R6 include phenyl optionally substituted by halogen, or trifluoromethyl, preferably at the 4-position and hexyl. Preferably, R6 is phenyl substituted by trifluoromethyl at the 4-position.
- Further representative examples of R6 include phenyl substituted by 1 or more C(1-3)alkyl. Preferably, R6 is phenyl substituted by ethyl in the 4-position.
- Preferably, R5 and R6 together form a 4-(phenyl)phenyl or a 2-(phenyl)pyridinyl substituent in which the remote phenyl ring may be optionally substituted by halogen or trifluoromethyl, preferably at the 4-position.
- Preferably X is C(2-4)alkylene, more preferably C(2-3)alkylene, most preferably, (CH2)2, or CH2S.
- It will be appreciated that within the compounds of formula (I) there is a sub-group of compounds (group A) in which:
- R1 is phenyl substituted by 2,3-difluoro;
- R2 and R3, together with the pyridone ring carbon atoms to which they are attached, form a fused 5-membered carbocyclic (cyclopentenyl) ring, or a fused benzo or pyrido ring;
- R4 is 2-(diethylamino)ethyl, 1-ethyl-piperidin-4-yl, 1-(2-methoxyethyl)piperidin-4-yl, 1-methylpiperidin-4-yl or 1-ethylpyrrolidin-3-yl;
- R5 is phenyl;
- R6 is phenyl substituted by ethyl or trifluoromethyl in the 4-position; and
- X is CH2S.
- It will be appreciated that within the compounds of formula (I) there is a further sub-group of compounds (group B) in which:
- R1 is phenyl substituted by 2,3-difluoro;
- R2 and R3, together with the pyridone ring carbon atoms to which they are attached, form a fused thiazolyl ring substituted by methyl, or a benzo or pyrido ring;
- R4 is 2-(diethylamino)ethyl, 1-ethyl-piperidin-4-yl, 1-(2-methoxyethyl)piperidin-4-yl, 1-methylpiperidin-4-yl or 1-ethylpyrrolidin-3-yl;
- R5 is phenyl;
- R6 is phenyl substituted by trifluoromethyl in the 4-position; and
- X is (CH2)2.
- It will be appreciated that within the compounds of formula (I) there is a further sub-group of compounds (group C) in which:
- R1 is phenyl substituted by 2,3-difluoro;
- R2 and R3, together with the pyridone ring carbon atoms to which they are attached, form a fused benzo or pyrido ring;
- R4 is 1-(2-methoxyethyl)piperidin-4-yl;
- R5 and R6 together form a 4-(phenyl)phenyl substituent in which the remote phenyl ring is substituted by trifluoromethyl, preferably at the 4-position; and
- X is CH2S or (CH2)2.
- It will be appreciated that compounds of the present invention may comprise one or more chiral centres so that stereoisomers may be formed. The present invention covers all such stereoisomers, including individual diastereoisomers and enantiomers, and mixtures thereof.
- It will be appreciated that in some instances, compounds of the present invention may include a basic function such as an amino group as a substituent. Such basic functions may be used to form acid addition salts, in particular pharmaceutically acceptable salts. Pharmaceutically acceptable salts include those described by Berge, Bighley, and Monkhouse,J. Pharm. Sci., 1977, 66, 1-19. Such salts may be formed from inorganic and organic acids. Representative examples thereof include maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, taurocholic acid, benzenesulfonic, p-toluenesulfonic, hydrochloric, hydrobromic, sulfuric, cyclohexylsulfamic, phosphoric and nitric acids.
- It will be appreciated that in some instances, compounds of the present invention may include a carboxy group as a substituent. Such carboxy groups may be used to form salts, in particular pharmaceutically acceptable salts. Pharmaceutically acceptable salts include those described by Berge, Bighley, and Monkhouse,J. Pharm. Sci., 1977, 66, 1-19. Preferred salts include alkali metal salts such as the sodium and potassium salts.
- When used herein, the term “alkyl” and similar terms such as “alkoxy” includes all straight chain and branched isomers. Representative examples thereof include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, t-butyl, n-pentyl and n-hexyl.
- When used herein, the term “aryl” refers to, unless otherwise defined, a mono- or bicyclic aromatic ring system containing up to 10 carbon atoms in the ring system, for instance phenyl or naphthyl.
- When used herein, the term “heteroaryl” refers to a mono- or bicyclic heteroaromatic ring system comprising up to four, preferably 1 or 2, heteroatoms each selected from oxygen, nitrogen and sulphur. Each ring may have from 4 to 7, preferably 5 or 6, ring atoms. A bicyclic heteroaromatic ring system may include a carbocyclic ring.
- When used herein, the terms “halogen” and “halo” include fluorine, chlorine, bromine and iodine and fluoro, chloro, bromo and iodo, respectively.
- Most preferred compounds of formula (1) are:
- N-(1-(2-methoxyethyl)piperidin-4-yl)-2-[2-(2,3-difluorobenzylthio)-4-oxo4H-quinolin-1-yl]-N-(4′-trifluoromethylbiphenyl-4-ylmethyl)acetamide;
- N-(1-(2-methoxyethyl)piperidin-4-yl)-2-[2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4H-[1,8]naphthyridin-1-yl]-N-(4′-trifluoromethylbiphenyl-4-ylmethyl)acetamide;
- or a pharmaceutically acceptable salt thereof, in particular the bitartrate, hydrochloride, dihydrochloride or paratoluenesulfonate salt.
- Since the compounds of the present invention, in particular compounds of formula (I), are intended for use in pharmaceutical compositions, it will be understood that they are each provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compounds of formula (I) may be used for preparing the more pure forms used in the pharmaceutical compositions. Although the purity of intermediate compounds of the present invention is less critical, it will be readily understood that the substantially pure form is preferred as for the compounds of formula (I). Preferably, whenever possible, the compounds of the present invention are obtained in crystalline form.
- When some of the compounds of this invention are allowed to crystallise or are re-crystallised from organic solvents, solvent of crystallisation may be present in the crystalline product. This invention includes within its scope such solvates. Similarly, some of the compounds of this invention may be crystallised or re-crystallised from solvents containing water. In such cases water of hydration may be formed. This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation. In addition, different crystallisation conditions may lead to the formation of different polymorphic forms of crystalline products. This invention includes within its scope all polymorphic forms of the compounds of formula (I).
- Compounds of the present invention are inhibitors of the enzyme lipoprotein associated phospholipase A2 (Lp-PLA2) and as such are expected to be of use in therapy, in particular in the treatment of atherosclerosis. In a further aspect therefore the present invention provides a compound of formula (I) for use in therapy.
- The compounds of formula (I) are inhibitors of lysophosphatidylcholine production by Lp-PLA2 and may therefore also have a general application in any disorder that involves endothelial dysfunction, for example atherosclerosis, diabetes, hypertension, angina pectoris and after ischaemia and reperfusion. In addition, compounds of formula (I) may have a general application in any disorder that involves lipid oxidation in conjunction with enzyme activity, for example in addition to conditions such as atherosclerosis and diabetes, other conditions such as rheumatoid arthritis, stroke, inflammatory conditions of the brain such as Alzheimer's Disease, myocardial infarction, ischaemia, reperfusion injury, sepsis, and acute and chronic inflammation.
- Further applications include any disorder that involves activated monocytes, macrophages or lymphocytes, as all of these cell types express Lp-PLA2. Examples of such disorders include psoriasis.
- Accordingly, in a further aspect, the present invention provides for a method of treating a disease state associated with activity of the enzyme Lp-PLA2 which method involves treating a patient in need thereof with a therapeutically effective amount of an inhibitor of the enzyme. The disease state may be associated with the increased involvement of monocytes, macrophages or lymphocytes; with the formation of lysophosphatidylcholine and oxidised free fatty acids; with lipid oxidation in conjunction with Lp-PLA2 activity; or with endothelial dysfunction.
- Compounds of the present invention may also be of use in treating the above mentioned disease states in combination with an anti-hyperlipidaemic, anti-atherosclerotic, anti-diabetic, anti-anginal, anti-inflammatory, or anti-hypertension agent or an agent for lowering Lp(a). Examples of the above include cholesterol synthesis inhibitors such as statins, anti-oxidants such as probucol, insulin sensitisers, calcium channel antagonists, and anti-inflammatory drugs such as NSAIDs. Examples of agents for lowering Lp(a) include the aminophosphonates described in WO 97/02037, WO 98/28310, WO 98/28311 and WO 98/28312 (Symphar SA and SmithKline Beecham).
- A preferred combination therapy will be the use of a compound of the present invention and a statin. The statins are a well known class of cholesterol lowering agents and include atorvastatin, simvarstatin, pravastatin, cerivastatin, fluvastatin, lovastatin and rosuvastatin (also referred to as S-4522 or ZD 4522, Astra Zeneca). The two agents may be administered at substantially the same time or at different times, according to the discretion of the physician.
- A further preferred combination therapy will be the use of a compound of the present invention and an anti-diabetic agent or an insulin sensitiser, as coronary heart disease is a major cause of death for diabetics. Within this class, preferred compounds for use with a compound of the present invention include the PPARgamma activators, for instance GI262570 (GlaxoSmithlhine) and the glitazone class of compounds such as rosiglitazone (Avandia, GlaxoSmithKline), troglitazone and pioglitazone.
- In therapeutic use, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides, in a further aspect, a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
- Suitable pharmaceutical compositions include those which are adapted for oral or parenteral administration or as a suppository.
- Suitable pharmaceutical compositions include those which are adapted for oral or parenteral administration or as a suppository. Compounds of formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges. A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent. A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule. Typical parenteral compositions consist of a solution or suspension of the compound of formula (I) in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration. A typical suppository formulation comprises a compound of formula (I) which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
- Preferably the composition is in unit dose form such as a tablet or capsule. Each dosage unit for oral administration contains preferably from 1 to 500 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I). The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 1000 mg, preferably between 1 mg and 500 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the formula (I), the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more.
-
- in which X, R1, R2 and R3 are as hereinbefore defined,
- with an amine compound of formula (III):
- R6—R5—CH2NHR4 (III)
- in which R4, R5 and R6 are as hereinbefore defined; under amide forming conditions.
- Suitable amide forming conditions are well known in the art and include treating the acid of formula (II) with the amine of formula (III) in the presence of a coupling agent such as 1-(3-dimethyl-aminopropyl)-3-ethylcarbodiimide (DEC) and 1-hydroxybenzotriazole (HOBt), or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) and di-isopropylethylamine, in an aprotic solvent such as dichloromethane or dimethylfomiamide.
-
- in which X, R1, R2 and R3 are as hereinbefore defined, and R11 is C(1-6)alkyl, for example ethyl or t-butyl,
- by treating with a de-esterifying agent, for instance, when R11 is t-butyl trifluoroacetic acid or when R11 is ethyl, sodium hydroxide in dioxan.
-
- Referring to the scheme, the ester (IV) is usually prepared by N-1 alkylation of (V) using (VI), in which R11 is as hereinbefore defined e.g. (VI) is t-butyl bromoacetate or ethyl bromoacetate, in the presence of a bas e.g. BuLi THF or sodium hydride in N-methyl pyrrolicinone (NMP) (step c).
- When X is CH2S, the key intermediate (IV) may be synthesised by reacting (XX) with dimethyloxosulfonium methylide, generated via the treatment of trimethylsulfoxonium iodide with sodium hydride at low temperature, to yield a sulfur ylid (XXII) (step q). Subsequent treatment of (XXII) with carbon disulfide in the presence of diisopropylamine, followed by R1CH2—L4, where L4 is a leaving group, yields intermediate (IV) (step r).
- Alternatively, when X is CH2S, the R1X substituent may be introduced by displacement of a leaving group L2 (e.g. Cl) (step e) either on a pyridine (VIII) or pyridine N-oxide (XIV), to give 2-substituted pyridines (VII) and (XV). Transformation of (VII) or (XV) to the 4-pyridone (V) is accomplished by deprotection of the 4-oxygen (e.g. using (Ph3P)3RhCl when in aq. ethanol when R12=allyl) (step d), followed, for (XVI), by removal of the N-oxide substituent, using hydrogen in the presence of Pd/C in acetic acid (step k). The pyridine (VIII) or pyridine N-oxide (XIV) may be prepared by steps (i), (h), (g), (f), and (j), in which:
- (j) treatment of (VIII) with m-chloroperbenzoic acid in dichloromethane;
- (f) treatment of (IX) with R12OH (X), in which R12 is allyl, and sodium hydride in DMF;
- (g) treatment of (XI) with phosphorus oxychloride;
- (h) treatment of (XII) with aq HCl with heating;
- (i) treatment of (XIII) with di-lower alkyl malonate and sodium alkoxide in alcohol (in which R13 is C(1-6)alkyl, typically R13=Et); and
- R1—CH2SH (XIX) is typically prepared from the thioacetate, which is formed from the corresponding alkyl bromide R1—CH2Br.
- Alternatively, when X is CH2S and R2 and R3, together with the pyridone ring carbon atoms to which they are attached, form a fused benzo ring, intermediate (IV) may be synthesised from known starting materials by steps (s), (c) and (v) in which:
- (s) treatment of Meldrum's acid (XXIII) with sodium hydride at low temperature, followed by reaction with phenylisothiocyanate and subsequent treatment with R1CH2—L4;
- (c) as hereinbefore discussed;
- (v) treatment of (XXV) with trifluoroacetic acid.
- When X is alkylene, it is preferable to use steps (m) and (h) (intermediates (XVII), (XVIII)) or steps (n) and (p) (intermediates (XIX), (XX), (XXI)) in which:
- (h) transformation of a 4-substituted pyridine into a 4-pyridone e.g. by treatment of (XVII) R14═Cl with aq HCl and dioxan, or deprotection of R14═OR12, e.g. using conditions of step (d).
- (m) chain extension of a 2-alkyl pyridine, e.g. where X═YCH2CH2 by treatment of a 2-methylpyridine (XVIII) with R1—Y—CH2—L4 (XVI) in which L4 is a leaving group and a strong base, such as BuLi, in THF.
- In the alternative route, the 3-ester group is removed from intermediate (XIX) R15═C(1-6)alkyl by heating in diphenyl ether where R15=tBu (step n); Intermediate (XIX) is formed from the 2,6-dioxo-1,3-oxazine (XX) and ester (XXI) by treatment with a base such as NaH in DMF or 1,8-diazabicyclo[5.4.0]undec-7-ene in dichloromethane.
- Synthesis of (XX) from known starting materials may be achieved via steps (w) and (c) or steps (y) and (c) in which:
- (w) treatment of (XXVII) with azidotrimethylsilane in THF;
- (y) treatment of (XXVI) with phosgene;
- (c) as hereinbefore described.
- It will be appreciated by those skilled in the art that all other starting materials and intermediates are either known compounds or may be prepared by literature methods, such as those described in “Comprehensive Organic Transformations: a guide to functional group preparations” by Richard Larock (VCH, 1989), incorporated herein by reference.
- As will be appreciated by those skilled in the art it may be necessary or desirable at any stage in the synthesis of compounds of formula (I) to protect one or more sensitive groups in the molecule so as to prevent undesirable side reactions. The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See for example, those described in ‘Protective Groups in Organic Synthesis’ by Theodora W Green and Peter G M Wuts, second edition, (John Wiley and Sons, 1991), incorporated herein by reference, which also describes methods for the removal of such groups.
- The present invention will now be illustrated by the following examples.
- The structure and purity of the intermediates and examples was confirmed by 1H-NMR and (in nearly all cases) mass spectroscopy, even where not explicitly indicated below
-
- A 3 L 3-neck flask fitted with top stirrer, condenser and argon inlet/outlet was charged with 4-trifluoro-methybenzene boronic acid (90.0 g, 0.474 mol), 4-bromobenzaldehyde (83.29 g, 0.450 mol) and 1,2-dimethoxyethane (1.3 L), followed by 2M aqueous sodium carbonate (474 ml) and palladium acetate (5.32 g, 0.0237 mol). The stirring mixture was heated to reflux for 4 h under argon, then allowed to cool to room temperature over 16 h. The reaction mixture was filtered through hyflo. The filtrate was diluted with saturated brine and extracted 3× with ethyl acetate. The combined extracts were dried over magnesium sulfate and filtered through hyflo, giving a clear orange filtrate which was evaporated to a solid (ca. 120 g, crude). Flash chromatography (silica, 10-50% dichloromethane in pet. ether, 10% steps) gave a white solid which dissolved in hexane (500 ml) on boiling. Crystallisation, finally in ice, gave the title compound as a solid which was filtered off, washed with ice cold hexane and dried, (86.33 g, 77%).1H-NMR (CDCl3) δ7.77-8.03 (8H, m), 10.09 (1H, s).
-
- 4-(4-Trifluoromethylphenyl)benzaldehyde (85.43 g, 0.3414 mol) (Int. A1) and 4A molecular sieve (400 g, predried at 120° C.) were suspended in dichloromethane (1.4 L), then N,N-diethyl-ethylenediamine (47.97 ml, 0.3414 mol) was added. The mixture was left at room temperature for 16 h with occasional shaking, then the sieves were filtered off and washed with dichloromethane. The combined filtrates were evaporated to a yellow solid and dried under high vacuum. This material (1 14.3 g, 0.328 mol) in ethanol (1 L) was cooled in an ice bath, and sodium borohydride (12.41 g, 0.328 mol) was added under argon with stirring. Hydrogen evolution was observed. After 30 min the ice bath was removed, and the cloudy yellow solution was left to stand at room temperature for 16 h. The solvent was removed in vacuo, water and brine were added, and the mixture was extracted 3× with dichloromethane. The combined extracts were dried over potassium carbonate and evaporated to give the title compound as a yellow solid, (112.1 g, 98%).1H-NMR (CDCl3) δ7.66 (4H, s), 7.53-7.56 (2H, m), 7.40-7.44 (2H, m), 3.86 (2H, s), 2.47-2.75 (9H, m), 0.96-1.10 (6H, m); MS(APCI+) found (M+1)=-351, C20H25F3N2 requires 350.
-
- Prepared by the method of intermediate A1 using 4-trifluoromethylbenzeneboronic acid and 4-bromobenzonitrile.1H-NMR (d6 DMSO) δ7.99-7.94 (6H, m), 7.86 (2H, d); MS(APCI+) found (M+1)=248, C14H8NF3 requires 247.
-
- (a) A solution of intermediate A3 (75.5 g, 0.306 mol) in anhydrous THF (500 ml) was added dropwise to a solution of lithium aluminum hydride (460 ml, 1.0M solution in TRF) at 0° C. under argon. The mixture was stirred at room temperature for 16 h, then water (17 ml), 10% aqueous sodium hydroxide solution (10 ml) and water (50 ml) were carefully added dropwise over 8 h under argon. The mixture was stirred for 16 h, then filtered through celite and the filtrate evaporated. The residue was dissolved in dichloromethane (500 ml) and washed with brine, dried and evaporated to give the title compound as a cream solid (66.3 g, 86%).1H-NMR (CDCl3) δ7.68 (4H, s), 7.57 (2H, d), 7.42 (2H, d), 3.94 (2H, s), 1.50 (2H, s); MS(APCI+) found (M-NH2)=235, C14H12F3N requires 251.
- (b) To a solution of intermediate A3 (96.7 g, 0.39 mol) in absolute ethanol (5L) and concentrated hydrochloric acid (200 ml) was added 10% palladium on charcoal (30.0 g, 54% H2O paste). The mixture was stirred under 50 psi hydrogen for 16 h. Additional 10% palladium on charcoal (25.0 g, 54% H2O paste) was added and the mixture was stirred under 50 psi hydrogen for further 16 h. The mixture was filtered through celite and the solvent evaporated to give the hydrochloride salt of the title compound as a cream solid (102.5 g, 91%). 1H-NMR (d6 DMSO) δ8.61 (3H, s), 7.93 (2H, d), 7.83 (2H, d), 7.80 (2H, d), 7.65 (2H, d), 4.08 (2H, s); MS(APCI+) found (M-NH2)=235, C14H12F3N requires 251.
-
- A mixture of intermediate A4 hydrochloride salt (6.0 g, 20.87 mmol), 1-methyl-piperidin-4-one (2.56 ml, 20.84 mmol), sodium triacetoxyborohydride (6.20 g, 29.25 mmol) and acetic acid (1.3 ml) in dichloroethane (50 ml) was stirred at room temperature under argon for 16 h then poured into 2M sodium hydroxide solution (150 ml). The organic phase was separated and the aqueous layer extracted with dichloromethane. The combined organic phases were washed with brine, dried and evaporated. Chromatography (silica, dichloromethane to 97:3 dichloromethane/methanolic ammonia) gave the product as a cream solid (6.3 g, 87%).1H-NMR (CDCl3) δ7.68 (4H, s), 7.57 (2H, d), 7.42 (2H, d), 3.87 (2H, s), 2.82 (2H, m), 2.52 (1H, m), 2.27 (3H, s), 1.90-2.02 (4H, m), 1.45-1.51 (2H, m); MS(APCI+) found (M+1)=349, C20H23N2F3 requires 348.
-
- The following intermediates were made by the method of Intermediate A1:
No. Precursors Name A7 4-bromobenzaldehyde, 4- 4-methylbenzeneboronic acid (4-methylphenyl)benzaldehyde A8 4-bromobenzaldehyde, 4- 4-ethylbenzeneboronic acid (4-ethylphenyl)benzaldehyde A9 4-isopropyliodobenzene 4- 4-formylbenzeneboronic acid (4-isopropylphenyl)benzaidehyde A10 4-bromo-o-xylene 4- 4-formylbenzeneboronic acid (3,4-dimethylphenyl)benzaldehyde A11 3,4-difluoroiodobenzene 4- 4-formylbenzeneboronic acid (3,4-difluorophenyl)benzaldehyde - The following intermediates were made by the method of Intermediate A2: Amine precursors were either commercially available, or readily prepared from commercially available materials by literature methods or minor modifications thereof.
No. Precursor Structure Name A20 Int. A1 N-(2-(piperidin-1-yl)ethyl)-4-(4- trifluoromethylphenyl)benzylamine A22 Int. A1 N-(2-(pyrrolidin-1-yl)ethyl)-4-(4- trifluoromethylphenyl)benzylamine A23 Int. A1 (±)-N-(1-ethylpyrrolidin-2-ylmethyl)- 4-(4-trifluoromethylphenyl)benzylamine A24 Int. A1 N-(3-diethylaminopropyl)-4-(4- trifluoromethylphenyl)benzylamine A25 Int. A1 N-(1-ethylpiperidin-4-ylmethyl)-4-(4- trifluoromethylphenyl)benzylamine A26 Int. A7 N-(2-diethylaminoethyl)-4-(4-methyl- phenyl)benzylamine A27 Int. A8 N-(2-diethylaminoethyl)-4-(4-ethyl- phenyl)benzylamine A28 Int. A9 N-(2-diethylaminoethyl)-4-(4- isopropylphenyl)benzylamine A29 Int. A8 N-(1-ethylpiperidin-4-yl)-4-(4-ethyl- phenyl)benzylamine A30 Int. A10 N-(2-diethylaminoethyl)-4-(3,4- dimethylphenyl)benzylamine A31 Int. A11 N-(2-diethylaminoethyl)-4-(3,4- difluorophenyl)benzylamine A32 Int. A1 N-(4-(pyrrolidin-1-yl)butyl)-4-(4- trifluoromethylphenyl)benzylamine A33 Int. A1 N-(2-(N′-t-butoxycarbonyl-N′- ethylamino)ethyl)-4-(4-trifluoro- methylphenyl)benzylamine - The following intermediates were made by the method of Intermediate A5: Piperidone precursors were either commercially available, or readily prepared from commercially available materials by literature methods or minor modifications thereof.
No. Precursor Structure Name A40 Int. A4 N-(1-ethylpiperidin-4-yl)-4-(4- trifluoromethylphenyl)benzylamine A41 Int. A4 N-(1-isopropylpiperidin-4-yl)-4- (4-trifluoromethylphenyl)benzylamine A42 Int. A4 N-(1-(2-methoxyethyl)piperidin-4- yl)-4-(4-trifluoromethylphenyl)- benzylamine A43 Int. A4 N-(1- ethoxycarbonylmethylpiperidin-4- yl)-4-(4-trifluoromethylphenyl)- benzylamine A44 Int. A6 N-(1-ethylpiperidin-4-yl)-4- (chlorophenyl)benzylamine A45 Int. A6 N-(1-methylpiperidin-4-yl)-4-(4- chlorophenyl)benzylamine A46 Int. A6 N-(1-isopropylpiperidin-4-yl)-4- (4-chlorophenyl)benzylamine A47 Int. A6 N-(1-(2-methoxyethyl)piperidin-4- yl)-4-(4-chlorophenyl)benzylamine A48 Int. A4 N-(1-(t-butoxycarbonyl)piperidin- 4-yl)-4-(4-trifluoromethyl- phenyl)benzylamine -
- Potassium thioacetate (13.45 g, 1.2 equiv) was added portionwise to a solution of 2,3-difluorobenzyl bromide (20 g, 1 equiv) in dimethylformamide (200 ml) and the reaction stirred for 4 h at room temperature. The resultant solid was filtered off and the filtrate partitioned between diethyl ether and water, the organic phase was dried and evaporated. Chromatography (silica, 20:1 petrol/ethyl acetate) gave the title compound as a yellow oil (18.35 g).1H-NMR (CDCl3) δ2.35 (3H, s), 4.15 (2H, d), 6.98-7.13 (5H, m).
-
- A mixture of thioacetic acid S-(2,3-difluorobenzyl)ester (Intermediate B1) (18.35 g, 1 equiv) and potassium carbonate (25.11 g, 2 equiv) in methanol (200 ml) and water (400 ml) was stirred overnight before being poured into dichloromethane (500 ml). The organic phase was dried and evaporated and distilled (125° C. @ 5.6 mBar) to give the title compound as a colourless oil (12.15 g).1H-NMR (CDCl3) δ 1.89 (1H, t), 3.78 (2H, d), 7.05 (3H, m).
-
- A mixture of ethyl 2-amino-1-cyclopentene-1-carboxylate (10.1 g, 1 equiv), diethyl malonate (9.9 ml, 1 equiv), sodium ethoxide (26.7 ml, 1.1 equiv, 21 wt. % solution in ethanol) in ethanol was heated in a sealed vessel to 110° C. for 96 h. After cooling the solvent was removed and the residue suspended in water. The suspension was acidified with aqueous hydrochloric acid (pH ˜3) and the precipitate was collected and dried to give the title compound as a light brown solid (11.52 g).1H-NMR (d6-DMSO) δ1.27 (3H, t), 2.00 (2H, qn), 2.60 (2H, t), 2.73 (2H, t), 4.30 (2H, q), 11.62 (1H, br s), 13.18 (1H, br s).
-
- A mixture of ethyl 2,4-dihydroxy-6,7-dihydro-5H-[1]pyrindine-3-carboxylate (Int. B3) (11.52 g) and aqueous hydrochloric acid (2M, 100 ml) was heated together overnight. After cooling the solvent was removed by freeze drying and the title compound obtained as a brown solid (8.02 g).1H-NMR (d6-DMSO) 2.09 (2H, qn), 2.72 (2H, t), 2.93 (2H, t), 6.56 (1H, s); MS (APCI+) found (M+1)=152; C8H9NO2 requires 151.
-
- A mixture of 2,4-dihydroxy-6,7-dihydro-5H-[1]pyrindine (Int B4) (8.02 g) and phosphorous oxychloride (40 ml) was heated to reflux overnight. The excess phosphorous oxychloride was evaporated off and the residue poured over ice. The resulting brown solid was filtered off and dried (7.36 g).1H-NMR (CDCl3) δ2.17 (2H, m), 2.96 (2H, t), 3.07 (2H, t), 7.12 (1H, s); MS (APCI+) found (M+1)=188; C8H7 35Cl2N requires 187.
-
- Allyl alcohol (4.1 ml, 1.2 equiv) was added dropwise to a suspension of sodium hydride (2.2 g, 1.1 equiv, 60% dispersion in mineral oil) in dimethylformamide (80 ml) under argon at 0° C. The reaction mixture was stirred for 20 min prior to adding dropwise to a solution of 2,4-dichloro-6,7-dihydro-5H-[1]pyrindine (Int. B5) (9.42 g, 1 equiv) in dimethylformamide (70 ml) at 0° C., stirring was continued at ambient temperature overnight. The solvent was evaporated and the residue partitioned between water and ethyl acetate, the organic phase was dried and evaporated. Chromatography (silica, 10:1 toluene/ethyl acetate) gave the title compound as an off white solid (8.99 g).1H-NMR (CDCl3) δ2.11 (2H, m), 2.84 (2H, t), 2.97 (2H, t), 4.58 (2H, m), 5.30-5.46 (2H, m), 5.94-6.07 (1H, m), 6.59 (1H, s); MS (APCI+) found (M+1)=210; C11H12 35ClNO requires 209.
-
- A mixture of 3-chloroperbenzoic acid (19.5 g, 1.5 equiv) and 4-allyloxy-2-chloro-6,7-dihydro-5H[1]-[1]pyrindine (Int B6) (8.99 g, 1 equiv) in dichloromethane (100 ml) was stirred at ambient temperature under argon for 4 h, washed with aqueous sodium bicarbonate, dried and evaporated. Chromatography (silica, 5% methanol in dichloromethane) gave the title compound as a white solid (6.98 g).1H-NMR (CDCl3) δ2.19 (2H, qn), 2.97 (2H, t), 3.22 (2H, t), 4.57 (2H, m), 5.30-5.45 (2H, m), 5.93-6.08 (1H, m), 6.80 (1H, s); MS (APCI+) found (M+1)=226; C11H12 35ClNO2 requires 225.
-
- 4-Fluorobenzyl mercaptan (1.59 g, 1.2 equiv) was added dropwise to a suspension of sodium hydride (0.372 g, 1.0 equiv, 60% dispersion in mineral oil) in dimethylformamide (30 ml) under argon at 0° C. The reaction was stirred for 20 min, before adding dropwise to a solution of 4-allyloxy-2-chloro-6,7-dihydro-5 H-[1]pyrindine-1-oxide (Int. B7) (2.1 g, 1 equiv) in dimethylformamide (20 ml) at 0° C., stirring was continued at ambient temperature overnight. The solvent was evaporated and the residue partitioned between water and ethyl acetate, the organic phase was dried and evaporated. Chromatography (silica, 3% methanol in dichloromethane) gave the title compound as an off white solid (2.65 g).1H-NMR (CDCl3) δ2.16 (2H, qn), 2.91 (2H, m), 3.18 (2H, t), 4.14 (2H, s), 4.43 (2H, m), 5.28 (2H, m), 5.84-5.97 (1H, m), 6.37 (1H, s), 7.00 (2H, m), 7.39 (2H, m); MS (APCI+) found (M+1)=332; C18H18FNO2S requires 331.
-
- A mixture of 4-allyloxy-2-(4-fluorobenzylthio)-6,7-dihydro-5H-[1]pyrindine 1-oxide (Int. B8) (2.65 ), triphenylphosphine rhodium (I) chloride (0.740 g, 10 mol %) and 1,4-diazobicyclo[2,2,2]octane (0.27 g, 30 mol %) in ethanol (90 ml) and water (10 ml) was heated to reflux overnight. The solvent was removed and the residue chromatographed (silica, 4% methanol in dichloromethane) to yield the title compound as a brown solid (1.75 g).1H-NMR (d6-DMSO) δ2.07 (2H, m), 2.80 (2H, t), 2.91 (2H, t), 4.14 (2H, s), 6.58 (1H, s), 7.15 (2H, m), 7.47 (2H, m); MS (APCI+) found (M+1)=292; C15H14FNO2S requires 291.
-
- Butyllithium (4.76 ml, 2.5M in hexanes, 1 equiv) was added dropwise to a solution of 4-chloroquinaldine (2.4 ml, 1 equiv) in tetrahydrofuran (30 ml) at −78° C. and the reaction mixture stirred for 15 min. 2,3-Difluorobenzyl bromide (1.82 ml, 1.2 equiv) was added dropwise and stirring was continued for 1 h. After warming to room temperature the solution was diluted with water and ethyl acetate and the organic phase dried and evaporated. Chromatography (silica, 10:1 petrol/ethyl acetate) gave the title compound as a white solid (3.16 g).1H-NMR (CDCl3) δ3.23 (4H, m), 6.89-6.99 (3H, m), 7.33 (1H, s), 7.59 (1H, m), 7.74 (1H, m), 8.04 (1H, d), 8.15 (1H, d); MS (APCI+) found (M+1)=304; C17H12 35ClF2N requires 303.
- The following intermediates were prepared by the method of intermediate B10
No. Precursor Structure Name B11 4-Fluorobenzyl bromide 4-Chloro-2-(2-(4-fluorophenyl)ethyl)- quinoline B12 3,4-Difluorobenzyl bromide 4-Chloro-2-(2-(3,4-difluorophenyl)- ethyl)quinoline B13 2,4-Difluorobenzyl bromide 4-Chloro-2-(2-(2,4-difluorophenyl)- ethyl)quinoline B14 2-Fluorobenzyl bromide 4-Chloro-2-(2-(2-fluorophenyl)- ethyl)quinoline B15 3-Chlorobenzyl bromide 4-Chloro-2-(2-(3-chlorophenyl)- ethyl)quinoline B16 2,3,4-Trifluoro- benzyl bromide 4-Chloro-2-(2-(2,3,4-trifluoro- phenyl)ethyl)quinoline B17 3-Fluorobenzyl bromide 4-Chloro-2-(2-(3-fluorophenyl)- ethyl)quinoline -
- A mixture of 2,4-dihydroxyquinoline (14 g) and phosphorus oxychioride (40 ml) was heated to reflux overnight. The excess phosphorous oxychloride was evaporated off and the residue poured over ice. The resulting solid was filtered off and dried to give the title compound as a brown solid (13.86 g).1H-NMR (CDCl3) δ7.82 (1H, m), 7.96 (2H, m), 8.03 (1H, d), 8.21 (1H, dd); MS (APCI+) found (M+1)=198; C9H5 35Cl2N requires 197.
-
- Allyl alcohol (7.1 ml, 1.2 equiv) was added dropwise to a suspension of sodium hydride (3.83 g, 1.1 equiv, 60% dispersion in mineral oil) in dimethylformamide (120 ml) under argon at 0° C. The reaction mixture was stirred for 20 min prior to adding dropwise to a solution of 2,4-dichloroquinoline (Int. B20) (17.26 g, 1 equiv) in dimethylformamide (80 ml) at 0° C., stirring was continued at ambient temperature overnight The solvent was evaporated and the residue partitioned between water and ethyl acetate, the organic phase was dried and evaporated. Chromatography (silica, toluene) gave the title compound as an off white solid (13.56 g).1H-NMR (CDCl3) δ4.77 (2H, m), 5.30-5.57 (2H, m), 6.08-6.20 (1H, m), 6.73 (1H, s), 7.52 (1H, m), 7.71 (1H, m), 7.92 (1H, d), 8.17 (1H, dd); MS (APCI+) found (M+1)=220; C12H10 35ClNO requires 219.
-
- 2,3-Difluorobenzyl mercaptan (Int B2) (2 g, 1.1 equiv) was added dropwise to a suspension of sodium hydride (0.477 g, 1.05 equiv, 60% dispersion in mineral oil) in dimethylformamide (50 ml) under argon at 0° C. The reaction mixture was stirred for 20 min, before adding dropwise to a solution of 4-allyloxy-2-chloroquinoline (Int. B21) (2.49 g, 1 equiv) in dimethylformamide (30 ml) at 0° C. and stirring was continued at ambient temperature overnight. The solvent was evaporated and the residue partitioned between water and ethyl acetate, the organic phase was dried and evaporated. Chromatography (silica, 2:1 petrol/toluene) gave the title compound as an off white solid (2.26 g).1H-NMR (CDCl3) δ4.68 (4H, m), 5.34-5.53 (2H, m), 6.06-6.17 (1H, m), 6.54 (1H, s), 6.96 (2H, m), 7.41 (2H, m), 7.41 (2H, m), 7.65 (1H, dt), 7.90 (1H, dd), 8.11 (1H, dd); MS (APCI+) found (M+1)=344; C19H15F2NOS requires 343.
-
-
- The title compound was prepared from Intermediate B7 and 2,3-difluorobenzylthiol by the method of Intermediate B8.
-
- The title compound was prepared from Intermediate B24 by the method of Intermediate B9.
-
- To a stirring solution of 2,3-pyridinedicarboxylic anhydride (100 g, 1 equiv) in anhydrous tetrahydrofuran (1L) was added dropwise under argon at 38-46° C. over 1.25 h azidotrimethylsilane (97.9 ml, 1.1 equiv). The temperature was maintained at 45-50° C. for a further 2 h then the mixture refluxed for 30 min, cooled to ambient temperature and ethanol (43 ml, 1.1 equiv) added dropwise. On stirring for 16 h an off-white solid was obtained which was filtered, washed and dried, to give the title compound (90.7 g).1H-NMR (d6-DMSO) δ7.25-7.35 (1H, m), 8.30-8.35 (1H, dd), 8.65-8.7 (1H, dd), 11.3 (1H, br s)
-
- Methyl 3-amino-5-methylthiophene-2-carboxylate (2.0 g, 11.7 mmol) and sodium hydroxide (0.89 g, 22.2 mmol) in 1:1 dioxan/water (40 ml) was heated at reflux for 18 h, then the solvent was removed in vacuo. The crude solid was dissolved in water (30 ml) and phosgene (15 ml, 20% solution in toluene, 30 mmol) was added over 10 min with stirring. After a further 30 min the precipitate was filtered off, washed with water and dried to yield the title compound (0.44 g).1H-NMR (CDCl3) δ2.5 (3H, s), 6.7 (1H, s), 12.5 (1H, s); MS (APCI+) found (M+H—CO2)=140.
- The following intermediates were prepared by the method of Intermediate B30:
No. Structure Name B31 1H-thieno[3,2-d][1,3]oxazine-2,4-dione B32 1H-thieno[2,3-d][1,3]oxazine-2,4-dione B33 1H-thieno[3,4-d][1,3]oxazine-2,4-dione B34 2-methylthiazolo[4,5-d][1,3]oxazine-5,7-dione B35 2-methyl-2,7-dihydropyrazolo[3,4-d][1,3]oxazine-4,6-dione B36 2-(4-methoxybenzyl)-2,7-dihydropyrazolo[3,4-d][,3]oxazine- 4,6-dione B37 4-fluoroisatoic anhydride -
-
- Tetrarnethylsilylazide (1.28 ml, 1 equiv) was added dropwise to a solution of 1-cyclopentene-1,2-dicarboxylic anhydride (1.33 g, 1 equiv) in dichloromethane (20 ml) and the mixture was warmed to 35° C. After ca. 4 h gas evolution had ceased. Ethanol (1 equiv) was added and stirring continued for 10 min, then the solvent was removed in vacuo and the residue triturated with ether to obtain the title compound (0.74 g).1H-NMR (d6-DMSO) δ2.00 (2H, m), 2.47 (2H, m), 2.68 (2H, m), 11.8 (1H, br s); MS (APCI−) found (M−1)=152; C7H7NO3 requires 153.
-
-
- A 2:1 mixture of 3- and 6-azaisatoic anhydride (3.55 g, 21.6 mmol) (Synthesis 1982, 11, 972) was added portionwise to a suspension of sodium hydride (0.95 g, 60% in oil, 23.8 mmol) in DMF (40 ml). After stirring for 1 h, ethyl bromoacetate (2.64 ml, 23.8 mmol) was added. The reaction mixture was stirred overnight. The solvent was removed under reduced pressure. Ice/water was added to the residue and stirred for 1h. The resulting pink solid was collected by filtration, washed with water and dried under vacuum at 40° C. The product was a 4:1 mixture of the [2,3-d] and the [3,2-d]isomers. 1H-NMR data of the title compound. 1H-NMR (d6-DMSO) δ1.21 (3H, t), 4.18 (2H, q), 4.92 (2H, s), 7.45 (1H, dd), 8.47 (1H, dd), 8.77 (1H, dd); MS (APCI+) found (M+1)=251; C11H10N2O5 requires 250.
- The title compound could also be prepared by the following method:
- To a stirring mixture of 3-azaisatoic anhydride (Int. B26) (84.36 g, 1 equiv) and N,N-diisopropylethylamine (94 ml, 1.05 equiv) in N-methylpyrrolidone (420 ml) was added dropwise under argon at 45-50° C., ethyl bromoacetate (57 ml, 1 equiv). After 16 h at 50° C. the mixture was cooled (ice bath) and water (560 ml) added with vigorous stirring. The solid which precipitated was filtered, washed with water and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. An insoluble solid was filtered off and discarded and the ethyl acetate layer washed again with saturated sodium bicarbonate, dried (Na2SO4) and evaporated. The residue was triturated with a 1:1 mixture of ether/light petrol, filtered, washed and dried to give the title compound as an off-white solid, yield (56.0 g).
- The following intermediates were prepared by the method of Intermediate B50:
No. Precursor Structure Name B51 Int. B40 ethyl(5-ethyl-2,6-dioxo-6H-[1,3]oxazin-3-yl)acetate B52 Int. B41 ethyl(4,5-dimethyl-2,6-dioxo-6H- [1,3]oxazin-3-yl)acetate B53 Int. B37 ethyl 7-fluoro-2,4-dioxo-4H-benzo[d][1,3]- oxazin-1-yl)acetate B54 Int. B30 ethyl(6-methyl-2,4-dioxo-4H- thieno[3,2-d][1,3]oxazin-1-yl)acetate B55 Int. B33 ethyl(2,4-dioxo-4H- thieno[3,4-d][1,3]oxazin-1-yl)acetate B56 Int. B31 ethyl(2,4-dioxo-4H-thieno[3,2-d]- [1,3]oxazin-1-yl)acetate B57 Int. B32 ethyl(2,4-dioxo-4H-thieno[2,3-d]- [1,3]oxazin-1-yl)acetate B58 Int. B34 ethyl(6-methyl-2,4-dioxo-4H- thiazolo[4,5-d][1,3]oxazin-1-yl)acetate B59 Int. B35 ethyl(2-methyl-4,6-dioxo-2,4-dihydro- pyrazolo[3,4-d][1,3]oxazin-7-yl)acetate B60 Int. B36 ethyl(2-(4-methoxybenzyl)-4,6-dioxo-2,4- dihydropyrazolo[3,4-d][1,3]oxazin-7-yl)acetate B61 Int. B45 ethyl(2,4-dioxo-1,5,6,7-tetrahydro- cyclopenta[d][1,3]oxazin-3-yl)acetate B62 Int. B46 ethyl(2,4-dioxo-5,6,7,8-tetrahydro-1H- benzo[d][1,3]oxazin-3-yl)acetate -
- To an ice cooled stirring suspension of sodium hydride (1.96 g, 49.1 mmol, 60% dispersion in oil) in dry tetrahydrofuran (100 ml) was added dropwise under an argon atmosphere tert-butylacetoacetate (7.4 ml, 44.6 mmol). After a further 15 min, n-butyllithium (18.7 ml, 46.8 mmol, 2.5M in hexanes) was added dropwise maintaining the reaction temperature below 10° C. 2,3-Difluorobenzyl bromide (11.08 g, 53.5 mmol) was added dropwise 20 min later, then the mixture allowed to warm to ambient temperature. After a further 15 min the reaction mixture was poured onto a mixture of water (150 ml) and glacial acetic acid (10 ml), extracted 3 times with ethyl acetate and the combined extracts washed with saturated sodium hydrogen carbonate then brine, dried (MgSO4) and evaporated to a yellow oil. Chromatography (fine silica, ethyl acetate-light petrol) gave the title compound as a yellow oil, yield 9.05 g (71%). 1H NMR (CDCl3) δ1.45 (9H, s), 2.84-2.91 (2H, m), 2.95-3.00 (2H, m), 3.35 (2H, s), 6.92-7.04 (3H, m).
-
- To a stirring suspension of sodium hydride (0.562 g, 14.06 mmol, 60% dispersion in oil) in dry DMF (50 ml) was added dropwise 5-(2,3-difluorophenyl)-3-oxopentanoic acid tert-butyl ester (Int. B70) (3.63 g, 12.78 mmol). After 10 min, (2,4-dioxo-4H-pyrido[2,3-d][1,3]oxazin-1-yl)acetic acid ethyl ester (Int. B50 (3.21 g, 12.78 mmol) was added and the mixture stirred for 16 h. The solvent was evaporated and the residue treated with saturated aq. ammonium chloride and extracted 3 times with ethyl acetate. The combined extracts were washed with brine, dried (MgSO4) and concentrated. Chromatography (fine silica, ethyl acetate-light petrol) gave the title compound as a light brown solid, yield 1.88 g (31%). 1H NMR (d6-DMSO) δ1.31 (3H, t), 1.63 (9H, s), 2.95-3.03 (2H, m), 3.08-3.13 (2H, m), 4,27 (2H, q), 5.31 (2H, s), 7.01-7.11(3H, m), 7.35-7.38 (1H, m), 8.67-8.71 (2H, m).
- The title compound was also made by the following method:
- To an ice-cooled solution of intermediate B50 (55.9 g, 1 equiv) and intermediate B70 (63.5 g, 1 equiv) in dichloromethane (700 ml) was added dropwise under argon over 45 min 1,8-diazabicyclo[5.4.0]undec-7-ene (40 ml, 1.2 equiv). After 1 h the ice bath was removed and after a further 2.5 h the mixture was washed with saturated aqueous ammonium chloride, dried (Na2SO4) and evaporated. The crude product was chromatographed (fine silica, ethyl acetate-dichloromethane) then triturated with light petrol to give the title compound (80.27 g).
- The following intermediates were prepared by the method of Intermediate B71:
No. Precursor Structure Name B72 Int. B51 2-[2-(2,3-difluorophenyl)ethyl)-3-tert- butoxycarbonyl-5-ethyl-4-oxo-4H- pyridin-1-yl]acetic acid, ethyl ester B73 Int. B52 2-[2-(2,3-difluorophenyl)ethyl)-3-tert- butoxycarbonyl-5,6-dimethyl-4-oxo- 4H-pyridin-1-yl]acetic acid, ethyl ester B74 Int. B54 5-[2-(2,3-difluorophenyl)ethyl)-6-tert- butoxycarbonyl-2-methyl-7-oxo-7H- tieno[3,2-b]pyridin-4-yl]acetic acid, ethyl ester B75 Int. B55 2-[2-(2,3-difluorophenyl)ethyl)-3-tert- butoxycarbonyl-4-oxo-4H- thieno[3,4-b]pyridin-1-yl]acetic acid, ethyl ester B76 Int. B58 2-[5-(2,3-difluorophenyl)ethyl)-6-tert- butoxycarbonyl-2-methyl-7-oxo-7H- thiazolo[4,5-b]pyridin-4-yl]acetic acid, ethyl ester B77 Int. B59 2-[6-(2,3-difluorophenyl)ethyl)-5-tert- butoxycarbonyl-2-methyl-4-oxo-4H- pyrazolo[3,4-b]pyridin-7-yl]acetic acid, ethyl ester B78 Int. B61 2-[2-(2,3-difluorophenyl)ethyl)-3-tert- butoxycarbonyl-4-oxo-5,6- trimethylenepyridin-1-yl]acetic acid, ethyl ester B79 Int. B62 2-[2-(2,3-difluorophenyl)ethyl)-3-tert- butoxycarbonyl-4-oxo-5,6- tetramethylenepyridin-1-yl]acetic acid, ethyl ester -
- Prepared from ethyl acetoacetate by the method of Int. B70.1H NMR (CDCl3) δ1.27 (3H, t), 2.86-3.02 (4H, m), 3.43 (2H, s), 4.18 (2H, q), 6.92-7.07 (3H, m).
-
- To sodium hydride (0.315 g) in dry DMF (8 ml) at 0° C. under argon was added a solution of intermediate B70 (2.23 g) in dry DMF (8 ml) dropwise. After stirring at 0° C. for 30 min, a solution of intermediate B60 (2.82 g) in dry DMF was added and the mixture allowed to warm to room temperature. After 4 h at room temperature, the mixture was poured into saturated ammonium chloride solution and extracted with ethyl acetate. The combined extracts were dried over MgSO4 and evaporated under reduced pressure to give an oil that was chromatographed on silica gel. This gave a yellow oil (2.3 g). A portion of this material (0.50 g) in TFA (5 ml) was stirred at room temperature for 4 h, then evaporated to dryness. A portion of the residue was added to diphenyl ether (5 ml), heated to reflux for 40 min, then cooled and poured into hexane. The precipitate was filtered off and washed with hexane to obtain the title compound. 1H-NMR (CDCl3) δ1.27 (3H, t), 2.81 (2H, m), 3.01 (2H, m), 3.81 (3H, s), 4.25 (2H, s), 5.27 (2H, s), 5.96 (1H, s), 6.88-7.10 (5H, m), 7.23 (2H, d), 7.88 (1H, s).
-
- A mixture of Int. B91 (0.48 g) and TFA (50 ml) was heated at reflux for 17 h, then the TFA was removed in vacuo. The residue was extracted with dichloromethane, and the combined extracts were chromatographed (silica, 10% methanol in dichloromethane) to obtain the title compound as a dark solid (0.23 g, 64%).1H-NMR (CDCl3) δ1.27 (3H, t), 2.85 (2H, m), 3.02 (2H, m), 4.97 (2H, s), 6.01 (1H, s), 6.95-7.09 (3H, m), 8.24 (1H, s).
-
- 4-Nitropyrazole (3.55 g, 1 equiv) in ethanol (150 ml) was hydrogenated over 10% palladium on charcoal, then the catalyst was filtered off, Int. B80 (8.0 g, 1 equiv) was added and the solvent was removed in vacuo. Concentrated hydrochloric acid (0.5 ml) was added, and the mixture was heated to 100° C. under argon for 2 h. Ethyl acetate was added and the solution was washed with aq. sodium bicarbonate, dried and evaporated. Chromatography (silica, dichloromethane/ethyl acetate) yielded the title compound as a pale solid (5.7 g, 56%).1H-NMR (CDCl3) δ1.29 (3H, t), 2.48 (2H, t), 2.80 (2H, t), 4.15 (2H, q), 4.74 (1H, s), 6.78 (1H, m), 6.95 (2H, m), 7.46 (2H, s), 9.75 (1H, s), 11.1 (1H, br s).
-
- Intermediate B93 (6.7 g) was added portionwise to refluxing Dowtherm (100 ml) and heating was continued for 1 h. After cooling, the mixture was poured into hexane and the precipitate was filtered off, washed with hexane and dried; yield 4.5 g (78%).1H-NMR (d6-DMSO) δ2.89 (2H, m), 3.06 (2H, m), 5.81 (1H, s), 7.07-7.36 (3H, m), 7.76 (1H, s), 11.7 (1H, br s), 13.6 (1H, br s).
-
- A mixture of Intermediate B94 (4.5 g) and phosphorus oxychloride (90 ml) was heated at reflux for 2 h, then excess phosphorus oxychloride was removed in vacuo and the residue was poured into water and basified with sodium bicarbonate. The product was extracted into ethyl acetate and the extracts dried and evaporated to obtain the title compound (4.6 g, 96%).1H-NMR (CDCl3) δ3.22 (4H, m), 6.89-7.06 (3H, m), 7.21 (1H, s), 8.34 (1H, s), 11.0 (1H, br s).
-
- A mixture of Intermediate B95 (4.3 g, 1 equiv), sodium hydroxide (l.5 g, 2.5 equiv) and 90% aq. ethanol (15 ml) was heated to reflux and a solution of iodomethane (1.82 ml, 2 equiv) in diethyl ether (15 ml) was added dropwise (CARE). After 3 h at reflux a flirter 2 equivalents of iodomethane was added, and heating was continued for 2 h. The solvent was removed in vacuo, the residue was dissolved in ethyl acetate, and the solution washed with water, dried and evaporated to obtain a crude mixture of products in a ratio of ca. 3:2. These were separated by chromatography (silica, dichloromethane-ethyl acetate). Early fractions gave the 1-methyl isomer (Int. B96, 2.1 g);1H-NMR (CDCl3) δ3.17 (4H, m), 4.36 (3H, s), 6.90-7.04 (3H, m), 7.12 (1H, s), 8.15 (1H, s). Later fractions gave the 2-methyl isomer (Int. B97, 1.2 g); 1H-NMR (CDCl3) δ3.16 (4H, m), 4.29 (3H, s), 6.90-7.04 (3H, m), 7.15 (1H, s), 8.14 (1H, s). The identity of the two isomers was confirmed by NOE experiments.
-
- A mixture of Int. B96 (2.1 g), 2M hydrochloric acid (10 ml) and dioxan (3 ml) was heated at reflux for 4 days, then extracted with dichloromethane/methanol. Drying and evaporation of the extracts gave the title compound (1.7 g).1H-NMR (d6-DMSO) δ2.98-3.14 (4H, m), 4.22 (3H, s), 6.22 (1H, s), 7.12-7.33 (3H, m), 7.89 (1H, s), 13 (1H, v br s); MS (APCI+) found (M+1)=290; C15H13F3N2O requires 289.
-
- Hydrolysis of Int. B97 was carried out by the method of Int. B98.1H-NMR (d6-DMSO) δ2.82 (2H, m), 3.03 (2H, m), 4.02 (3H, s), 5.66 (1H, s), 7.10 (2H, m), 7.25 (1H, m), 8.00 (1H, s), 11.5 (1H, b br s); MS (APCI+) found (M+1)=290; C15H13F3N2O requires 289.
-
- To a solution of trimethylsulphoxonium iodide (99 g, 0.45 mol) in DMSO (1L) at 5° C. was added sodium hydride (19.4 g, 0.485 mol, 60% in oil) over 0.5 h and the solution stirred for a flither 0.5 h until the reaction subsided. Ethyl 2-(2,4-dioxo-4H-benzo[d][1,3]oxazin-1-yl)acetate (100 g, 0.44 mol) was then added to the solution over 0.33 h and stirred for a further 3 h after which time the reaction mixture was heated at 50° C. for 1.5 h. After cooling to ambient the solution was poured onto ice and the precipitate filtered off and washed with water then pentane. The solids were dried in vacuo at 40° C. to provide the product (124.4 g, 94%).1H-NMR (d6-DMSO) δ1.2 (3H, t), 3.5 (6H, s), 3.98 (2H, q), 5.46 (1H, s), 6.44 (1H, d), 6.52 (1H, t), 7.17 (1H, t), 7.47 (1H, d), 8.93 (1H, br t).
- The following intermediates were prepared by the method of intermediate B100
No. Precursor Structure Name B101 Int. B53 Dimethyloxosulphonium-2-(ethoxycarbonyl- methylamino)-4-fluorobenzoylmethylide B102 Int. B56 Dimethyloxosulphonium-3-(ethoxycarbonyl- methylamino)thien-2-ylcarbonylmethylide B103 Int. B57 Dimethyloxosulphonium-2-(ethoxycarbonyl- methylamino)thien-3-ylcarbonylmethylide B104 Int. B59 Dimethyloxosulphonium-3-(ethoxycarbonyl- methylamino)-1-methylpyrazin-4- ylcarbonylmethylide B105 Int. B50 Dimethyloxosulphonium-2-(ethoxycarbonyl- methylamino)pyridin-3-ylcarbonylmethylide -
- To hexane washed sodium hydride (7.45 g, 60% in oil) under argon, was added N-methylpyrrolidone (NMP) (270 ml) and the mixture cooled in an ice-salt bath. 2,2-Dimethyl-1,3-dioxane-4,6-dione (26.8 g) was added portionwise over 20 min keeping the temperature between 5-10° C. Effervescence was noted during the addition. The mixture was stirred at room temperature for 1 h and phenylisothiocyanate (25.2 g) added over 15 min. The mixture was stirred at room temperature for 2.5 h and cooled to 15° C. in a cold water bath. 2,3-Difluorobenzyl bromide (38.6 g) was added over 10 min and stirred at room temperature overnight. The solvent was removed under reduced pressure and the residue partitioned between ethyl acetate (1.2L) and water. The organic layer was washed with further water and then brine and dried over MgSO4. The solvent was removed under reduced pressure and the residue triturated with 40-60° C. petrol and the solid collected by filtration. Crystallisation from methyl t.butyl ether gave the title compound as a pale yellow solid (51.4 g). 1H-NMR (d6-DMSO) δ1.64 (6H, s), 4.16 (2H, d), 7.1-7.25 (2H, m), 7.25-7.5 (6H, m), 12.12 (1H, br s); MS (APCI−) found (M−1)=404; C20H17F2NO4S requires 405.
-
- To hexane washed sodium hydride (1.0 g, 60% in oil) under argon, was added NMP (30 ml). A solution of 5-(1-(2,3-Difluorobenzylthio)-1-phenylaminomethylene)-2,2dimethyl-[1,3]dioxane-4,6-dione (10.0 g) (intermediate B110) in NMP (20 ml) was added by syringe over 15 min at room temperature and stirred for 30 min. Ethyl bromoacetate (4.5 g) was added and the mixture heated at 60° C. for 6 h. The mixture was partitioned between ethyl acetate and water and the aqueous layer extracted with further ethyl acetate. The combined organic layers were washed with further water and brine, dried over MgSO4, and the solvent removed under reduced pressure. The orange oil so obtained was triturated with diethyl ether/40-60° C. petrol to give a solid that was collected by filtration. This solid was recrystallised from methyl t-butyl ether to give the title compound (7.37 g). 1H-NMR (d6-DMSO) δ1.24 (3H, t), 1.55 (6H, br s), 4.19 (2H, q), 4.37 (2H, d), 4.81 (2H, br s), 6.85-7.5 (8H, 2×m).
-
- A mixture of 2-amino-6-methylpyridine (0.55 g, 1 equiv), Int. B80 (1.5 g, 1.15 equiv) and polyphosphoric acid (3 ml) was heated to 110° C. for 6 h, then ice/water was added and the solution adjusted to pH 7 with aq. sodium hydroxide. The precipitate was filtered off, washed with water and dried to obtain the title compound (1.3 g).1H-NMR (d6-DMSO) δ2.89 (2H, m), 3.04 (3H, s), 3.12 (2H, m), 6.11 (1H, s), 6.62 (1H, d), 6.95-7.04 (3H, m), 7.35-7.44 (2H, m); MS (APCI+) found (M+1)=301; C17H14F2N2O requires 300.
-
- A mixture of Int. B112 (1.0 g) and diphenyl ether (10 ml) was heated to reflux for 4 h, then cooled to 0° C. The resulting solid was filtered off, washed thoroughly with hexane and dried to obtain the title compound (0.67 g).1H-NMR (d6-DMSO) δ2.58 (3H, s), 2.91 (2H, m), 3.09 (2H, m), 5.90 (1H, s), 6.62 (1H, d), 7.10-7.30 (4H, m), 8.26 (1H, d); MS (APCI+) found (M+1)=301; C17H14F2N2O requires 300.
-
- A mixture of 4-allyloxy-2-(2,3-difluorobenzylthio)quinoline (Int. B22) (2.24 g), triphenylphosphine rhodium (I) chloride (0.302 g, 5 mol %) and 1,4-diazobicyclo[2,2,2]octane (0.147 g, 20 mol %) in ethanol (30 ml) and water (1.5 ml) was heated to reflux for 4 h. The solvent was removed and the residue partitioned between water and dichloromethane, the organic phase dried and evaporated. Chromatography (silica, 4% methanol in dichloromethane) yielded the title compound as an off white solid (1.25 g).1H-NMR (d6-DMSO) δ4.55 (2H, s), 6.37 (1H, br s), 7.15 (1H, m), 7.31 (3H, m), 7.65 (2H, m), 8.02 (1H, d), 11.75 (1H, br s); MS (APCI+) found (M+1)=304; C16H11F2NOS requires 303.
-
-
- 4-Chloro-2-(2,3-difluorophenylethyl)quinoline (Int B10) (2.83 g) was heated to reflux in aqueous hydrochloric acid (2M, 15 ml) and dioxane (6 ml) for 72 h. The reaction mixture was extracted with dichloromethane (90 ml) and methanol (10 ml), and the organic phase dried and evaporated to give the title compound as a white solid (2.61 g).1H-NMR (d6-DMSO) δ3.15 (4H, s), 6.46 (1H, s), 7.15 (2H, m), 7.27 (1H, m), 7.51 (1H, m), 7.82 (2H, m), 8.15 (1H, d); MS (APCI+) found (M+1)=286; C17H13F2NO requires 285.
- The following intermediates were prepared by the method of intermediate C3:
No. Precursor Structure Name C4 Int. B11 2-(2-(4-Fluorophenyl)ethyl)-1H-quinolin-4-one C5 Int. B12 2-(2-(3,4-Difluorophenyl)ethyl)-1H-quinolin-4- one C6 Int. B13 2-(2-(2,4-Difluorophenyl)ethyl)-1H-quinolin-4- one C7 Int. B14 2-(2-(2-Fluorophenyl)ethyl)-1H-quinolin-4-one C8 Int. B15 2-(2-(3-Chlorophenyl)ethyl)-1H-quinolin-4-one C9 Int. B16 2-(2-(2,3,4-Trifluorophenyl)ethyl)-1H-quinolin-4- one C10 Int. B17 2-(2-(3-Fluorophenyl)ethyl)-1H-quinolin-4-one -
- A mixture of 2-(4-fluorobenzylthio)-1-oxy-6,7-dihydro-5H-[1]pyrindin-4-ol (Int. B9) (1.54 g) and palladium/carbon (0.3 g, 20 wt %) in acetic acid (80 ml) was heated to 50° C. in an atmosphere of H2 at 50 psi overnight. The catalyst was filtered off and solvent evaporated to give the title compound as a brown foam (1.21 g). 1H-NMR (CDCl3) δ2.03 (2H, m), 2.81 (4H, m), 4.14 (2H, s), 6.46 (1H, s), 6.89 (2H, m), 7.21 (2H, m); MS (APCI+) found (M+1)=276; C15H14FNOS requires 275.
-
-
- Butyllithium (2.5 M in hexanes, 1.52 ml, 1.05 equiv) was added dropwise to a solution of 2-(2,3-difluorobenzylthio)-1H-quinolin-4-one (Int. C1) (1.1 g, 1 equiv) in tetrahydrofuran (20 ml) at 0° C. under argon. The reaction mixture was stirred for 10 min prior to the addition of t-butyl bromoacetate (1.76 ml), 3 equiv) and stirring continued for 60 h at 45° C. The solution was diluted with dichloromethane (40 ml) and washed with aqueous ammonium chloride and aqueous sodium bicarbonate, dried and evaporated. Chromatography (silica, 5% [2M ammonia in methanol] in dichloromethane) yielded the title compound as a yellow foam (0.193 g).1H-NMR (CDCl3) δ1.44 (9H, s), 4.29 (2H, s), 5.30 (2H, br s), 6.45 (1H, s), 7.06-7.24 (4H, m), 7.39 (1H, t), 7.63 (1H, dt), 8.41 (1H, dd); MS (APCI+) found (M+1)=418; C22H21F2NO3S requires 417.
- The following intermediates were prepared by the method of Intermediate D1:
No. Precursor Structure Name D2 Int. C3 [2-(2-(2,3-Difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester. D3 Int. C2 [2-(4-Fluorobenzylthio)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester. D4 Int. C4 [2-(2-(4-Fluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester. D5 Int. C5 [2-(2-(3,4-Difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester. D6 Int. C6 [2-(2-(2,4-Difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester. D7 Int. C7 [2-(2-(2-Fluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester. D8 Int. C8 [2-(2-(3-Chlorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester. D9 Int. C9 [2-(2-(2,3,4-Trifluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]acetic acid tert butyl ester. D10 Int. C10 [2-(2-(3-Fluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]acetic acid tert butyl ester. D11 Int. B99 t-Butyl [5-(2-(2,3-difluorophenyl)ethyl)-2- methyl-7-oxo-2,7-dihydropyrazolo[4,3-b]- pyridin-4-yl]acetate D12 Int. B98 t-Butyl [5-(2-(2,3-difluorophenyl)ethyl)1- methyl-7-oxo-1,7-dihydropyrazolo[4,3-b]- pyridin-4-yl]acetate D13 Int. C12 t-Butyl [2-(2,3-difluorobenzylthio)-4-oxo- 5,6-trimethylenepyridin-1-yl]acetate D14 Int. C3 Methyl 2-(2-(2-(2,3-difluorophenyl)ethyl)- 4-oxo-4H-quinolin-1-yl)acetate D15 Int. B113 Ethyl [2-(2-(2,3-difluorophenyl)ethyl)-7- methyl-4-oxo-4H-[1,8]naphthyridin-1-yl]- acetate -
- A mixture of 2-(4-fluorobenzylthio)-1,5,6,7-tetrahydro-[1]pyrindin-4-one (Int. C11) (1.21 g, 1 equiv), t-butyl iodoacetate (3.18 g, 3 equiv) and diisopropylethylamine (3.05 ml, 4 equiv) in dichloromethane (40 ml) was stirred at ambient temperature under argon for 48 h, then the solution was washed with aqueous ammonium chloride and aqueous sodium bicarbonate, dried and evaporated. Chromatography (silica, 5% methanol in dichloromethane) yielded the title compound as a off white foam (0.982 g).1H-NMR (CDCl3) δ1.47 (9H, s), 2.09 (2H, m), 2.84 (4H, m), 4.07 (2H, s), 4.56 (2H, s), 6.45 (1H, s), 6.99 (2H, m), 7.25 (2H, m); MS (APCI+) found (M+1)=390; C21H24FNO3S requires 389.
-
- (a) A mixture of dimethyloxosulphonium-2-(ethoxycarbonylmethylamino)benzoylmethylide (0.30 g, 1.01 mmol) (intermediate B100), carbon disulphide (0.13 ml, 2.05 mmol) and diisopropylethylamine (0.35 ml, 2.02 mmol) in DMF (4 ml) was shaken under argon for 18 h then 2,3-difluorobenzyl bromide (0.42 g, 2.02 mmol) added and the reaction shaken for a further 7 h. The solution was concentrated and the residues separated between ethyl acetate and water. The organics were isolated, dried (MgSO4) and concentrated. Purification by chromatography over silica eluting using a gradient from dichloromethane to dichloromethane/ether 3:1 yielded the title compound (0.14 g, 36%). 1H-NMR (d6-DMSO) δ1.2 (3H, t, J=7Hz), 4.18 (2H, q, J=7Hz), 4.5 (2H, s), 5.3 (2H, s), 6.3 (1H, s), 7.18 (1H, m), 7.3 (1H, m), 7.4 (2H, m), 7.6 (1H, d, J=8.5Hz), 7.7 (1H, t, J=7Hz), 8.1 (1H, d, J=8 Hz). MS (APCI+) found (M+1)=390; C20H17F2NO3S requires 389.
- (b) Ethyl (1-(2,3-difluorobenzylthio)-1-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-ylidene)-methyl)-phenylamino)acetate (intermediate B111) (0.85 g) under argon was stirred with trifluoroacetic acid (10 ml) at room temperature overnight. The mixture was evaporated under reduced pressure, dissolved in dichloromethane, washed with sodium bicarbonate solution and dried over Na2SO4. The solvent was removed under reduced pressure and the residue triturated with diethyl ether to give the title compound (0.43 g). 1H-NMR (CDCl3) δ1.27 (3H, t), 4.26 (2H, q), 4.29 (2H, s), 5.1 (2H, br s), 6.45 (1H, s), 6.95-7.25 (4H, m), 7.39 (1H, t), 7.64 (1H, dt), 8.42 (1H, dd). Mass spectrum as above.
-
- (3-tert-Butoxycarbonylmethyl-2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-4H-[1,8]naphthyridin-1-yl)acetic acid ethyl ester (Int. B71) (1.35 g, 2.86 mmol) was added portionwise to boiling diphenyl ether (10 ml) with stirring. After 20 min, the dark solution was allowed to cool to ambient temperature. Petroleum ether (b.p. 60-80° C.) was added to the point of cloudiness to give the product as a crystalline solid (0.724 g).1H NMR (d6-DMSO) δ1.19 (3H, t), 3.02-3.09 (4H, m), 4.16 (2H, q), 5.31 (2, s), 6.10 (1H, s), 7.13-7.21 (2H, m), 7.26-7.33 (1H, m), 7.46-7.49 (1H, m), 8.49 (1H, m), 8.76 (1H, m). MS (APCI+), found (M+1)=373, C20H18F2N2O3 requires 372.
- The following intermediates were prepared by the method of Intermediate D26:
No. Precursor Structure Name D27 Int. B72 Ethyl [2-(2-(2,3-difluorophenyl)ethyl)- 5-ethyl-4-oxo-4H-pyridin-1-yl]acetate D28 Int. B73 Ethyl [2-(2-(2,3-difluorophenyl)ethyl)- 5,6-dimethyl-4-oxo-4H-pyridin-1-yl]- acetate D29 Int. B74 Ethyl 5-[2-(2-(2,3- difluorophenyl)ethyl)-2-methyl-7-oxo- 7H-thieno[3,2-b]pyridin-4-yl]acetate D30 Int. B75 Ethyl [2-(2-(2,3-difluorophenyl)ethyl)- 4-oxo-4H-thieno[3,4-b]pyridin-1-yl]- acetate D31 Int. B76 Ethyl [5-(2-(2,3-difluorophenyl)ethyl)- 2-methyl-7-oxo-7H-thiazolo[4,5-b]- pyridin-4-yl]acetate D32 Int. B77 Ethyl [6-(2-(2,3-difluorophenyl)ethyl)- 2-methyl-4-oxo-4H-pyrazolo[3,4-b]- pyridin-7-yl]acetate D33 Int. B78 Ethyl [2-(2-(2,3-difluorophenyl)ethyl)- 4-oxo-5,6-trimethylenepyridin-1-yl]- acetate D34 Int. B79 Ethyl [2-(2-(2,3-difluorophenyl)ethyl)- 4-oxo-5,6-tetramethylenepyridin-1-yl]- acetate - The following intermediates were prepared by the method of Intermediate D25, method A:
No. Precursor Structure Name D40 Int. B101 Ethyl [2-(2,3-difluorobenzylthio)-7- fluoro-4-oxo-4H-quinolin-1-yl]acetate D41 Int. B102 Ethyl [5-(2,3-difluorobenzylthio)-7- oxo-7H-thieno[3,2-b]pyridin-4-yl]- acetate D42 Int. B103 Ethyl [5-(2,3-difluorobenzylthio)-7- oxo-7H-thieno[2,3-b]pyridin-4-yl]- acetate D43 Int. B104 Ethyl [6-(2,3-difluorobenzylthio)-2- methyl-4-oxo-2,4-dihydro- pyrazolo[3,4-b]pyridin-7-yl]acetate D44 Int. B105 Ethyl [2-(2,3-difluorobenzylthio)-4- oxo-4H-[1,8]naphthyridin-1-yl]acetate -
- A mixture of Intermediate B92 (0.120 g, 1 equiv), potassium carbonate (0.070 g, 1.5 equiv) and iodoethane (1 equiv) in dry DMF (1.5 ml) was stirred at room temperature for 4 days. Ethyl acetate was added, the solution was washed with aq. sodium bicarbonate, then dried and evaporated Chromatography (silica, 0-10% methanol in dichloromethane) gave the title compound as abrown solid (0.1 g, 77%).1H-NMR (CDCl3) δ1.28 (3H, t), 1.54 (3H, t), 2.82 (2H, m), 3.02 (2H, m), 4.21-4.28 (4H, 2×q), 4.93 (2H, s), 5.96 (1H, s), 6.93-7.08 (3H, m), 8.01 (1H, s); MS (APCI+) found (M+1)=390; C20H21F2O3 requires 389.
- The following intermediate was prepared by the method of Intermediate 50:
No. Precursor Structure Name D51 Int. B92, 2-iodo- propane Ethyl [6-(2-(2,3-difluorophenyl)ethyl)- 2-isopropyl-4-oxo-2,4-dihydropyrazolo- [3,4-b]pyridin-7-yl]acetate D52 Int. B92, 1-bromo-2- methoxy- ethane Ethyl [6-(2-(2,3-difluorophenyl)ethyl)- 2-(2-methoxyethyl)-4-oxo-2,4-dihydro- pyrazolo[3,4-b]pyridin-7-yl]acetate -
- (a) Trifluoroacetic acid (0.5 ml) was added to a solution of Int. D1 (0.193 g) in dichloromethane (5 ml) under argon, and stirred overnight at room temperature. Evaporation of the solvent and trituration with ether gave the title compound as a white solid (0.153 g).
- (b) To a solution of Int. D25 (21.56 g, 0.055 mol) in dioxan (200 ml) was added sodium hydroxide (6.0 g, 0.15 mol) in water (200 ml) and the solution stirred for 2.5 h then concentrated. The residues were dissolved in water and acidified to pH 2 with 2M hydrochloric acid and the precipitate collected and washed sequentially with water, ether and then hexane. The solids were dried in vacuo at 40° C. to provide the title compound (20.0 g, 100%).1H-NMR (d6-DMSO) δ4.5 (2H, s), 5.2 (2H, br s), 6.3 (1H, s), 7.18 (1H, m), 7.3 (1H, m), 7.4 (2H, m), 7.6 (1H, d, J=8.5 Hz), 7.7 (1H, t, J=8 Hz), 8.1 (1H, d, J=8 Hz). MS (APCI+) found (M+1)=362; C18H13F2NO3S requires 361.
- The following intermediates were prepared by the method of Intermediate E1(a):
No. Precursor Structure Name E2 Int. D2 [2-(2-(2,3-Difluorophenyl)ethyl)-4- oxo-4H-quinolin-1-yl]-acetic acid E3 Int. D3 [2-(4-Fluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-acetic acid E4 Int. D20 [2-(4-Fluorobenzylthio)-4-oxo-4,5,6,7- tetrahydro-[1]pyridin-1-yl]-acetic acid E5 Int. D4 [2-(2-(4-Fluorophenyl)ethyl-4-oxo- 4H-quinolin-1-yl]-acetic acid E6 Int. D5 [2-(2-(3,4-Difluorophenyl)ethyl)-4- oxo-4H-quinolin-1-yl]-acetic acid E7 Int. D6 [2-(2-(2,4-Difluorophenyl)ethyl)-4- oxo-4H-quinolin-1-yl]-acetic acid E8 Int. D7 [2-(2-(2-Fluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-acetic acid E9 Int. D8 [2-(2-(3-Chlorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-acetic acid E10 Int. D9 [2-(2-(2,3,4-Trifluorophenyl)ethyl)-4- oxo-4H-quinolin-1-yl]-acetic acid E11 Int. D10 [2-(2-(3-Fluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-acetic acid E12 Int. D13 [2-(2,3-difluorobenzylthio)-4-oxo-5,6- trimethylenepyridin-1-yl]acetic acid E13 Int. D11 [5-(2-(2,3-difluorophenyl)ethyl)-2- methyl-7-oxo-2,7- dihydropyrazolo[4,3-b]pyridin-4-yl]- acetic acid E14 Int. D12 [5-(2-(2,3-difluorophenyl)ethyl)-1- methyl-7-oxo-1,7- dihydropyrazolo[4,3-b]pyridin-4-yl]- acetic acid - The following intermediates were prepared by the method of Intermediate E1(b):
No. Precursor Structure Name E2 Int. D14 (2-(2-(2,3-difluorophenyl)ethyl)-4- oxo-4H-quinolin-1-yl)acetic acid E21 Int. D26 (2-[2-(2,3-difluorophenyl)ethyl]-4- oxo-4H-[1,8]naphthyridin-1-yl)acetic acid E22 Int. D40 [2-(2,3-difluorobenzylthio)-7-fluoro-4- oxo-4H-quinolin-1-yl]acetic acid E23 Int. D27 [2-(2-(2,3-difluorophenyl)ethyl)-5- ethyl-4-oxo-4H-pyridin-1-yl]acetic acid E24 Int. D28 [2-(2-(2,3-difluorophenyl)ethyl)-5,6- dimethyl-4-oxo-4H-pyridin-1-yl]acetic acid E25 Int. D41 [5-(2,3-difluorobenzylthio)-7-oxo-7H- thieno[3,2-b]pyridin-4-yl]acetic acid E26 Int. D29 5-[2-(2-(2,3-difluorophenyl)ethyl)-2- methyl-7-oxo-7H-thieno[3,2- b]pyridin-4-yl]acetic acid E27 Int. D30 [2-(2-(2,3-difluorophenyl)ethyl)-4- oxo-4H-thieno[3,4-b]pyridin-1-yl]-acetic acid E28 Int. D31 [5-(2-(2,3-difluorophenyl)ethyl)-2- methyl-7-oxo-7H-thiazolo[4,5-b]- pyridin-4-yl]acetic acid E29 Int. D43 [6-(2,3-difluorobenzylthio)-2-methyl- 4-oxo-2,4-dihydropyrazolo[3,4-b]- pyridin-7-yl]acetic acid E30 Int. D32 [6-(2-(2,3-difluorophenyl)ethyl)-2- methyl-4-oxo-4H-pyrazolo[3,4-b]- pyridin-7-yl]acetic acid E31 Int. D50 [6-(2-(2,3-difluorophenyl)ethyl)-2- ethyl-4-oxo-2,4- dihdropyrazolo[3,4-b]pyridin-7-yl]- acetic acid E32 Int. D51 [6-(2-(2,3-difluorophenyl)ethyl)-2- isopropyl-4-oxo-2,4-dihydropyrazolo- [3,4-b]pyridin-7-yl]acetic acid E33 Int. D15 [2-(2-(2,3-difluorophenyl)ethyl)-7- methyl-4-oxo-4H-[1,8]naphthyridin-1- yl]acetic acid E34 Int. D44 [2-(2,3-difluorobenzylthio)-4-oxo-4H- [1,8]naphthyridin-1-yl]acetic acid E35 Int. D42 [5-(2,3-difluorobenzylthio)-7-oxo-7H- thieno[2,3-b]pyridin-4-yl]acetic acid E36 Int. D33 [2-(2-(2,3-difluorophenyl)ethyl)-4- oxo-5,6-trimethylenepyridin-1-yl]- acetic acid E37 Int. D34 [2-(2-(2,3-difluorophenyl)ethyl)-4- oxo-5,6-tetramethylenepyridin-1-yl]- acetic acid E38 Int. D52 [6-(2-(2,3-difluorophenyl)ethyl)- 2-(2-methoxyethyl)-4-oxo-2,4- dihydropyrazolo[3,4-b]pyridin-7-yl]acetic acid -
- A mixture of 2-(2-(2,3-difluorobenzylthio)-4-oxo-4H-quinolin-1-yl)acetic acid (Int. E1) (0.15 g, 1 equiv), N,N-diethyl-N′-(4′-trifluoromethylbiphenyl-4-ylmethyl)ethane-1,2-diamine (Int. A2) (0.145 g, 1 equiv), O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) (0.154 g, 1.2 equiv) and diisopropylamine (0.174 ml, 2.4 equiv) in dichloromethane (10 ml) was stirred at room temperature overnight, then washed with aqueous ammonium chloride and aqueous sodium bicarbonate. The organic layer was dried and evaporated, and the product purified by column chromatography (silica, 4% [2M ammonia in methanol] in dichloromethane). Product fractions were evaporated to an off-white foam (0.201 g). This free base (0.201 g) was dissolved in methanol (10 ml), tartaric acid (0.044 g) was added, the mixture stirred for 5 min then evaporated. Trituration with ether gave the bitartrate salt as an off-white solid (0.209 g).1H-NMR (d6-DMSO, ca 2:1 rotamer mixture) δ1.03 (6H, m), 2.59 (6H, m), 3.41-3.62 (2H, m), 4.26 (2H, 2× s), 4.65-4.83 (2H, m), 5.12-5.56 (2H, m), 6.44 (1H, 2× s), 6.93-7.12 (3H, m), 7.30-7.75 (11H, m), 8.41 (1H, 2× d); MS (APCI+) found (M+1)=694; C38H36F5N3O2S requires 693.
-
- A mixture of 2-[2-(2-(2,3-difluorophenyl)ethyl)4oxo-4H-quinolin-1-yl]-acetic acid (Int. E2) (0.26 g, 1 equiv), N,N-diethyl-N′-(4′-trifluoromethylbiphenyl-4-ylmethyl)ethane-1,2-diamine (Int A2) (0.265 g, 1 equiv), HATU (0.28 g, 1.2 equiv) and diisopropylamine (0.32 ml, 2.4 equiv) in dichloromethane (15 ml) was stirred at room temperature overnight, then washed with aqueous ammonium chloride and aqueous sodium bicarbonate. The organic layer was dried and evaporated, and the product purified by column chromatography (silica, 2% [2M ammonia in methanol] in dichloromethane). Product fractions were evaporated to an off-white foam (0.201 g). Trituration with ether gave the title compound as a white solid (0.476 g).1H-NMR (d6-DMSO, ca 2:1 rotamer mixture) δ0.93 (6H, 2× t), 2.38-2.80 (4H, m), 2.90-3.05 (4H, m), 3.45 (2H, m), 4.30-4.95 (4H, m), 5.23-5.58 (2H, m), 6.06 (1H, 2× s), 7.14-7.38 (7H, m), 7.50-7.95 (7H, m), 8.16 (1H, m); MS (APCI+) found (M+1)=676; C39H38F5N3O2 requires 675.
- N-(2-Diethylaminoethyl)-2-[2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4H-quinolin-1-yl]-N-(4′-trifluoromethylbiphenyl-4-ylmethyl)acetamide bitartrate
- Treatment of N-(2-Diethylaminoethyl)-2-[2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4H-quinolin-1-yl]-N-(4′-trifluoromethylbiphenyl-4-ylmethyl)acetamide (Ex 2) with d-tartaric acid as for Example 1 gave the title compound as the bitartrate salt.
-
- The free base was prepared from Int. E12 and Int. A2 by the method of Example 1. The bitartrate was formed as in example 1.1H NMR (d6-DMSO) δ0.93, 0.99 (6H, 2× t), 1.95 (2H, m), 2.57-2.88 (8H, m), 3.21-3.60 (4H, m), 4.21 (2H, s), 4.23, 4.29 (2H, 2× s), 4.64, 4.75 (2H, 2× s) 6.15 6.17 (1H, 2× s), 7.12-7.21 (2H, m), 7.34-7.45 (3H, m), 7.67 (1H, d), 7.71 (1H, d), 7.85 (4H, m); MS (APCI) found (M+1)=684; C37H38F5N3O2S requires 683.
-
- The free base was prepared from Int. E1 and Int. A42 by the method of Example 1, except using DMF as solvent in place of dichloromethane. 1.97 g of this material was crystallised from n.butyl acetate (10 ml) to give the title compound (1.35 g).1H-NMR (CD3OD) δ1.7-2.05 (4H, m), 2.05-2.3 (2H, 2× t), 2.5-2.65 (2H, m), 2.95-3.1 (2H, m), 3.3 (3H, s), 3.45-3.55 (2H, m), 3.9-4.05+4.4-4.5 (1H, 2× m), 4.37+4.48 (2H, 2×s), 4.71+4.87 (2H, 2× br s), 5.31+5.68 (2H, 2× s), 6.44+6.52 (1H, 2×s), 6.95-7.3 (3H, m), 7.35-7.85 (11H, m), 8.2-8.35 (1H, m); MS (APCI+) found (M+1) 736; C40H38F5N3O3S requires 735.
-
- The free base was prepared from Int. E1 and Int. A5 by the method of Example 1, except using DMF as solvent in place of dichloromethane. Chromatography (acetone to acetone/MeOH 4:1) yielded the free base (˜7:3 rotomer mixture);1H-NMR (CDCl3) δ1.7-1.8 (3.7H, m), 1.9-2.15 (2.3H, m), 2.26 (2.1H, s), 2.3 (0.9H, s), 2.9 (1.4H, d, J=11.5 Hz), 2.98 (0.6H, d, J=10 Hz), 3.7 (0.3H, m), 4.2 (1.4H,s), 4.27 (0.6H, s), 4.62 (0.7H, m), 4.69 (0.6H, s), 4.73 (1.4H, s), 5.01 (1.4H, br s), 5.35 (0.6H, (0.6H, br s), 6.41 (0.7H, s), 6.49 (0.3H, s), 6.9-7.2 (4H, m), 7.29-7.75 (1OH, m), 8.38 (0.7H, d, J=8 Hz), 8.4 (0.3H, d, J=8 Hz); MS (APCI+) found (M+1)=692; C38H34F5N3O2S requires 691
- Conversion to bitartrate salt was carried out as in Example 1.
-
- To a stirring mixture of intermediate A5 (12.53 g, 1 equiv) and diisopropylethylamine (18.82 ml, 3 equiv) in dry THF (125 ml) under an argon atmosphere was added in one portion O-(7-azabenzotriazol-1-yl)N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) (16.65 g, 1.5 equiv). A solution of Int. E21 (12.4 g, 1 equiv), in dry N-methylpyrrolidone (25 ml) and dry THF (100 ml) was then added dropwise over 1.5 h. After 72 h the solvents were evaporated under reduced pressure and the residue treated with aqueous sodium bicarbonate and extracted 3 times with ethyl acetate. The combined extracts were washed with aqueous sodium bicarbonate, aqueous ammonium chloride then aqueous sodium bicarbonate, dried (Na2SO4) and evaporated. The residue was chromatographed (fine silica, 2M ammonia in methanol/dichloromethane) and the product obtained dissolved in dichloromethane and washed twice with 0.5M aqueous sodium hydroxide then brine, dried (Na2SO4) and the solvent evaporated. Crystallisation then recrystallisation from acetonitrile gave the free base, 10.75 g. This material (10.69 g, 1 equiv) together with L-tartaric acid (2.39 g, 1 equiv) was dissolved in methanol (50 ml) and evaporated to a thick syrup which was triturated with ether to give the bitartrate salt as an off-white solid (12.4 g). 1H NMR (d6-DMSO), 81.58-1.66 and 1.80-2.05 (4H, m), 2.40-2.65 (5H, m), 2.93-3.19 (6H, m), 4.15 (2H, s), 4.16-4.38 (1H, m), 4.62, 4.88, 5.42, 5.68 (4H, 4× s), 6.00, 6.03 (1H, 2× s), 7.10-7.97 (13H, m), 8.48 (1H, m), 8.82-8.90 (1H, m); MS (APCI+) found (M+1)=675; C38H35F5N4O2 requires 674.
-
- To a stirring mixture of Int. A42 (14.12 g, 1 equiv) and diisopropylethylamine (18.82 ml, 3 equiv) in dry THF (125 ml) under an argon atmosphere was added in one portion O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) (16.65 g, 1.5 equiv). A solution of Int. E21 (12.4 g, 1 equiv), in dry N-methylpyrrolidone (25 ml) and dry THF (100 ml) was then added dropwise over 1.5 h. After 16 h the solvents were evaporated under reduced pressure and the residue treated with 1M hydrochloric acid (200 ml) and extracted 3 times with ethyl acetate. The combined extracts were washed with 1M hydrochloric acid (200 ml), brine, 2M sodium hydroxide ×2, dried (Na2SO4) and evaporated. The residue was chromatographed (fine silica, 2M ammonia in methanol/dichloromethane) and the oil obtained dissolved in ether and allowed to crystallise then recrystallised from dichloromethane/ether, yield 11.98 g (free base). 13.64 g of title compound formed in the same manner as above was recrystallised from hot n.butyl acetate (70 ml) to give crystalline title compound (11.5 g). 1H NMR (CD3OD), δ1.6-2.35 (6H, m), 2.45-2.65 (2H, 2× m), 2.9-3.12 (4H, m), 3.12-3.55 (2H, 2×t), 4.17+4.40 (1H, 2× m), 4.71+4.93 (2H, s), 5.3-6.0 (2H, br), 6.26+6.31 (1H, 2×s), 7.0-7/35 (3H, m), 7.3-7.4 (1H, d), 7.45-7.6 (2H, m), 7.6-7.9 (6H, m), 8.61 (1H, br t), 8.87 (1H, m); MS (APCI+) found (M+1)=719, C40H39F5N4O3 requires 718.
-
- The free base was prepared from Int. E34 and Int. A42 by the method of Example 7. Chromatography (EtOAc/acetone/MeOH 9:1) yielded the free base.1H-NMR (d6-DMSO) (˜1:1 rotomer mixture): a δ1.55 (1H, br d, 11 Hz), 1.75-1.9 (4H, m), 2.15 (0.5H, t, J=8 Hz), 2.3 (1H, br t, J=11 Hz), 2.66 (2H, m), 3.06 (2H, br t, 12 Hz), 3.2 (1.5H, s), 3.25 (1.5H, s), 3.3 (0.5H, t, J=7 Hz), 3.45 (2H, m), 4.1 (0.5H, m), 4.2 (2H, s), 4.25 (0.5H, m), 4.5 (1H, s), 4.59 (2H, br s), 4.8 (1H, br), 5.75 (1H, br), 6.35 (0.5H, s), 6.38 (0.5H, s), 7.16 (1H, m), 7.2-7.4 (4H, m), 7.6 (2H, d, J=8 Hz), 7.7 (5H, m), 8.5 (1H, m), 8.7 (2H, br), 8.82 (1H, m); MS (APCI+) found (M+1)=737; C39H37F5N4O3S requires 736.
-
- The free base was prepared from Int. E1 and Int A29 by the method of Example 1, except using DMF as solvent in place of dichloromethane. The bitartrate salt was formed as in example 1.1H NMR (d6-DMSO) δ1.07 (3H, t), 1.22 (3H, t), 1.70-1.91 (4H, m), 2.37 (2H, m), 2.66 (4H, m), 3.20 (2H,m), 4.12 (2H, s), 4.44 (3H, m), 4.70 (2H, m), 5.34 (2H, m), 6.27, 6.33 (1H, 2× s), 7.11-7.76 (14H,m), 8.14 (1H, m); MS (APCI) found (M+1)=666; C40H41F2N3O2S requires 665.
-
- Prepared from intermediate E28 (0.15 g) and intermediate A40 (0.149 g) using HATU (0.188 g) and diisopropylamine (0.172 ml) followed by bitartrate salt formation as in example 1.1H-NMR (d6-DMSO) δ0.95-1.15 (3H, m), 1.6-2.1 (4H, m), 2.84 (3H, 2×s), 2.3-3.25 (10H, m) 4.14 (2H, s), 4.05-4.4 (1H, 2×m), 4.62+4.83 (2H, 2× br s), 5.37+5.62 (2H, 2×br s), 6.02+6.05 (1H 2× s), 7.05-7.4 (4H, m), 7.5-7.7 (2H, m), 7.7-8.0 (5H, m); MS (APCI+) found (M+1)=709; C38H37F5N4O2S requires 708.
-
- Prepared from intermediate E2 (0.295 g) and A23 (0.30 g) using HATU (0.395 g) and diisopropylamine (0.3 ml) followed by bitartrate salt formation as in example 1. Spectral details of the free base are quoted below.1H-NMR (CDCl3) δ1.0-1.2 (3H, m), 1.8-2.15 (1H, m), 2.15-3.15 (11H, m), 4.6-5.2 (5H, m), 6.14+6.24 (1H, 2× s), 6.8-7.8 (14H, m), 8.25-8.45 (1H, m); MS (APCI+) found (M+1)=674; C39H36F5N3O2 requires 673.
-
- Prepared from intermediate E1 (0.312 g) and A23 (0.30 g) using HATU (0.395 g) and diisopropylamine (0.3 ml) followed by bitartrate salt formation as in example 1. Spectral details of the free base are quoted below.1H-NMR (CDCl3) δ0.95-1.35 (3H, m), 1.8-2.8 (6H, m), 2.8-3.1 (2H, m), 4.19+4.25 (2H, 2×s), 4.5-5.5 (5H, m), 6.36+6.43 (1H, 2× s), 6.85-7.2 (4H, m), 7.2-7.85 (10H, m), 8.25-8.5 (1H, m).
-
- Example 5 was converted to the bitartrate by the method of example 1.
-
- Example 5 (1.0 g) was dissolved in isopropanol (10 ml) and 1 M HCl in diethyl ether (4 ml) added. A thick precipitate formed. The mixture was evaporated under reduced pressure and the residue dissolved in isopropanol (10 ml) with heating. On cooling a thick precipitate formed that was filtered and dried. 0.2 g of this material was recrystallised from further isopropanol (10 ml) to give the title compound (0.132 g).1H-NMR (CD3OD) δ1.9-2.6 (4H, m), 3.0-3.5 (4H, m), 3.36+3.41 (3H, 2×s), 3.5-3.8 (4H, m), 7.0-7.5 (4H, m), 7.5-7.65 (3H, m), 7.65-7.85 (5H, m), 7.9-8.2 (2H, m), 8.4-8.55 (1H, m).
-
- To a solution of example 5 (1.0 g) in tetrahydrofuran (THF) (10 ml) was added a solution of paratoluenesulphonic acid monohydrate (1 equiv) in THF (5 ml) and the mixture stirred at 0° C. After 18 h, further THF was added and the mixture filtered and dried to give a solid (0.87 g). 0.7 g of this material was dissolved in THF (9 ml) and left at 0° C. for 18 h. The solid formed was filtered and washed with further THF (2 ml) and dried to give the title compound as a crystalline salt (0.67 g).1H-NMR (CD3OD) δ1.9-2.4 (4H, m), 2.31 (3H, s), 3.0-3.45 (7H, m′s), 3.5-3.75 (4H, m), 4.3-4.55 (3H, m), 4.6-5.0 (2H, m), 5.40+5.73 (2H, 2× s), 6.47 (1H, s), 6.95-7.3 (5H, m), 7.3-7.85 (13H, m),
-
- Example 8 (8 g, 1 equiv) together with L-tartaric acid (1.67 g, 1 equiv) was dissolved in methanol (50 ml) and evaporated to a thick syrup which was triturated with ether to give the bitartrate salt as an off-white solid (9.54 g).1H NMR (CD3OD), δ1.53-1.64 and 1.70-1.87 (4H, m), 2.15-2.43 and 2.55-2.69 (4H, m), 2.93-3.50 (11 H, m), 4.05-4.32 (1H, m), 4.19 (2H, s), 4.61, 4.87, 5.42, 5.67 (4H, 4× s), 6.08, 6.11 (1H, 2× s), 7.09-7.94 (12H, m), 8.49 (1H, m), 8.82-8.90 (1H, m); MS (APCI+) found (M+1)=719, C40H39F5N4O3 requires 718.
-
- Example 8 (0.5 g) in methylethylketone (4 ml) was mixed with 4M HCl in dioxane (0.174 ml). After 18 h at 0° C., a small amount of solid was filtered off. The mother liquors were evaporated under reduced pressure and the residue crystallised from acetone (4 ml). The solid so formed was recrystallised from acetone to give the title compound (0.336 g).1H NMR (CD3OD), δ1.85-2.5 (4H, m), 2.95-3.15 (4H, br), 3.15-3.5 (7H, ss+m), 3.8 (4H, m), 4.38+4.61 (1H, br m), 4.74+4.97 (2H, 2×s), 5.4-6.0 (2H, br), 6.29 (1H, s), 7.0-7.25 (3H, m), 7.3-7.65 (2H, m), 7.65-7.9 (7H, m), 8.6-8.7 (1H, m), 8.8-8.9 (1H, m).
-
- Example 8 (0.321 g) in ethanol (3 ml) was stirred overnight with 4M HCl in dioxan (0.25 ml). The solid was collected by filtration, washed with ethanol and dried to give the title compound (0.31 g).1H NMR (CD3OD), δ1.8-2.55 (4H, m), 3.0-3.8 (15H, m), 4.15-5.1 (3H, m), 5.6-6.6 (2H, br), 6.94+6.97 (1H, 2×s), 7.0-7.25 (3H, m), 7.3-7.95 (9H, m), 8.8-8.95 (1H, m), 9.15-9.25 (1H, m).
- The following Examples were made by the general method of Example 1, using an appropriate solvent such as dimethylformamide or dichloromethane:
Ex. No. Precursors Structure Name 20 Int. E3 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(4- fluorobenzylthio)-4-oxo-4H-quinolin-1- yl]-N-(4′-trifluoromethylbiphenyl-4- ylmethyl)-acetamide bitartrate 21 Int. E4 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(4- fluorobenzylthio)-4-oxo-5,6-trimethylene- pyridin-1-yl]-N-(4′- trifluoromethyl-biphenyl-4- ylmethyl)acetamide bitartrate 22 Int. E12 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2,3- difluorobenzylthio)-4-oxo-5,6- trimethylenepyridin-1-yl]-N-(4′- trifluoromethyl-biphenyl-4- ylmethyl)acetamide bitartrate 23 Int. E5 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(4- fluorophenyl)ethyl)4-oxo-4H- methylbiphenyl-4-ylmethyl)-acetamide 24 Int. E6 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2- (3,4-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 25 Int. E8 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2- (2-fluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 26 Int. E9 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2- (3-chlorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 27 Int. E21 Int A2 N-(2-Diethylaminoethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-[1,8]naphthyridin-1-yl)]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 28 Int. E21 Int A40 N-(1-Ethylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-[1,8]naphthyridin-1-yl)]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide 29 Int. E2 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 30 Int. E2 Int. A22 N-(2-Pyrrolidin-1-ylethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)-acetamide bitartrate 31 Int. E2 Int. A41 N-(1-Isopropylpiperidin-4-yl)-2-[2- (2-(2,3-difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 32 Int. E2 Int. A20 N-(2-piperidin-1-ylethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 33 Int. E22 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2,3- difluorobenzylthio)7-fluoro-4-oxo- 4H-quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 34 Int. E26 Int. A2 N-(2-Diethylaminoethyl)-5-[2-(2- (2,3-difluorophenyl)ethyl)-2-methyl-7- oxo-7H-thieno[3,2-b]pyridin-4-yl]-N-(4′- trifluoromethylbiphenyl-4-ylmethyl)- acetamide bitartrate 35 Int. E24 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-5,6- dimethyl-4-oxo-4H-pyridin-1-yl]- N-(4′-trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 36 Int. E23 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-5-ethyl- 4-oxo-4H-pyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 37 Int. E2 Int. A42 N-(1-(2-methoxyethyl)piperidin-4-yl)-2-[2- (2-(2,3-difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 38 Int. E2 Int. A5 N-(1-methylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 39 Int. E27 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-thieno[3,4-b]pyridin-1-yl]-N- (4′-trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 40 Int. E1 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[2-(2,3- difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 41 Int. E1 Int. A22 N-(2-pyrrolidin-1-ylethyl)-2-[2- (2,3-difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 42 Int. E30 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[6-(2- (2,3-difluorophenyl)ethyl)-2- methyl-4-oxo-4H-pyrazolo[3,4- b]pyridin-7-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 43 Int. E1 Int. A41 N-(1-isopropylpiperidin-4-yl)-2-[2- (2,3-difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 44 Int. E2 Int. A25 N-(1-ethylpiperidin-4-ylmethyl)-2- [2-(2-(2,3-difluorophenyl)ethyl)-4- oxo-4H-quinolin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 45 Int. E1 Int. A24 N-(3-Diethylaminopropyl)-2-[2- (2,3-difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 46 Int. E2 Int. A32 N-(4-pyrrolidin-1-ylbutyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)4-oxo- 4H-quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 47 Int. E2 Int. A24 N-(3-Diethylaminopropyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitaxtrate 48 Int. E1 Int. A32 N-(4-pyrrolidin-1-ylbutyl)-2-[2- (2,3-difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 49 Int. E25 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[5-(2,3- difluorobenzylthio)-7-oxo-7H- thieno[3,2-b]pyridin-4-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 50 Int. E28 Int. A2 N-(2-Diethylaminoethyl)-2-[5-(2- (2,3-difluorophenyl)ethyl)-2- methyl-7-oxo-7H-thiazolo[4,5- b]pyridin-4-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 51 Int. E1 Int. A27 N-(2-Diethylaminoethyl)-2-[2-(2,3- difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(4′-ethylbiphenyl- 4-ylmethyl)acetamide bitartrate 52 Int. E2 Int. A27 N-(2-Diethylaminoethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′- ethylbiphenyl-4-ylmethyl)- acetamide bitartrate 53 Int. E1 Int. A28 N-(2-Diethylaminoethyl)-2-[2-(2,3- difluorobenzyltbio)-4-oxo-4H- quinolin-1-yl]-N-(4′- isopropylbiphenyl4-ylmethyl)- acetamide bitartrate 54 Int. E2 Int. A28 N-(2-Diethylaminoethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′- isopropylbiphenyl-4-ylmethyl)- acetamide bitartrate 55 Int. E34 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2,3- difluorobenzylthio)-4-oxo-4H- [1,8]naphthyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 56 Int. E34 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[2-(2,3- difluorobenzylthio)-4-oxo-4H- [1,8]naphthyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 57 Int. E2 Int. A26 N-(2-Diethylaminoethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 58 Int. E1 Int. A26 N-(2-Diethylaminoethyl)-2-[2-(2,3- difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(4′- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 59 Int. E2 Int. A43 N-(1-Ethoxycarbonylmethylpiperidin-4-yl)-2- [2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 60 Int. E21 Int. A41 N-(1-isopropylpiperidin-4-yl)-2-[2- (2-(2,3-difluorophenyl)ethyl)-4- oxo-4H-[1,8]naphthyridin-1-yl]-N- (4′-trifluoromethyibiphenyl-4- ylmethyl)acetamide bitartrate 61 Int. E1 Int. A30 N-(2-Diethylaminoethyl)-2-[2-(2,3- difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(3′,4′- dimethylbiphenyl-4-ylmethyl)- acetamide bitartrate 62 Int. E21 Int. A48 N-(1-(t-butoxycarbonyl)piperidin-4- yl)-2-[2-(2-(2,3- difluorophenyl)ethyl)-4-oxo-4H- [1,8]naphthyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 63 Int. E1 Int. A31 N-(2-Diethylaminoethyl)-2-[2-(2,3- difluoroberizylthio)-4-oxo-4H- quinolin-1-yl]-N-(3′,4′- difluorobiphenyl-4-ylmethyl)- acetamide bitartrate 64 Int. E35 Int. A2 N-(2-Diethylaminoethyl)-2-[6-(2,3- difluorobenzylthio)-4-oxo-4H- thieno[2,3-b]pyridin-7-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 65 Int. E34 Int. A5 N-(1-methylpiperidin-4-yl)-2-[2- (2,3-difluorobenzylthio)-4-oxo-4H- [1,8]naphthyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 66 Int. E2 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[2-(2- (2,3,4-trifluorophenylethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 67 Int. E29 Int. A2 N-(2-diethylaminoethyl)-2-[6-(2,3- difluorobenzylthio)-2-methyl-4- oxo-2,4-dihydro- pyrazolo[3,4-b]pyridin-7-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 68 Int. E31 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[6-(2- (2,3-difluorophenyl)ethyl)-2-ethyl- 4-oxo-2,4- dihydropyrazolo[3,4-b]pyridin-7- yl]-N-(4′-trifluoromethylbiphenyl- 4-ylmethyl)acetamide bitartrate 69 Int. E32 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[6-(2- (2,3-difluorophenyl)ethyl)-2-isopropyl-4- oxo-2,4-dihydropyrazolo[3,4-b]pyridin-7- yl]-N-(4′-trifluoromethylbiphenyl- 4-ylmethyl)acetamide bitartrate 70 Int. E2 Int. A29 N-(1-Ethylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′-ethyl- biphenyl-4-ylmethyl)acetamide bitartrate 71 Int. E28 Int. A41 N-(1-isopropylpiperidin-4-yl)-2-[5- (2-(2,3-difluorophenyl)ethyl)-2- methyl-7-oxo-7H-thiazolo[4,5- b]pyridin-4-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 72 Int. E28 Int. A42 N-(1-(2-methoxyethyl)piperidin-4- yl)-2-[5-(2-(2,3- difluorophenyl)ethyl)-2-methyl-7- oxo-7H-thiazolo[4,5-b]pyridin-4- yl]-N-(4′-trifluoromethylbiphenyl- 4-ylmethyl)acetamide bitartrate 73 Int. E36 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 5,6-trimethylenepyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 74 Int. E36 Int. A5 N-(1-methylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 5,6-trimethylenepyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 75 Int. E36 Int. A42 N-(1-(2-methoxyethyl)piperidin-4- yl)-2-[2-(2,3- difluorophenyl)ethyl)-4-oxo-5,6- trimethylenepyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 76 Int. E36 Int. A41 N-(1-isopropylpiperidin-4-yl)-2-[2- (2-(2,3-difluorophenyl)ethyl)-4- oxo-5,6-trimethylenepyridin-1-yl]- N-(4′-trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 77 Int. E13 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[5-(2- (2,3-difluorophenyl)ethyl)-2- methyl-7-oxo-2,7- dihydropyrazolo[4,3-b]pyridin-4- yl]-N-(4′-trifluoromethylbiphenyl- 4-ylmethyl)acetamide bitartrate 78 Int. E14 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[5-(2- (2,3-difluorophenyl)ethyl)-1- methyl-7-oxo-1,7- dihydropyrazolo[4,3-b]pyridin-4- yl]-N-(4′-trifluoromethylbiphenyl- 4-ylmethyl)acetamide bitartrate 79 Int. E36 Int. A2 N-(1-Ethylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 5,6-trimethylenepyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 80 Int. E33 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-7- methyl-4-oxo-4H- [1,8]naphthyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 81 Int. E33 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-7- methyl-4-oxo-4H- [1,8]naphthyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 82 Int. E33 Int. A5 N-(1-methylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-7- methyl-4-oxo-4H- [1,8]naphthyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 83 Int. E33 Int. A41 N-(1-isopropylpiperidin-4-yl)-2-[2- (2-(2,3-difluorophenyl)ethyl)-7- methyl-4-oxo-4H- [1,8]naphthyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 84 Int. E33 Int. A42 N-(1-(2-methoxyethyl)piperidin-4- yl)-2-[2-(2-(2,3- difluorophenyl)ethyl)-7-methyl-4- oxo-4H-[1,8]naphthyridin-1-yl]-N- (4′-trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 85 Int. E12 Int. A5 N-(1-methylpiperidin-4-yl)-2-[2- (2,3-difluorobenzylthio)-4-oxo-5,6- trimethylenepyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 86 Int. E12 Int. A40 N-(1-Ethylpiperidin-4-yl)-2-[2-(2,3- difluorobenzylthio)-4-oxo-5,6- trimethylenepyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 87 Int. E12 Int. A41 N-(1-isopropylpiperidin-4-yl)-2-[2- (2,3-difluorobenzylthio)-4-oxo-5,6- trimethylenepyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 88 Int. E12 Int. A42 N-(1-(2-methoxyethyl)piperidin-4- yl)-2-[2-(2,3-difluorobenzylthio)-4- oxo-5,6-trimethylenepyridin-1-yl]- N-(4′-trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 89 Int. E37 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 5,6-tetramethylenepyridin-1-yl]-N- (4′-trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 90 Int. E1 Int. A45 N-(1-methylpiperidin-4-yl)-2-[2- (2,3-difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(4′- chlorobiphenyl-4-ylmethyl)- acetamide bitartrate 91 Int. E2 Int. A45 N-(1-methylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′- chlorobiphenyl-4-ylmethyl)- acetamide bitartrate 92 Int. E2 Int. A44 N-(1-Ethylpiperidin-4-yl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′- chlorobiphenyl-4-ylmethyl)- acetamide bitartrate 93 Int. E2 Int. A47 N-(1-(2-methoxyethyl)piperidin-4- yl)-2-[2-(2-(2,3- difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′- chlorobiphenyl-4-ylmethyl)- acetamide bitartrate 94 Int. E2 Int. A46 N-(1-isopropylpiperidin-4-yl)-2-[2- (2-(2,3-difluorophenyl)ethyl)-4- oxo-4H-quinolin-1-yl]-N-(4′- chlorobiphenyl-4-ylmethyl)- acetamide bitartrate 95 Int. E30 Int. A2 N-(2-diethylaminoethyl)-2-[6-(2- (2,3-difluorophenyl)ethyl)-2- methyl-4-oxo-4H-pyrazolo[3,4- b]pyridin-7-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 96 Int. E34 Int. A48 N-(1-(t-butoxycarbonyl)piperidin-4- yl)-2-[2-(2,3-difluorobenzylthio)-4- oxo-4H-[1,8]naphthyridin-1-yl]-N- (4′-trifluoromethylbiphenyl-4- ylmethyl)acetamide 97 Int. E38 Int. A40 N-(1-ethylpiperidin-4-yl)-2-[6-(2- (2,3-difluorophenyl)ethyl)-2-(2- methoxyethyl)-4-oxo-4H-pyrazolo- [3,4-b]pyridin-7-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate - The following intermediates were prepared by the method of Example 1, but were not included in biological testing:
No. Precursors Structure Name F1 Int. E1 Int. A48 N-(1-(t-butoxycarbonyl)piperidin-4- yl)-2-[2-(2,3-difluorobenzylthio)-4- oxo-4H-quinolin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide F2 Int. E2 Int. A48 N-(1-(t-butoxycarbonyl)piperidin-4- yl)-2-[2-(2-(2,3- difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide F3 Int. E36 Int. A48 N-(1-(t-butoxycarbonyl)piperidin-4- yl)-2-[2-(2-(2,3- difluorophenyl)ethyl)-4-oxo-5,6- trimethylenepyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide F4 Int. E1 Int. A33 N-(2-(N′-ethyl-N′-(t- butoxycarbonyl)aminoethyl)-2-[2- (2,3-difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide F5 Int. E2 Int. A33 N-(2-(N′-ethyl-N′-(t- butoxycarbonyl)aminoethyl)-2-[2- (2-(2,3-difluorophenyl)ethyl)-4- oxo-4H-quinolin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide -
- A solution of N,N-diethyl-N′-(4′-trifluoromethyl-biphenyl-4-ylmethyl)ethane-1,2-diamine (0.242 g, 0.69 mmol) (Int. A2), 1-(3-dimethylaminopropyl)3-ethylcarbodiimide (0.265 g, 1.39 mmol), 1-hydroxybenzotriazole hydrate (0.02 g), 2-(4-oxo-2-[2-(2,3,4-trifluorophenyl)ethyl]-4H-quinolin-1-yl)-acetic acid (Int E10) (0.25, 0.69 mmol) and N,N-diisopropylethylamine (0.15 ml, 0.86 mmmol) in dichloromethane (5 ml) was stirred at ambient temperature overnight then washed with aqueous sodium bicarbonate and evaporated. The residue was purified by chromatography (10 g silica cartridge, dichloromethane-50% acetone/dichloromethane) and triturated with hexane to give the title compound as a white solid (0.23 g, 47%).1H-NMR (d6 DMSO, rotamer mixture) δ0.89-0.98 (6H, m), 2.33-2.67 (6H, m), 2.84-3.00 (4H, m), 3.45-3.61 (2H, m), 4.67/4.92 (2H, 2× s), 5.24/5.50 (2H, 2× s), 6.02/6.05 (1H, 2× s), 7.19-7.20 (4H, m), 7.51-7.88 (9H, m), 8.16 (1H, t); MS (APCI+) found (M+1)=694; C39H37F6N3O2 requires 693.
- d-Tartaric acid (0.028 g, 0.19mmol) was added to a solution of the free base (0.13 g, 0.19 mmol) in methanol (5 ml) with stirring. The resulting solution was evaporated to yield the salt (0.158 g).1H-NMR (d6 DMSO, rotamer mixture) δ1.00 (6H, br s), 2.51-2.97 (10H, m), 3.64 (2H, br s), 4.23 (2H, br s), 4.67/4.93 (2H, 2× s), 5.28/5.50 (2H, 2× s), 6.05 (1H, br s) 7.23-7.83 (13H, m), 8.17 (1H, s); MS (APCI+) found (M+1)=694; C39H37F6N3O2 requires 693.
- The following compounds were prepared by the method of Example 99
Ex. No. Precursors Structure Name 100 Int. E7 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2- (2,4-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 101 Int. E11 Int. A2 N-(2-Diethylaminoethyl)-2-[2-(2- (3-fluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate -
- To intermediate F1 (0.55 g) in dichloromethane (6 ml) was added trifluoroacetic acid (2.5 ml) at room temperature. The mixture was stirred for 2 h, the solvent removed under reduced pressure and diethyl ether added. The solid so formed was filtered and washed with diethyl ether to give a solid that was partitioned between dilute sodium bicarbonate and dichloromethane. The aqueous layer was extracted with further dichloromethane and the combined organic layers dried over K2CO3, filtered and evaporated under reduced pressure to a solid (0.42 g). This free base (0.42 g) was dissolved in methanol (10 ml), tartaric acid (0.044 g) was added, the mixture stirred for 5 min then evaporated under reduced pressure. Trituration with ether gave the bitartrate salt as an off-white solid (0.46 g). 1H-NMR (d6 DMSO, rotamer mixture) δ1.6-2.05 (4H, m), 2.7-3.05 (2H, m), 3.1-3.4 (2H, m), 3.88 (2H, s), 4.1-5.8 (7H, br ms) 6.27+6.32 (1H, 2×s), 7.05+7.55 (6H, m), 7.55-7.95 (8H, m), 8.14 (1H, dt); MS (APCI+) found (M+1)=678; C37H32F5N3O2S requires 677.
- The following examples were prepared by the method of Example 105:
Ex. No. Precursors Structure Name 106 Int. F2 N-(piperidin-4-yl)-2-[2-(2-(2,3- difluorophenyl)ethyl)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide bitartrate 107 Int. F3 N-(piperidin-4-yl)-2-[2-(2-(2,3- difluorophenyl)ethyl)-4-oxo-5,6- trimethylenepyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4- ylmethyl)acetamide bitartrate 108 Example 62 N-(piperidin-4-yl)-2-[2-(2-(2,3- difluorophenyl)ethyl)-4-oxo-4H- [1,8]naphthyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4-yl- methyl)acetamide bitartrate 109 Example 96 N-(piperidin-4-yl)-2-[2-(2,3- difluorobenzylthio)-4-oxo-4H- [1,8]naphthyridin-1-yl]-N-(4′- trifluoromethylbiphenyl-4-yl- methyl)acetamide trifluoroacetate 110 Int. F4 N-(2-ethylaminoethyl)-2-[2-(2,3- difluorobenzylthio)-4-oxo-4H- quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide 111 Int. F5 N-(2-ethylaminoethyl)-2-[2-(2- (2,3-difluorophenyl)ethyl)-4-oxo- 4H-quinolin-1-yl]-N-(4′-trifluoro- methylbiphenyl-4-ylmethyl)- acetamide -
- A mixture of Example 59 (0.18 g, 1 equiv), lithium borohydride (0.12 ml, 2M in THF, 1 equiv) and dry THF (2 ml) was heated at reflux under argon overnight, then a further 0.06 ml portion of lithium borohydride solution was added and heating continued for 4 h. Evaporation, aqueous workup and chromatography (silica, 0-10% methanol in dichloromethane) gave the title compound (0.06 g). The bitartrate was prepared as in example 1.1H-NMR (DMSO, rotamer mixture) δ1.5-2.1 (4H, m), 2.5-3.65 (12H, m), 4.15 (2H, s), 3.85-5.8 (SH, br m), 6.01+6.06 (1H, 2× s), 7.0-7.95 (14H, m), 8.05-8.2 (1H, m); MS (APCI+) found (M+1)=704; C40H38F5N3O3 requires 703.
- Biological Data
- 1. Screen for Lp-PLA2 inhibition.
-
- Assays were performed in 96 well titre plates.
- Recombinant LpPLA2 was purified to homogeneity from baculovirus infected Sf9 cells, using a zinc chelating column, blue sepharose affinity chromatography and an anion exchange column. Following purification and ultrafiltration, the enzyme was stored at 6 mg/ml at 4° C. Assay plates of compound or vehicle plus buffer were set up using automated robotics to a volume of 170 μl. The reaction was initiated by the addition of 20 μl of 10× substrate (A) to give a final substrate concentration of 20μM and 10 μl of diluted enzyme to a final 0.2 nM LpPLA2.
- The reaction was followed at 405 nm and 37° C. for 20 minutes using a plate reader with automatic mixing. The rate of reaction was measured as the rate of change of absorbance.
- Results
- The compounds described in the Examples were tested as described above and had IC50 values in the range <0.1 to 100 nM.
Claims (18)
1. A compound of formula (I):
in which:
R1 is an aryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-6)alkyl, C(1-6)alkoxy, C(1-6)alkylthio, hydroxy, halogen, CN, mono to perfluoro-C(1-4)alkyl, mono to perfluoro-C(1-4)alkoxyaryl, and arylC(1-4)alkyl;
R2 is halogen, C(1-3)alkyl, C(1-3)alkoxy, hydroxyC(1-3)alkyl, C(1-3)alkylthio, C(1-3)alkylsulphinyl, aminoC(1-3)alkyl, mono- or di-C(1-3)alkylaminoC(1-3)allyl, C(1-3)alkylcarbonylaminoC(1-3)alkyl, C(1-3)alkoxyC(1-3)alkylcarbonylaminoC(1-3)alkyl, C(1-3)alkylsulphonylaminoC(1-3)alkyl, C(1-3)alkylcarboxy, C(1-3)alkylcarboxyC(1-3)alkyl, and
R3 is hydrogen, halogen, C(1-3)alkyl, or hydroxyC(1-3)alkyl; or
R2 and R3 together with the pyridone ring carbon atoms to which they are attached form a fused 5-or 6-membered carbocyclic ring; or
R2 and R3 together with the pyridone ring carbon atoms to which they are attached form a fused benzo or heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from halogen, C(1-4)alkyl, cyano, C(1-3)alkoxyC(1-3)alkyl, C(1-4)alkoxy or C(1-4)alkylthio, or mono to perfluoro-C(1-4)alkyl;
R4 is hydrogen, C(1-6)alkyl which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from hydroxy, halogen, OR7, COR7, carboxy, COOR7, CONR9R10, NR9R10, NR7COR8, mono- or di-(hydroxyC(1-6)allyl)amino and N-hydroxyC(1-6)alkyl-N—C(1-6)alkylamino; or
R4 is Het-C(0-4)alkyl in which Het is a 5- to 7-membered heterocyclyl ring comprising N and optionally O or S, and in which N may be substituted by COR7, COOR7, CONR9R10, or C(1-6)alkyl optionally substituted by 1, 2 or 3 substituents selected from hydroxy, halogen, OR7, COR7, carboxy, COOR7, CONR9R10 or NR9R10, for instance, piperidin4-yl, pyrrolidin-3-yl;
R5 is an aryl or a heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-6)alkyl, C(1-6)alkoxy, C(1-6)alkylthio, arylC(1-6)alkoxy, hydroxy, halogen, CN, COR7, carboxy, COOR7, NR7COR8, CONR9R10, SO2NR9R10, NR7SO2R8, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy;
R6 is an aryl or a heteroaryl ring which is further optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-6)alkyl, C(1-6)alkoxy, C(1-6)alkylthio, C(1-6)alkylsulfonyl, arylC(1-6)alkoxy, hydroxy, halogen, CN, COR7, carboxy, COOR7, CONR9R10, NR7COR8, SO2NR9R10, NR7SO2R8, NR9R10, mono to perfluoro-C1-4)alkyl and mono to perfluoro-C(1-4)alkoxy, or C(5-10)alkyl;
R7 and R8 are independently hydrogen or C(1-12)alkyl, for instance C(1-4)alkyl (e.g. methyl or ethyl);
R9 and R10 which may be the same or different is each selected from hydrogen, or C(1-12)alkyl, or R9 and R10 together with the nitrogen to which they are attached form a 5- to 7 membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C(1-4)alkyl, C(1-4)alkylcarboxy, aryl, e.g. phenyl, or aralkyl, e.g benzyl, for instance morpholine or piperazine; and
X is a C(2-4)alkylene group (optionally substituted by 1, 2 or 3 substituents selected from methyl and ethyl), CH═CH, (CH2)nS or (CH2)nO where n is 1, 2 or 3.
2. A compound of formula (I) as claimed in claim 1 in which R1 is phenyl optionally substituted by halogen, C(1-6)alkyl, trifluoromethyl, C(1-6)alkoxy.
3. A compound of formula (I) as claimed in claim 1 or 2 in which R2 and R3 together with the pyridone ring carbon atoms to which they are attached form a fused thiazolyl ring substituted by methyl, or a fused 5-membered carbocyclic (cyclopentenyl) ring, or a fused benzo, pyrido, thieno or pyrazolo ring.
4. A compound of formula (I) as claimed in any of claims 1 to 3 in which R4 is selected from the group consisting of 2-(diethylamino)ethyl, 1-ethyl-piperidin-4-yl, 1-(2-methoxyethyl)piperidin-4-yl, 1-methylpiperdin-4-yl or 1-ethylpyrrolidin-3-yl.
5. A compound of formula (I) as claimed in any of claims 1 to 4 in which R5 is phenyl.
6. A compound of formula (I) as claimed in any of claims 1 to 5 in which R6 is phenyl substituted by trifluoromethyl or ethyl in the 4-position.
7. A compound of formula (I) as claimed in any of claims 1 to 6 in which R5 and R6 together form a 4-(phenyl)phenyl or a 2-(phenyl)pyridinyl substituent in which the remote phenyl ring may be optionally substituted by halogen or trifluoromethyl, preferably at the 4-position.
8. A compound of formula (I) as claimed in any of claims 1 to 7 in which X is C(2-4)alkylene or CH2S.
9. A compound of formula (I) as claimed in any of claims 1 to 8 in which R1 is phenyl substituted by 2,3-difluoro; R2 and R3, together with the pyridone ring carbon atoms to which they are attached, form a fused 5-membered carbocyclic (cyclopentenyl) ring, or a fused benzo or pyrido ring; R4 is 2-(diethylamino)ethyl, 1-ethyl-piperidin-4-yl, 1-(2-methoxyethyl)piperidin-4-yl, 1-methylpiperidin-4-yl or 1-ethylpyrrolidin-3-yl; R5 is phenyl; R6 is phenyl substituted by ethyl or trifluoromethyl in the 4-position; and X is CH2S.
10. A compound of formula (I) as claimed in any of claims 1 to 9 in which R1 is phenyl substituted by 2,3-difluoro; R2 and R3, together with the pyridone ring carbon atoms to which they are attached, form a fused thiazolyl ring substituted by methyl, or a benzo or pyrido ring; R4 is 2-(diethylamino)ethyl, 1-ethyl-piperidin-4-yl, 1-(2-methoxyethyl)piperidin-4-yl, 1-methylpiperidin-4-yl or 1-ethylpyrrolidin-3-yl; R5 is phenyl; R6 is phenyl substituted by trifluoromethyl in the 4-position; and X is (CH2)2.
11. A compound of formula (I) as claimed in any of claims 1 to 10 in which R1 is phenyl substituted by 2,3-difluoro; R2 and R3, together with the pyridone ring carbon atoms to which they are attached, form a fused benzo or pyrido ring; R4 is 1-(2-methoxyethyl)piperidin-4-yl; R5 and R6 together form a 4-(phenyl)phenyl substituent in which the remote phenyl ring is substituted by trifluoromethyl, preferably at the 4-position; and X is CH2S or (CH2)2.
12. A compound of formula (I) as claimed in claim 1 and as named in any one of Examples 1 to 115.
13. A compound of formula (I) as defined in claim 1 selected from the group consisting of
N-(1-(2-methoxyethyl)piperidin-4-yl)-2-[2-(2,3-difluorobenzylthio)-4-oxo-4H-quinolin-1-yl]-N-(4′-trifluoromethylbiphenyl-4-ylmethyl)acetamide;
N-(1-(2-methoxyethyl)piperidin-yl)-2-[2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4H-[1,8]naphthyridin-1-yl]-N-(4′-trifluoromethylbiphenyl-4-ylmethyl)acetamide;
or a pharmaceutically acceptable salt thereof, in particular the bitartrate, hydrochloride, dihydrochloride or paratoluenesulfonate salt.
14. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 and a pharmaceutically acceptable carrier.
15. A compound of formula (I) as claimed in claim 1 for use in therapy.
16. The use of a compound of formula (I) as claimed in claim 1 for the manufacture of a medicament for treating atherosclerosis.
17. A method of treating a disease state associated with activity of the enzyme Lp-PLA2 which method involves treating a patient in need thereof with a therapeutically effective amount of a compound of formula (1) as claimed in claim 1 .
18. A process for preparing a compound of formula (I) as defined in claim 1 which process comprises reacting an acid compound of formula (II):
in which X, R1, R2 and R3 are as hereinbefore defined, with an amine compound of formula (III):
R6—R5—CH2NHR4 (III)
in which R4, R5 and R6 are as hereinbefore defined; under amide forming conditions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/900,489 US7235566B2 (en) | 2000-10-10 | 2004-07-28 | Pyridinone derivatives for treatment of atherosclerosis |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0024808.8A GB0024808D0 (en) | 2000-10-10 | 2000-10-10 | Novel compounds |
GB0024808.8 | 2000-10-10 | ||
PCT/EP2001/011610 WO2002030904A1 (en) | 2000-10-10 | 2001-10-05 | Pyridinone derivatives for treatment of atherosclerosis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/900,489 Continuation US7235566B2 (en) | 2000-10-10 | 2004-07-28 | Pyridinone derivatives for treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040063753A1 true US20040063753A1 (en) | 2004-04-01 |
Family
ID=9901006
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/399,022 Abandoned US20040063753A1 (en) | 2000-10-10 | 2001-10-05 | Pyridinone derivatives for treatment of atherosclerosis |
US10/900,489 Expired - Lifetime US7235566B2 (en) | 2000-10-10 | 2004-07-28 | Pyridinone derivatives for treatment of atherosclerosis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/900,489 Expired - Lifetime US7235566B2 (en) | 2000-10-10 | 2004-07-28 | Pyridinone derivatives for treatment of atherosclerosis |
Country Status (29)
Country | Link |
---|---|
US (2) | US20040063753A1 (en) |
EP (2) | EP1326841B1 (en) |
JP (1) | JP4212354B2 (en) |
KR (1) | KR100824134B1 (en) |
CN (2) | CN1280275C (en) |
AR (1) | AR035349A1 (en) |
AT (1) | ATE538096T1 (en) |
AU (2) | AU2002210524B2 (en) |
BR (1) | BRPI0114576B1 (en) |
CA (1) | CA2425268C (en) |
CY (2) | CY1112442T1 (en) |
CZ (1) | CZ304558B6 (en) |
DK (2) | DK1326841T3 (en) |
ES (2) | ES2399325T3 (en) |
GB (1) | GB0024808D0 (en) |
GC (1) | GC0000307A (en) |
HK (2) | HK1058036A1 (en) |
HU (1) | HU230767B1 (en) |
IL (2) | IL155278A0 (en) |
MX (1) | MXPA03003176A (en) |
MY (1) | MY135766A (en) |
NO (1) | NO325107B1 (en) |
NZ (1) | NZ525225A (en) |
PL (1) | PL207560B1 (en) |
PT (2) | PT1326841E (en) |
SI (2) | SI2258688T1 (en) |
TW (1) | TWI293293B (en) |
WO (1) | WO2002030904A1 (en) |
ZA (1) | ZA200302785B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US20080090853A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
WO2008141176A1 (en) * | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
US20150094331A1 (en) * | 2009-07-28 | 2015-04-02 | Auspex Pharmaceuticals, Inc. | Quinolone inhibitors of lipoprotein-associated phospholipase a2 |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0108396B1 (en) * | 2000-02-16 | 2015-05-19 | Smithkline Beecham Plc | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
WO2005113797A2 (en) | 2004-04-16 | 2005-12-01 | Glaxo Group Limited | METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
EP2977452A3 (en) | 2007-05-11 | 2016-05-25 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
US8575348B2 (en) | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
WO2011049722A1 (en) * | 2009-10-19 | 2011-04-28 | Merck Sharp & Dohme Corp. | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS |
AU2011268127B2 (en) | 2010-06-18 | 2016-01-14 | Whitehead Institute For Biomedical Research | PLA2G16 as a target for antiviral compounds |
JP2013544854A (en) * | 2010-12-06 | 2013-12-19 | グラクソ グループ リミテッド | Compound |
US20130252963A1 (en) | 2010-12-06 | 2013-09-26 | Yun Jin | Pyrimidinone compounds for use in the treatment of disease or conditions mediated by lp-pla2 |
JP2013545792A (en) | 2010-12-17 | 2013-12-26 | グラクソ グループ リミテッド | Methods for treating and preventing eye diseases |
WO2013000108A1 (en) * | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | Azole heterocylic compounds, preparation methods, pharmaceutical compositions and uses thereof |
AU2012289492B2 (en) | 2011-07-27 | 2016-02-04 | Glaxo Group Limited | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1H)-one compounds use as Lp-PLA2 inhibitors |
AR087309A1 (en) | 2011-07-27 | 2014-03-12 | Glaxo Group Ltd | HETEROCICLIC COMPOUND OF SUBSTITUTED CONDENSED RINGS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NEUROGENERATIVE DISEASES AND ATEROSCLEROSIS |
EP2751094B1 (en) | 2011-09-01 | 2018-06-20 | Glaxo Group Limited | Novel crystal form |
CA2899143A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
JP2016508995A (en) | 2013-01-25 | 2016-03-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Compound |
BR112015017759B1 (en) | 2013-01-25 | 2022-05-24 | Glaxosmithkline Intellectual Property Development Limited | LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 INHIBITOR COMPOUNDS (LP-PLA2) BASED ON 2,3-DIHYDROIMIDAZOLE[1,2-C]PYRIMIDIN5(1H)-ONA, AND A PHARMACEUTICAL COMPOSITION COMPRISING SUCH COMPOUNDS |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
CN104840963B (en) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | The pharmaceutical composition of the inhibitor containing lipoprotein-associated phospholipase A_2 and application |
KR20180011843A (en) | 2015-06-11 | 2018-02-02 | 바실리어 파마슈티카 인터내셔널 리미티드 | Efflux-pump inhibitors and their therapeutic uses |
CN112574221B (en) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | Tetracyclic pyrimidinone compounds, preparation method, composition and application thereof |
CA3156783A1 (en) | 2019-11-09 | 2021-05-14 | Yun Jin | Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof |
CN112510260B (en) * | 2020-11-27 | 2022-11-04 | 珠海市赛纬电子材料股份有限公司 | Electrolyte additive, non-aqueous electrolyte and lithium ion battery |
CN115304620A (en) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5769527A (en) | 1986-07-17 | 1998-06-23 | Vari-Lite, Inc. | Computer controlled lighting system with distributed control resources |
US5585246A (en) | 1993-02-17 | 1996-12-17 | Biometric Imaging, Inc. | Method for preparing a sample in a scan capillary for immunofluorescent interrogation |
JPH08500740A (en) | 1993-06-25 | 1996-01-30 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Lipoprotein-related phospholipase A-2, its inhibitors and their use in diagnosis and therapy |
ES2159573T3 (en) | 1993-10-06 | 2001-10-16 | Icos Corp | ACETILHIDROLASA OF THE PLATE ACTIVATOR FACTOR. |
GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
MX9704736A (en) | 1994-12-22 | 1997-10-31 | Smithkline Beecham Plc | Substituted azetidin-2-ones for treatment of atherosclerosis. |
CH690264A5 (en) | 1995-06-30 | 2000-06-30 | Symphar Sa | aminophosphonates substituted derivatives, their preparation process and their use for preparing pharmaceutical compositions. |
CN1197452A (en) | 1995-07-01 | 1998-10-28 | 史密丝克莱恩比彻姆有限公司 | Azetidinone derivatives for treatment of atherosclerosis |
FR2743912B1 (en) | 1996-01-24 | 1998-04-10 | Matra Communication | KEY EQUATION RESOLUTION CIRCUIT AND REED-SOLOMON DECODER INCORPORATING SUCH A CIRCUIT |
US5684794A (en) | 1996-01-25 | 1997-11-04 | Hazeltine Corporation | Validation of subscriber signals in a cellular radio network |
GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
CN1328277C (en) * | 1996-12-05 | 2007-07-25 | 安姆根有限公司 | Substituted pyrimidinone and pyridinone compounds and their use |
GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
WO1999024420A1 (en) | 1997-11-06 | 1999-05-20 | Smithkline Beecham Plc | Pyrimidinone compounds and pharmaceutical compositions containing them |
EP1105377B1 (en) | 1998-08-21 | 2003-10-08 | SmithKline Beecham plc | Pyrimidinone derivatives for the treatment of atherosclerosis |
GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
AU766003B2 (en) | 1999-05-01 | 2003-10-09 | Smithkline Beecham Plc | Pyrimidinone compounds |
GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
-
2000
- 2000-10-10 GB GBGB0024808.8A patent/GB0024808D0/en not_active Ceased
-
2001
- 2001-10-05 PT PT01978400T patent/PT1326841E/en unknown
- 2001-10-05 US US10/399,022 patent/US20040063753A1/en not_active Abandoned
- 2001-10-05 AU AU2002210524A patent/AU2002210524B2/en not_active Ceased
- 2001-10-05 HU HU0302480A patent/HU230767B1/en not_active IP Right Cessation
- 2001-10-05 SI SI200131019T patent/SI2258688T1/en unknown
- 2001-10-05 CN CNB018201253A patent/CN1280275C/en not_active Expired - Fee Related
- 2001-10-05 JP JP2002534290A patent/JP4212354B2/en not_active Expired - Fee Related
- 2001-10-05 IL IL15527801A patent/IL155278A0/en unknown
- 2001-10-05 MX MXPA03003176A patent/MXPA03003176A/en active IP Right Grant
- 2001-10-05 PT PT101777738T patent/PT2258688E/en unknown
- 2001-10-05 CN CN200610128890XA patent/CN1951917B/en not_active Expired - Fee Related
- 2001-10-05 EP EP01978400A patent/EP1326841B1/en not_active Expired - Lifetime
- 2001-10-05 CA CA2425268A patent/CA2425268C/en not_active Expired - Fee Related
- 2001-10-05 DK DK01978400.8T patent/DK1326841T3/en active
- 2001-10-05 PL PL366334A patent/PL207560B1/en unknown
- 2001-10-05 ES ES10177773T patent/ES2399325T3/en not_active Expired - Lifetime
- 2001-10-05 EP EP10177773A patent/EP2258688B1/en not_active Expired - Lifetime
- 2001-10-05 WO PCT/EP2001/011610 patent/WO2002030904A1/en active IP Right Grant
- 2001-10-05 AT AT01978400T patent/ATE538096T1/en active
- 2001-10-05 SI SI200131008T patent/SI1326841T1/en unknown
- 2001-10-05 AU AU1052402A patent/AU1052402A/en active Pending
- 2001-10-05 CZ CZ2003-1009A patent/CZ304558B6/en not_active IP Right Cessation
- 2001-10-05 KR KR1020037005084A patent/KR100824134B1/en active IP Right Grant
- 2001-10-05 NZ NZ525225A patent/NZ525225A/en not_active IP Right Cessation
- 2001-10-05 ES ES01978400T patent/ES2378059T3/en not_active Expired - Lifetime
- 2001-10-05 BR BRPI0114576A patent/BRPI0114576B1/en not_active IP Right Cessation
- 2001-10-05 DK DK10177773.8T patent/DK2258688T3/en active
- 2001-10-08 TW TW090124779A patent/TWI293293B/en not_active IP Right Cessation
- 2001-10-08 MY MYPI20014669A patent/MY135766A/en unknown
- 2001-10-08 GC GCP20011661 patent/GC0000307A/en active
- 2001-10-10 AR ARP010104760A patent/AR035349A1/en active IP Right Grant
-
2003
- 2003-04-08 IL IL155278A patent/IL155278A/en not_active IP Right Cessation
- 2003-04-09 NO NO20031626A patent/NO325107B1/en not_active IP Right Cessation
- 2003-04-09 ZA ZA200302785A patent/ZA200302785B/en unknown
- 2003-12-08 HK HK03108904.5A patent/HK1058036A1/en not_active IP Right Cessation
- 2003-12-08 HK HK10111562.3A patent/HK1144941A1/en not_active IP Right Cessation
-
2004
- 2004-07-28 US US10/900,489 patent/US7235566B2/en not_active Expired - Lifetime
-
2012
- 2012-03-07 CY CY20121100228T patent/CY1112442T1/en unknown
-
2013
- 2013-02-08 CY CY20131100118T patent/CY1113648T1/en unknown
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7705005B2 (en) | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US20080090853A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
WO2008048866A3 (en) * | 2006-10-13 | 2008-12-24 | Glaxo Group Ltd | Bicyclic heteroaromatic compounds |
WO2008141176A1 (en) * | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
CN101687009A (en) * | 2007-05-11 | 2010-03-31 | 宾夕法尼亚大学理事会 | Methods of treatment of skin ulcers |
US20100239565A1 (en) * | 2007-05-11 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
EA018101B1 (en) * | 2007-05-11 | 2013-05-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Methods of treatment of skin ulcers |
US9029383B2 (en) | 2007-05-11 | 2015-05-12 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
CN105748480A (en) * | 2007-05-11 | 2016-07-13 | 宾夕法尼亚大学理事会 | Methods of treatment of skin ulcers |
US20150094331A1 (en) * | 2009-07-28 | 2015-04-02 | Auspex Pharmaceuticals, Inc. | Quinolone inhibitors of lipoprotein-associated phospholipase a2 |
US9512104B2 (en) * | 2009-07-28 | 2016-12-06 | Auspex Pharmaceuticals, Inc. | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040063753A1 (en) | Pyridinone derivatives for treatment of atherosclerosis | |
AU2002210524A1 (en) | Pyridinone derivatives for treatment of atherosclerosis | |
US7462620B2 (en) | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | |
US20050245552A1 (en) | N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis | |
US9266841B2 (en) | Compounds | |
US20050153964A1 (en) | Novel compounds | |
WO2003042206A1 (en) | Pyridinone and pyrimidinone compounds | |
US20050033052A1 (en) | Novel compounds | |
US20050043335A1 (en) | Heterocyclic derivatives of glycinamide and their medical use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SMITHKLINE BEECHAM P.L.C., UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IFE, ROBERT JOHN;HICKEY, DEIRDRE MARY BERNADETTE;LEACH, COLIN ANDREW;AND OTHERS;REEL/FRAME:013961/0065;SIGNING DATES FROM 20030619 TO 20030721 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |